Olaparib Clinical Trials (2026): 409 Studies for Ovarian Cancer & Breast Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
409 Olaparib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 229 indications (including Ovarian Cancer & Breast Cancer) and 87,625 total planned enrollment. 41 Phase 3 Olaparib trials and 206 Phase 2, 6 Phase 4 are listed. 93 Olaparib clinical trials are actively recruiting at 2,053 U.S. sites across 51 states. Most recent activity: NCT03486873 (Aug 2043).
Where to Participate: All Olaparib Trial Sites in the U.S. (2,053 sites across 51 states)
Every actively recruiting Olaparibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | O'Neal Comprehensive Cancer Center at UAB | Birmingham35294 | NCT05952453 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT04711824 | Map |
| AL | University of Alabama at Birmingham | Birmingham35294 | NCT01042379 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05554328 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT05564377 | Map |
| AL | University of Alabama at Birmingham Cancer Center | Birmingham35233 | NCT06580314 | Map |
| AL | University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham35294 | NCT02693535 | Map |
| AL | University of South Alabama Mitchell Cancer Institute | Mobile36688 | NCT05554328 | Map |
| AL | University of South Alabama Mitchell Cancer Institute | Mobile36688 | NCT05564377 | Map |
| AK | Alaska Breast Care and Surgery LLC | Anchorage99508 | NCT06580314 | Map |
| AK | Alaska Oncology and Hematology LLC | Anchorage99508 | NCT06580314 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05554328 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT05564377 | Map |
| AK | Alaska Women's Cancer Care | Anchorage99508 | NCT06580314 | Map |
| AK | Anchorage Associates in Radiation Medicine | Anchorage98508 | NCT06580314 | Map |
| AK | Katmai Oncology Group | Anchorage99508 | NCT06580314 | Map |
| AK | Providence Alaska Medical Center | Anchorage99508 | NCT06580314 | Map |
| AZ | Banner MD Anderson Cancer Center ( Site 0066) | Gilbert85234 | NCT06966700 | Map |
| AZ | CTCA at Western Regional Medical Center | Goodyear85338 | NCT05554328 | Map |
| AZ | CTCA at Western Regional Medical Center | Goodyear85338 | NCT05564377 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT05554328 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT05564377 | Map |
| AZ | Kingman Regional Medical Center | Kingman86401 | NCT04858334 | Map |
| AZ | Cancer Center at Saint Joseph's | Phoenix85004 | NCT06580314 | Map |
| AZ | Cancer Treatment Centers of America-Phoenix | Phoenix85338 | NCT02693535 | Map |
| AZ | Mayo Clinic Cancer Center ( Site 0034) | Phoenix85054 | NCT06966700 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT06580314 | Map |
| AZ | Arizona Cancer Center at UMC North ( Site 0018) | Tucson85719 | NCT03486873 | Map |
| AZ | University of Arizona Cancer Center ( Site 0035) | Tucson85719 | NCT06966700 | Map |
| AR | Highlands Oncology Group - Fayetteville | Fayetteville72703 | NCT06580314 | Map |
| AR | Mercy Hospital Fort Smith | Fort Smith72903 | NCT06580314 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT05564377 | Map |
| AR | NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro72401 | NCT04858334 | Map |
| AR | CARTI Cancer Center | Little Rock72205 | NCT06580314 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT06580314 | Map |
| AR | Highlands Oncology Group - Rogers | Rogers72758 | NCT06580314 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT06580314 | Map |
| CA | Kaiser Permanente-Deer Valley Medical Center | Antioch94531 | NCT06580314 | Map |
| CA | Mission Hope Medical Oncology - Arroyo Grande | Arroyo Grande93420 | NCT06580314 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05554328 | Map |
| CA | PCR Oncology | Arroyo Grande93420 | NCT05564377 | Map |
| CA | Sutter Auburn | Auburn95602 | NCT02693535 | Map |
| CA | Sutter Auburn Faith Hospital | Auburn95602 | NCT06580314 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn95603 | NCT06580314 | Map |
| CA | Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 0054) | Bakersfield93309 | NCT03486873 | Map |
| CA | Kaiser Permanente-Bellflower | Bellflower90706 | NCT06580314 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT04858334 | Map |
| CA | Alta Bates Summit Medical Center-Herrick Campus | Berkeley94704 | NCT06580314 | Map |
| CA | Sutter Alta Bates | Berkeley94705 | NCT02693535 | Map |
| CA | Providence Saint Joseph Medical Center/Disney Family Cancer Center | Burbank91505 | NCT06580314 | Map |
| CA | Roy and Patricia Disney Family Cancer Center ( Site 0055) | Burbank91505 | NCT06966700 | Map |
| CA | Mills-Peninsula Medical Center | Burlingame94010 | NCT06580314 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park95682 | NCT06580314 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT05564377 | Map |
| CA | Mercy Cancer Center - Carmichael | Carmichael95608 | NCT06580314 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT05564377 | Map |
| CA | Mercy San Juan Medical Center | Carmichael95608 | NCT06580314 | Map |
| CA | Eden Hospital Medical Center | Castro Valley94546 | NCT06580314 | Map |
| CA | Sutter Davis Hospital | Davis95616 | NCT06580314 | Map |
| CA | University of California - Davis, Comprehensive Cancer Center | Davis95817 | NCT01042379 | Map |
| CA | City of Hope | Duarte91010 | NCT01042379 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT05238922 | Map |
| CA | Kaiser Permanente Dublin | Dublin94568 | NCT06580314 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT05564377 | Map |
| CA | Mercy Cancer Center - Elk Grove | Elk Grove95758 | NCT06580314 | Map |
| CA | Stanford Cancer Center Emeryville | Emeryville94608 | NCT06580314 | Map |
| CA | UC San Diego Health System - Encinitas | Encinitas92024 | NCT05564377 | Map |
| CA | MemorialCare Orange Coast Medical Center | Fountain Valley92708 | NCT06785636 | Map |
| CA | Kaiser Permanente-Fremont | Fremont94538 | NCT06580314 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT04858334 | Map |
| CA | Palo Alto Medical Foundation-Fremont | Fremont94538 | NCT06580314 | Map |
| CA | Fresno Cancer Center | Fresno93720 | NCT06580314 | Map |
| CA | Kaiser Permanente Fresno Orchard Plaza | Fresno93720 | NCT06580314 | Map |
| CA | Kaiser Permanente-Fresno | Fresno93720 | NCT06580314 | Map |
| CA | Providence Medical Foundation ( Site 0080) | Fullerton92835 | NCT06966700 | Map |
| CA | Kaiser Permanente South Bay | Harbor City90710 | NCT06580314 | Map |
| CA | City of Hope-Lennar Foundation Cancer Center | Irvine92618 | NCT05238922 | Map |
| CA | Kaiser Permanente-Irvine | Irvine92618 | NCT06580314 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT04633239 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT05564377 | Map |
| CA | UC San Diego Moores Cancer Center | La Jolla92093 | NCT06580314 | Map |
| CA | UCSD Moores Cancer Center ( Site 0039) | La Jolla92037 | NCT06353386 | Map |
| CA | University of California San Diego | La Jolla92093-0698 | NCT01042379 | Map |
| CA | University of California San Diego - Moores Cancer Center | La Jolla92093 | NCT05498272 | Map |
| CA | Cancer and Blood Research Center | Los Alamitos90720 | NCT06785636 | Map |
| CA | Cedars Sinai Medical Center | Los Angeles90048 | NCT06580314 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05554328 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT05564377 | Map |
| CA | Kaiser Permanente Los Angeles Medical Center | Los Angeles90027 | NCT06580314 | Map |
| CA | Kaiser Permanente West Los Angeles | Los Angeles90034 | NCT06580314 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT04633239 | Map |
| CA | The Angeles Clinic and Research Institute - West Los Angeles Office | Los Angeles90025 | NCT05564377 | Map |
| CA | The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate | Los Angeles90025 | NCT02693535 | Map |
| CA | UCLA Hematology/Oncology - Santa Monica ( Site 0044) | Los Angeles90404 | NCT06353386 | Map |
| CA | UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0009) | Los Angeles90095 | NCT03486873 | Map |
| CA | University of Southern California | Los Angeles90033 | NCT01042379 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT04633239 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT05238922 | Map |
| CA | Mercy Cancer Center | Merced95340 | NCT06580314 | Map |
| CA | Kaiser Permanente- Modesto MOB II | Modesto95356 | NCT06580314 | Map |
| CA | Kaiser Permanente-Modesto | Modesto95356 | NCT06580314 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT04858334 | Map |
| CA | Memorial Medical Center | Modesto95355 | NCT06580314 | Map |
| CA | Palo Alto Medical Foundation-Camino Division | Mountain View94040 | NCT06580314 | Map |
| CA | Palo Alto Medical Foundation-Gynecologic Oncology | Mountain View94040 | NCT06580314 | Map |
| CA | Providence Queen of The Valley | Napa94558 | NCT06580314 | Map |
| CA | HOAG Memorial Hospital Presbyterian | Newport Beach92663 | NCT01042379 | Map |
| CA | Hoag Memorial Hospital Presbyterian ( Site 0010) | Newport Beach92663 | NCT06966700 | Map |
| CA | Sutter Cancer Research Consortium | Novato94945 | NCT06580314 | Map |
| CA | Kaiser Permanente - Oakland Medical Center | Oakland94611 | NCT02693535 | Map |
| CA | Kaiser Permanente Oakland-Broadway | Oakland94611 | NCT06580314 | Map |
| CA | Kaiser Permanente-Oakland | Oakland94611 | NCT06580314 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT05564377 | Map |
| CA | Saint Joseph Hospital - Orange | Orange92868 | NCT05554328 | Map |
| CA | Saint Joseph Hospital - Orange | Orange92868 | NCT05564377 | Map |
| CA | Saint Joseph Hospital - Orange | Orange92868 | NCT04858334 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT04633239 | Map |
| CA | Palo Alto Medical Foundation Health Care | Palo Alto94301 | NCT06580314 | Map |
| CA | Stanford Cancer Center ( Site 0086) | Palo Alto94304 | NCT03486873 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT05554328 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT05564377 | Map |
| CA | Stanford Cancer Institute Palo Alto | Palo Alto94304 | NCT06580314 | Map |
| CA | Sutter Palo Alto Medical Foundation: Palo Alto | Palo Alto94301 | NCT02693535 | Map |
| CA | Kaiser Permanente - Panorama City | Panorama City91402 | NCT06580314 | Map |
| CA | Huntington Memorial Hospital | Pasadena91105 | NCT06580314 | Map |
| CA | Kaiser Permanente-Rancho Cordova Cancer Center | Rancho Cordova95670 | NCT06580314 | Map |
| CA | Kaiser Permanente- Marshall Medical Offices | Redwood City94063 | NCT06580314 | Map |
| CA | Kaiser Permanente-Richmond | Richmond94801 | NCT06580314 | Map |
| CA | Kaiser Permanente-Riverside | Riverside92505 | NCT06580314 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT05564377 | Map |
| CA | Mercy Cancer Center - Rocklin | Rocklin95765 | NCT06580314 | Map |
| CA | Rohnert Park Cancer Center | Rohnert Park94928 | NCT06580314 | Map |
| CA | Kaiser Permanente - Roseville Medical Center | Roseville95661 | NCT02693535 | Map |
| CA | Kaiser Permanente-Roseville | Roseville95661 | NCT06580314 | Map |
| CA | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville95661 | NCT06580314 | Map |
| CA | Sutter Roseville | Roseville95661 | NCT02693535 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT04858334 | Map |
| CA | Sutter Roseville Medical Center | Roseville95661 | NCT06580314 | Map |
| CA | The Permanente Medical Group-Roseville Radiation Oncology | Roseville95678 | NCT06580314 | Map |
| CA | Kaiser Permanente - Sacramento Medical Center | Sacramento95814 | NCT02693535 | Map |
| CA | Kaiser Permanente Downtown Commons | Sacramento95814 | NCT06580314 | Map |
| CA | Kaiser Permanente-South Sacramento | Sacramento95823 | NCT06580314 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT05564377 | Map |
| CA | Mercy Cancer Center - Sacramento | Sacramento95816 | NCT06580314 | Map |
| CA | South Sacramento Cancer Center | Sacramento95823 | NCT06580314 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT04858334 | Map |
| CA | Sutter Medical Center Sacramento | Sacramento95816 | NCT06580314 | Map |
| CA | Sutter Sacramento | Sacramento95816 | NCT02693535 | Map |
| CA | Kaiser Permanente-San Diego Zion | San Diego92120 | NCT06580314 | Map |
| CA | Sharp Memorial Hospital | San Diego92123 | NCT05564377 | Map |
| CA | UC San Diego Medical Center - Hillcrest | San Diego92103 | NCT05564377 | Map |
| CA | California Pacific Medical Center Research Institute | San Francisco94115 | NCT02693535 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT04858334 | Map |
| CA | California Pacific Medical Center-Pacific Campus | San Francisco94115 | NCT06580314 | Map |
| CA | Kaiser Permanente - San Francisco Medical Center | San Francisco94115 | NCT02693535 | Map |
| CA | Kaiser Permanente - South San Francisco Medical Center | San Francisco94080 | NCT02693535 | Map |
| CA | Kaiser Permanente-San Francisco | San Francisco94115 | NCT06580314 | Map |
| CA | Sutter Cancer Research Consortium | San Francisco94115 | NCT02693535 | Map |
| CA | UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0004) | San Francisco94158 | NCT03486873 | Map |
| CA | University of California San Francisco (UCSF) | San Francisco94115 | NCT01042379 | Map |
| CA | University of California, San Francisco | San Francisco94143 | NCT06177171 | Map |
| CA | Kaiser Permanente - San Jose Medical Center | San Jose95119 | NCT02693535 | Map |
| CA | Kaiser Permanente-Santa Teresa-San Jose | San Jose95119 | NCT06580314 | Map |
| CA | Stanford Cancer Center South Bay | San Jose95124 | NCT06580314 | Map |
| CA | Kaiser Permanente - San Leandro Medical Center | San Leandro94577 | NCT02693535 | Map |
| CA | Kaiser Permanente San Leandro | San Leandro94577 | NCT06580314 | Map |
| CA | Pacific Central Coast Health Center-San Luis Obispo | San Luis Obispo93401 | NCT06580314 | Map |
| CA | Kaiser Permanente-San Marcos | San Marcos92078 | NCT06580314 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT04858334 | Map |
| CA | Mills Health Center | San Mateo94401 | NCT06580314 | Map |
| CA | Kaiser San Rafael-Gallinas | San Rafael94903 | NCT06580314 | Map |
| CA | Ridley-Tree Cancer Center | Santa Barbara93105 | NCT06580314 | Map |
| CA | Sutter Sansum Clinic | Santa Barbara93105 | NCT02693535 | Map |
| CA | Kaiser Permanente - Santa Clara Medical Center | Santa Clara95051 | NCT02693535 | Map |
| CA | Kaiser Permanente Medical Center - Santa Clara | Santa Clara95051 | NCT06580314 | Map |
| CA | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz95065 | NCT04858334 | Map |
| CA | Palo Alto Medical Foundation-Santa Cruz | Santa Cruz95065 | NCT06580314 | Map |
| CA | Santa Cruz Radiation Oncology Medical Group | Santa Cruz95065 | NCT06580314 | Map |
| CA | Sutter Palo Alto Medical Foundation: Fremont | Santa Cruz994538 | NCT02693535 | Map |
| CA | Sutter Palo Alto Medical Foundation: Santa Cruz | Santa Cruz95065 | NCT02693535 | Map |
| CA | Mission Hope Medical Oncology - Santa Maria | Santa Maria93444 | NCT06580314 | Map |
| CA | Providence Saint John's Health Center ( Site 0059) | Santa Monica90404 | NCT03486873 | Map |
| CA | Saint John's Cancer Institute | Santa Monica90404 | NCT05564377 | Map |
| CA | UCLA Hematology/Oncology - Parkside ( Site 0021) | Santa Monica90404 | NCT06797635 | Map |
| CA | Kaiser Permanente-Santa Rosa | Santa Rosa95403 | NCT06580314 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT04858334 | Map |
| CA | Providence Medical Foundation - Santa Rosa | Santa Rosa95403 | NCT06580314 | Map |
| CA | Providence Santa Rosa Memorial Hospital | Santa Rosa95405 | NCT06580314 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT04858334 | Map |
| CA | Sutter Pacific Medical Foundation | Santa Rosa95403 | NCT06580314 | Map |
| CA | Kaiser Permanente Cancer Treatment Center | South San Francisco94080 | NCT06580314 | Map |
| CA | Kaiser Permanente-South San Francisco | South San Francisco94080 | NCT06580314 | Map |
| CA | Kaiser Permanente-Stockton | Stockton95210 | NCT06580314 | Map |
| CA | Saint Joseph's Medical Center | Stockton95204 | NCT06580314 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT04858334 | Map |
| CA | Palo Alto Medical Foundation-Sunnyvale | Sunnyvale94086 | NCT06580314 | Map |
| CA | Sutter Palo Alto Medical Foundation: Sunnyvale | Sunnyvale94086 | NCT02693535 | Map |
| CA | Torrance Memorial Physician Network - Cancer Care | Torrance90505 | NCT06580314 | Map |
| CA | Kaiser Permanente Medical Center-Vacaville | Vacaville95688 | NCT06580314 | Map |
| CA | Northbay Cancer Center | Vacaville95687 | NCT04858334 | Map |
| CA | Kaiser Permanente - Vallejo Medical Center | Vallejo94589 | NCT02693535 | Map |
| CA | Kaiser Permanente-Vallejo | Vallejo94589 | NCT06580314 | Map |
| CA | Sutter Solano Medical Center/Cancer Center | Vallejo94589 | NCT06580314 | Map |
| CA | John Muir Medical Center-Walnut Creek | Walnut Creek94598 | NCT06580314 | Map |
| CA | Kaiser Permanente - Walnut Creek Medical Center | Walnut Creek94596 | NCT02693535 | Map |
| CA | Kaiser Permanente-Walnut Creek | Walnut Creek94596 | NCT06580314 | Map |
| CA | VA Greater Los Angeles Healthcare System, West Los Angeles, CA | West Los Angeles90073 | NCT04038502 | Map |
| CA | Helios Clinical Research ( Site 0061) | Whittier90602 | NCT06966700 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT05564377 | Map |
| CA | Woodland Memorial Hospital | Woodland95695 | NCT06580314 | Map |
| CA | Kaiser Permanente-Woodland Hills | Woodland Hills91367 | NCT06580314 | Map |
| CO | Call for Information (Investigational Site 2041) | Aurora80045 | NCT02861573 | Map |
| CO | CU Medicine Clinics | Aurora80045 | NCT06856499 | Map |
| CO | Rocky Mountain Regional VA Medical Center, Aurora, CO | Aurora80045 | NCT04038502 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05564377 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT06580314 | Map |
| CO | University of Colorado Cancer Center | Aurora80045 | NCT01042379 | Map |
| CO | University of Colorado Cancer Center ( Site 0021) | Aurora80045 | NCT03486873 | Map |
| CO | University of Colorado Health | Aurora80045 | NCT06785636 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT05887609 | Map |
| CO | Universtiy of Colorado Hospital | Aurora80045 | NCT06856499 | Map |
| CO | Memorial Hospital North | Colorado Springs80920 | NCT06580314 | Map |
| CO | Penrose-Saint Francis Healthcare | Colorado Springs80907 | NCT06580314 | Map |
| CO | Rocky Mountain Cancer Centers-Penrose | Colorado Springs80907 | NCT06580314 | Map |
| CO | Saint Francis Cancer Center | Colorado Springs80923 | NCT06580314 | Map |
| CO | UCHealth Memorial Hospital Central | Colorado Springs80909 | NCT06580314 | Map |
| CO | Intermountain Health Cancer Center Saint Joseph ( Site 0062) | Denver80218 | NCT06966700 | Map |
| CO | Rocky Mountain Cancer Centers (RMCC) ( Site 8006) | Denver80220 | NCT06966700 | Map |
| CO | UCHealth - Cherry Creek | Denver80206 | NCT06580314 | Map |
| CO | CommonSpirit Cancer Center Mercy | Durango81301 | NCT06580314 | Map |
| CO | Mercy Medical Center | Durango81301 | NCT06580314 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT05564377 | Map |
| CO | Cancer Care and Hematology-Fort Collins | Fort Collins80528 | NCT06580314 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT05564377 | Map |
| CO | Poudre Valley Hospital | Fort Collins80524 | NCT06580314 | Map |
| CO | Intermountain Health St. Mary's Regional Hospital ( Site 0054) | Grand Junction81501 | NCT06966700 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT05564377 | Map |
| CO | UCHealth Greeley Hospital | Greeley80631 | NCT06580314 | Map |
| CO | UCHealth Highlands Ranch Hospital | Highlands Ranch80129 | NCT06580314 | Map |
| CO | Saint Anthony Hospital | Lakewood80228 | NCT06580314 | Map |
| CO | Rocky Mountain Cancer Centers-Sky Ridge | Lone Tree80124 | NCT05238922 | Map |
| CO | Longmont United Hospital | Longmont80501 | NCT06580314 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT05564377 | Map |
| CO | Medical Center of the Rockies | Loveland80538 | NCT06580314 | Map |
| CO | Saint Mary Corwin Medical Center | Pueblo81004 | NCT06580314 | Map |
| CO | Saint Anthony North Hospital | Westminster80023 | NCT06580314 | Map |
| CT | Saint Vincent's Medical Center (SVMC) | Bridgeport06606 | NCT02693535 | Map |
| CT | Danbury Hospital | Danbury06810 | NCT06580314 | Map |
| CT | Smilow Cancer Hospital Care Center-Fairfield | Fairfield06824 | NCT06580314 | Map |
| CT | Smilow Cancer Hospital Care Center at Greenwich | Greenwich06830 | NCT06580314 | Map |
| CT | Hartford Healthcare Alliance (Data Collection Only) | Hartford06102 | NCT05188508 | Map |
| CT | Hartford Hospital | Hartford06102 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Saint Francis | Hartford06105 | NCT06580314 | Map |
| CT | Midstate Medical Center (MSMC) | Meriden06451 | NCT02693535 | Map |
| CT | The Hospital of Central Connecticut (HOCC) Cancer Center | New Britain06053 | NCT02693535 | Map |
| CT | Smilow Cancer Center/Yale-New Haven Hospital | New Haven06510 | NCT06580314 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT01042379 | Map |
| CT | Yale University | New Haven06520 | NCT06580314 | Map |
| CT | Norwalk Hospital | Norwalk06856 | NCT06580314 | Map |
| CT | William W. Backus Hospital | Norwich06360 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center at Long Ridge | Stamford06902 | NCT06580314 | Map |
| CT | Charlotte Hungerford | Torrington06790 | NCT02693535 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT06580314 | Map |
| CT | Smilow Cancer Hospital-Waterbury Care Center | Waterbury06708 | NCT06580314 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT06580314 | Map |
| CT | Windham Hospital (WH) | Willimantic06226 | NCT02693535 | Map |
| DE | Beebe Medical Center | Lewes19958 | NCT06580314 | Map |
| DE | Beebe South Coastal Health Campus | Millville19967 | NCT06580314 | Map |
| DE | Christiana Care Health System-Christiana Hospital | Newark19718 | NCT06580314 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT05564377 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT06580314 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT05564377 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT06580314 | Map |
| DE | Beebe Health Campus | Rehoboth Beach19971 | NCT06580314 | Map |
| DE | Christiana Care Health System-Wilmington Hospital | Wilmington19801 | NCT06580314 | Map |
| DC | Georgetown University Medical Center | Washington D.C.20007 | NCT01042379 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT04858334 | Map |
| DC | Washington DC VA Medical Center, Washington, DC | Washington D.C.20422-0001 | NCT04038502 | Map |
| FL | AdventHealth Altamonte | Altamonte Springs32701 | NCT04858334 | Map |
| FL | AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0044) | Altamonte Springs32701 | NCT06966700 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05554328 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT05564377 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Aventura | Aventura33180 | NCT02693535 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05554328 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT05564377 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04858334 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Lennar | Coral Gables33146 | NCT02693535 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05554328 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT05564377 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04858334 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Deerfield Beach | Deerfield Beach33442 | NCT02693535 | Map |
| FL | Broward Health Medical Center | Fort Lauderdale33316 | NCT05564377 | Map |
| FL | Broward Health Medical Center | Fort Lauderdale33316 | NCT06580314 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT02693535 | Map |
| FL | Holy Cross Hospital | Fort Lauderdale33308 | NCT06580314 | Map |
| FL | Holy Cross Hospital, Michael & Dianne Bienes Comp Cancer Ctr ( Site 0022) | Fort Lauderdale33308 | NCT03486873 | Map |
| FL | Florida Cancer Specialists - South ( Site 7004) | Fort Myers33901 | NCT06966700 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT05564377 | Map |
| FL | UF Health Cancer Institute - Gainesville | Gainesville32610 | NCT06580314 | Map |
| FL | University of Florida Health | Gainesville32610 | NCT02693535 | Map |
| FL | Bioresearch Partner ( Site 0072) | Hialeah33013 | NCT06966700 | Map |
| FL | Memorial Healthcare System | Hollywood33028 | NCT04711824 | Map |
| FL | Exelixis Clinical Site #15 | Jacksonville32224 | NCT05932862 | Map |
| FL | Mayo Clinic Hospital ( Site 0013) | Jacksonville32224 | NCT06966700 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05554328 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT05564377 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT04585958 | Map |
| FL | Orlando Health Cancer Institute - Lake Mary | Lake Mary32746 | NCT06580314 | Map |
| FL | BAPTIST ALLIANCE - MCI (Data Collection Only) | Miami33143 | NCT05188508 | Map |
| FL | Mount Sinai Medical Center | Miami33140 | NCT06785636 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05554328 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT05564377 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT04858334 | Map |
| FL | University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 0051) | Miami33136 | NCT06353386 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05554328 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05564377 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04858334 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Alex's Place | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building | Miami33136 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Kendall | Miami33176 | NCT02693535 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Sole Mia | Miami33181 | NCT02693535 | Map |
| FL | Mount Sinai Medical Center Comprehensive Cancer Center | Miami Beach33140 | NCT05238922 | Map |
| FL | Mount Sinai Medical Center Comprehensive Cancer Center ( Site 0031) | Miami Beach33140 | NCT03486873 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT05554328 | Map |
| FL | University of Miami Sylvester Comprehensive Cancer Center at Sole Mia | North Miami33181 | NCT05564377 | Map |
| FL | Health Central | Ocoee34761 | NCT06580314 | Map |
| FL | Advent Health | Orlando32804 | NCT06915025 | Map |
| FL | AdventHealth Orlando | Orlando32803 | NCT04858334 | Map |
| FL | Exelixis Clinical Site #8 | Orlando32827 | NCT05932862 | Map |
| FL | Orlando Health Cancer Institute | Orlando32806 | NCT06580314 | Map |
| FL | Orlando VA Medical Center, Orlando, FL | Orlando32827 | NCT04038502 | Map |
| FL | Sacred Heart Hospital | Pensacola32504 | NCT06580314 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05554328 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT05564377 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT04858334 | Map |
| FL | University of Miami/Sylvester Cancer Institute - Plantation | Plantation33324 | NCT02693535 | Map |
| FL | Florida Cancer Specialists - North ( Site 7002) | St. Petersburg33701 | NCT06966700 | Map |
| FL | Exelixis Clinical Site #16 | Tampa33612 | NCT05932862 | Map |
| FL | H. Lee Moffitt Cancer Center and Research Institute | Tampa33612 | NCT01042379 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT05524935 | Map |
| FL | Moffitt Cancer Center | Tampa33612 | NCT01042379 | Map |
| GA | University Cancer and Blood Center LLC | Athens30607 | NCT06580314 | Map |
| GA | Cancer Treatment Centers of America - Atlanta | Atlanta30265 | NCT02693535 | Map |
| GA | Emory Saint Joseph's Hospital | Atlanta30342 | NCT06580314 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT06785636 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT04585958 | Map |
| GA | Emory University Hospital Midtown | Atlanta30308 | NCT06580314 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT04585958 | Map |
| GA | Emory University Hospital/Winship Cancer Institute | Atlanta30322 | NCT06580314 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322 | NCT02693535 | Map |
| GA | Grady Health System | Atlanta30303 | NCT06580314 | Map |
| GA | Northside Hospital | Atlanta30342 | NCT06580314 | Map |
| GA | Winship Cancer Institute of Emory University | Atlanta30322 | NCT01042379 | Map |
| GA | Augusta University ( Site 0077) | Augusta30912 | NCT03486873 | Map |
| GA | Augusta University Medical Center | Augusta30912 | NCT06580314 | Map |
| GA | Atlanta VA Medical and Rehab Center, Decatur, GA | Decatur30033 | NCT04038502 | Map |
| GA | Emory Decatur Hospital | Decatur30033 | NCT06580314 | Map |
| GA | Northwest Georgia Oncology Centers PC ( Site 0061) | Marietta30060 | NCT03486873 | Map |
| GA | City of Hope Cancer Center - Atlanta ( Site 0102) | Newnan30265 | NCT06966700 | Map |
| GA | Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion | Savannah31405 | NCT02693535 | Map |
| GA | Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute | Savannah31405 | NCT02693535 | Map |
| GA | Summit Cancer Care | Savannah31405 | NCT02693535 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT05564377 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT04858334 | Map |
| HI | Hawaii Cancer Care - Westridge | ‘Aiea96701 | NCT06580314 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT05564377 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT04858334 | Map |
| HI | Pali Momi Medical Center | ‘Aiea96701 | NCT06580314 | Map |
| HI | Queen's Cancer Center - Pearlridge | ‘Aiea96701 | NCT06580314 | Map |
| HI | The Cancer Center of Hawaii-Pali Momi | ‘Aiea96701 | NCT06580314 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT02693535 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT05554328 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT05564377 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT04858334 | Map |
| HI | The Queen's Medical Center - West Oahu | ‘Ewa Beach96706 | NCT06580314 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT05564377 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT04858334 | Map |
| HI | Hawaii Cancer Care Inc - Waterfront Plaza | Honolulu96813 | NCT06580314 | Map |
| HI | Kaiser Permanente Moanalua Medical Center | Honolulu96819 | NCT06580314 | Map |
| HI | Kaiser Permanente Moanalua Medical Center ( Site 0063) | Honolulu96813 | NCT03486873 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT05554328 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT05564377 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96826 | NCT06580314 | Map |
| HI | Kuakini Medical Center | Honolulu96817 | NCT06580314 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT05554328 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT05564377 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT04858334 | Map |
| HI | Queen's Cancer Cenrer - POB I | Honolulu96813 | NCT06580314 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT05554328 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT05564377 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT04858334 | Map |
| HI | Queen's Cancer Center - Kuakini | Honolulu96817 | NCT06580314 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT05554328 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT05564377 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT04858334 | Map |
| HI | Queen's Medical Center | Honolulu96813 | NCT06580314 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT05564377 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT04858334 | Map |
| HI | Straub Clinic and Hospital | Honolulu96813 | NCT06580314 | Map |
| HI | The Cancer Center of Hawaii-Liliha | Honolulu96817 | NCT06580314 | Map |
| HI | The Queen's Medical Center - Kuakini | Honolulu96817 | NCT02693535 | Map |
| HI | The Queen's Medical Center - POB I | Honolulu96813 | NCT02693535 | Map |
| HI | The Queen's Medical Center - Punchbowl | Honolulu96813 | NCT02693535 | Map |
| HI | University of Hawaii Cancer Center | Honolulu96813 | NCT05564377 | Map |
| HI | University of Hawaii Cancer Center | Honolulu96813 | NCT06580314 | Map |
| HI | Wilcox Memorial Hospital and Kauai Medical Clinic | Lihue96766 | NCT06580314 | Map |
| ID | Boise VA Medical Center, Boise, ID | Boise83702 | NCT04038502 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05554328 | Map |
| ID | Saint Alphonsus Cancer Care Center-Boise | Boise83706 | NCT05564377 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05554328 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT05564377 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT04858334 | Map |
| ID | Saint Luke's Cancer Institute - Boise | Boise83712 | NCT06580314 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05554328 | Map |
| ID | Saint Alphonsus Cancer Care Center-Caldwell | Caldwell83605 | NCT05564377 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05554328 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT05564377 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT04858334 | Map |
| ID | Kootenai Health - Coeur d'Alene | Coeur d'Alene83814 | NCT06580314 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05554328 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT05564377 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT04858334 | Map |
| ID | Saint Luke's Cancer Institute - Fruitland | Fruitland83619 | NCT06580314 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05554328 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT05564377 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT04858334 | Map |
| ID | Saint Luke's Cancer Institute - Meridian | Meridian83642 | NCT06580314 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05554328 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT05564377 | Map |
| ID | Saint Alphonsus Cancer Care Center-Nampa | Nampa83687 | NCT04858334 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05554328 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT05564377 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT04858334 | Map |
| ID | Saint Luke's Cancer Institute - Nampa | Nampa83687 | NCT06580314 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05554328 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT05564377 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT04858334 | Map |
| ID | Kootenai Clinic Cancer Services - Post Falls | Post Falls83854 | NCT06580314 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05554328 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT05564377 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT04858334 | Map |
| ID | Kootenai Clinic Cancer Services - Sandpoint | Sandpoint83864 | NCT06580314 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05554328 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT05564377 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT04858334 | Map |
| ID | Saint Luke's Cancer Institute - Twin Falls | Twin Falls83301 | NCT06580314 | Map |
| IL | OSF Saint Anthony's Health Center | Alton62002 | NCT06580314 | Map |
| IL | Advocate Outpatient Center - Aurora | Aurora60506 | NCT06580314 | Map |
| IL | Rush-Copley Medical Center | Aurora60504 | NCT06580314 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05554328 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT05564377 | Map |
| IL | Advocate Good Shepherd Hospital | Barrington60010 | NCT06580314 | Map |
| IL | Carle BroMenn Outpatient Center | Bloomington61704 | NCT06580314 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05554328 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT05564377 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT04858334 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT06580314 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05554328 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT05564377 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT04858334 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT06580314 | Map |
| IL | Memorial Hospital of Carbondale | Carbondale62902 | NCT06580314 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT05564377 | Map |
| IL | SIH Cancer Institute | Carterville62918 | NCT06580314 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05554328 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT05564377 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT04858334 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT06580314 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05554328 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT05564377 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT04858334 | Map |
| IL | Centralia Oncology Clinic | Centralia62801 | NCT06580314 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05554328 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT05564377 | Map |
| IL | Advocate Illinois Masonic Medical Center | Chicago60657 | NCT06580314 | Map |
| IL | Cancer Treatment Centers of America-Chicago | Chicago60099 | NCT02693535 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT05554328 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT05564377 | Map |
| IL | John H Stroger Jr Hospital of Cook County | Chicago60612 | NCT06580314 | Map |
| IL | Mount Sinai Hospital Medical Center | Chicago60608 | NCT05564377 | Map |
| IL | Northwestern Memorial Hospital | Chicago60611 | NCT05887609 | Map |
| IL | Northwestern University | Chicago60611 | NCT05564377 | Map |
| IL | The University of Chicago ( Site 0020) | Chicago60637 | NCT03486873 | Map |
| IL | University of Chicago | Chicago60453 | NCT01042379 | Map |
| IL | University of Chicago | Chicago60637 | NCT06785636 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05554328 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05564377 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT06580314 | Map |
| IL | University of Chicago Medical Center | Chicago60615 | NCT04515836 | Map |
| IL | University of Illinois | Chicago60612 | NCT05554328 | Map |
| IL | University of Illinois | Chicago60612 | NCT05564377 | Map |
| IL | University of Illinois | Chicago60612 | NCT04858334 | Map |
| IL | University of Illinois | Chicago60612 | NCT06580314 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05554328 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT05564377 | Map |
| IL | AMG Crystal Lake - Oncology | Crystal Lake60014 | NCT06580314 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05554328 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT05564377 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT04858334 | Map |
| IL | Carle at The Riverfront | Danville61832 | NCT06580314 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05554328 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT05564377 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT04858334 | Map |
| IL | Cancer Care Specialists of Illinois - Decatur | Decatur62526 | NCT06580314 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05554328 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT05564377 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT04858334 | Map |
| IL | Decatur Memorial Hospital | Decatur62526 | NCT06580314 | Map |
| IL | Northwestern Medicine Cancer Center Kishwaukee | DeKalb60115 | NCT05564377 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05554328 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT05564377 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT04858334 | Map |
| IL | Illinois CancerCare-Dixon | Dixon61021 | NCT06580314 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05554328 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT05564377 | Map |
| IL | Advocate Good Samaritan Hospital | Downers Grove60515 | NCT06580314 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05554328 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT05564377 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT04858334 | Map |
| IL | Carle Physician Group-Effingham | Effingham62401 | NCT06580314 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05554328 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT05564377 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT04858334 | Map |
| IL | Crossroads Cancer Center | Effingham62401 | NCT06580314 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05554328 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT05564377 | Map |
| IL | Advocate Sherman Hospital | Elgin60123 | NCT06580314 | Map |
| IL | Elmhurst Memorial Hospital | Elmhurst60126 | NCT04858334 | Map |
| IL | Elmhurst Memorial Hospital | Elmhurst60126 | NCT06580314 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05554328 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT05564377 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT04858334 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT06580314 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05554328 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT05564377 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05554328 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT05564377 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT04858334 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT06580314 | Map |
| IL | Northwestern Medicine Cancer Center Delnor | Geneva60134 | NCT05564377 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05554328 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT05564377 | Map |
| IL | Northwestern Medicine Glenview Outpatient Center | Glenview60026 | NCT05564377 | Map |
| IL | Northwestern Medicine Grayslake Outpatient Center | Grayslake60030 | NCT05564377 | Map |
| IL | Ingalls Memorial Hospital | Harvey60426 | NCT05564377 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05554328 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT05564377 | Map |
| IL | Advocate South Suburban Hospital | Hazel Crest60429 | NCT06580314 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05554328 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT05564377 | Map |
| IL | UChicago Medicine AdventHealth Cancer Institute Hinsdale | Hinsdale60521 | NCT06580314 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05554328 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT05564377 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT04858334 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT06580314 | Map |
| IL | Northwestern Medicine Lake Forest Hospital | Lake Forest60045 | NCT05564377 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05554328 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT05564377 | Map |
| IL | AMG Libertyville - Oncology | Libertyville60048 | NCT06580314 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05554328 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT05564377 | Map |
| IL | Condell Memorial Hospital | Libertyville60048 | NCT06580314 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05554328 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT05564377 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT04858334 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT06580314 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05554328 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT05564377 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT04858334 | Map |
| IL | Carle Physician Group-Mattoon/Charleston | Mattoon61938 | NCT06580314 | Map |
| IL | Loyola University | Maywood60153 | NCT01042379 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05564377 | Map |
| IL | SSM Health Good Samaritan | Mount Vernon62864 | NCT06580314 | Map |
| IL | Edward Hospital/Cancer Center | Naperville60540 | NCT04858334 | Map |
| IL | Edward Hospital/Cancer Center | Naperville60540 | NCT06580314 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05554328 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05564377 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT06580314 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT05554328 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT05564377 | Map |
| IL | Carle BroMenn Medical Center | Normal61761 | NCT06580314 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05554328 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT05564377 | Map |
| IL | Carle Cancer Institute Normal | Normal61761 | NCT06580314 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05554328 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT05564377 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT04858334 | Map |
| IL | Cancer Care Center of O'Fallon | O'Fallon62269 | NCT06580314 | Map |
| IL | HSHS Saint Elizabeth's Hospital | O'Fallon62269 | NCT06580314 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05554328 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT05564377 | Map |
| IL | Advocate Christ Medical Center | Oak Lawn60453-2699 | NCT06580314 | Map |
| IL | Advocate Outpatient Center - Oak Lawn | Oak Lawn60453 | NCT06580314 | Map |
| IL | Northwestern Medicine Orland Park | Orland Park60462 | NCT05564377 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05554328 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05564377 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT06580314 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05554328 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT05564377 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT04858334 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT06580314 | Map |
| IL | Advocate High Tech Medical Park | Palos Heights60463 | NCT06580314 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05554328 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT05564377 | Map |
| IL | Advocate Lutheran General Hospital | Park Ridge60068 | NCT06580314 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05554328 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT05564377 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT04858334 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT06580314 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05554328 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT05564377 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT04858334 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT06580314 | Map |
| IL | Methodist Medical Center of Illinois | Peoria61636 | NCT06580314 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05554328 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT05564377 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT04858334 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT06580314 | Map |
| IL | Valley Radiation Oncology | Peru61354 | NCT06580314 | Map |
| IL | Edward Hospital/Cancer Center?Plainfield | Plainfield60585 | NCT04858334 | Map |
| IL | Edward Hospital/Cancer Center?Plainfield | Plainfield60585 | NCT06580314 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05554328 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT05564377 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT04858334 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT06580314 | Map |
| IL | Mercyhealth Cancer Institute - Rockford | Rockford61114 | NCT05564377 | Map |
| IL | UW Health Carbone Cancer Center Rockford | Rockford61114 | NCT06580314 | Map |
| IL | Memorial Hospital East | Shiloh62269 | NCT05564377 | Map |
| IL | Orchard Healthcare Research Inc. ( Site 0006) | Skokie60077 | NCT06797635 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05554328 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT05564377 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT04858334 | Map |
| IL | Southern Illinois University School of Medicine | Springfield62702 | NCT06580314 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05554328 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT05564377 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT04858334 | Map |
| IL | Springfield Clinic | Springfield62702 | NCT06580314 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05554328 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT05564377 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT04858334 | Map |
| IL | Springfield Memorial Hospital | Springfield62781 | NCT06580314 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05554328 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT05564377 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT04858334 | Map |
| IL | Carle Cancer Center | Urbana61801 | NCT06580314 | Map |
| IL | Northwestern Medicine Cancer Center Warrenville | Warrenville60555 | NCT05564377 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05554328 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT05564377 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT04858334 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT06580314 | Map |
| IL | Rush-Copley Healthcare Center | Yorkville60560 | NCT06580314 | Map |
| IN | IU Health North Hospital | Carmel46032 | NCT06580314 | Map |
| IN | Northwest Cancer Center - Main Campus | Crown Point46307 | NCT06580314 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT05554328 | Map |
| IN | UChicago Medicine Northwest Indiana | Crown Point46307 | NCT06580314 | Map |
| IN | Northwest Oncology LLC | Dyer46311 | NCT06580314 | Map |
| IN | Fort Wayne Medical Oncology and Hematology ( Site 0084) | Fort Wayne46804 | NCT06966700 | Map |
| IN | Parkview Regional Medical Center | Fort Wayne46845 | NCT06580314 | Map |
| IN | Goshen Center for Cancer Care | Goshen46526 | NCT06580314 | Map |
| IN | Northwest Cancer Center - Hobart | Hobart46342 | NCT06580314 | Map |
| IN | Saint Mary Medical Center | Hobart46342 | NCT06580314 | Map |
| IN | Ascension Saint Vincent Indianapolis Hospital | Indianapolis46260 | NCT06580314 | Map |
| IN | Community Health Network | Indianapolis46250 | NCT06785636 | Map |
| IN | Community Health Network (The University of Texas MD Anderson Cancer Center) | Indianapolis46250 | NCT02693535 | Map |
| IN | Franciscan Health ( Site 0077) | Indianapolis46237 | NCT06966700 | Map |
| IN | Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis46202 | NCT04711824 | Map |
| IN | Indiana University/Melvin and Bren Simon Cancer Center | Indianapolis46202 | NCT06580314 | Map |
| IN | Saint Catherine Hospital | Indianapolis46312 | NCT06580314 | Map |
| IN | Sidney and Lois Eskenazi Hospital | Indianapolis46202 | NCT06580314 | Map |
| IN | Woodland Cancer Care Center | Michigan City46360 | NCT05564377 | Map |
| IN | The Community Hospital | Munster46321 | NCT06580314 | Map |
| IN | Women's Diagnostic Center - Munster | Munster46321 | NCT06580314 | Map |
| IN | Memorial Hospital of South Bend | South Bend46601 | NCT06580314 | Map |
| IN | Northwest Cancer Center - Valparaiso | Valparaiso46383 | NCT06580314 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT04858334 | Map |
| IA | Mary Greeley Medical Center | Ames50010 | NCT06580314 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT04858334 | Map |
| IA | McFarland Clinic - Ames | Ames50010 | NCT06580314 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05554328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT05564377 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT04858334 | Map |
| IA | Saint Anthony Regional Hospital | Carroll51401 | NCT04858334 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT05564377 | Map |
| IA | Mercy Hospital | Cedar Rapids52403 | NCT06580314 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT05564377 | Map |
| IA | Oncology Associates at Mercy Medical Center | Cedar Rapids52403 | NCT06580314 | Map |
| IA | Mercy Cancer Center-West Lakes | Clive50325 | NCT04858334 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT05554328 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT04858334 | Map |
| IA | Methodist Jennie Edmundson Hospital | Council Bluffs51503 | NCT06580314 | Map |
| IA | Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ | Council Bluffs51503 | NCT06580314 | Map |
| IA | Greater Regional Medical Center | Creston50801 | NCT04858334 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT04858334 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT04858334 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05554328 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT05564377 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT04858334 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05554328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT05564377 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT04858334 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05554328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT05564377 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT04858334 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT04858334 | Map |
| IA | McFarland Clinic - Trinity Cancer Center | Fort Dodge50501 | NCT06580314 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Fort Dodge | Fort Dodge50501 | NCT04858334 | Map |
| IA | University of Iowa Hospital and Clinics ( Site 0026) | Iowa City52242 | NCT03486873 | Map |
| IA | University of Iowa/Holden Comprehensive Cancer Center | Iowa City52242 | NCT06580314 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT04858334 | Map |
| IA | McFarland Clinic - Marshalltown | Marshalltown50158 | NCT06580314 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05554328 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT05564377 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT04858334 | Map |
| IA | Mercy Medical Center-West Lakes | West Des Moines50266 | NCT04858334 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT04633239 | Map |
| KS | Central Care Cancer Center - Garden City | Garden City67846 | NCT06580314 | Map |
| KS | Central Care Cancer Center - Great Bend | Great Bend67530 | NCT06580314 | Map |
| KS | HaysMed | Hays67601 | NCT04858334 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT04858334 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT04858334 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT04858334 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT04858334 | Map |
| KS | University of Kansas Hospital-Indian Creek Campus | Overland Park66211 | NCT04858334 | Map |
| KS | Freeman Physician Group of Pittsburg | Pittsburg66762 | NCT04858334 | Map |
| KS | Mercy Hospital Pittsburg | Pittsburg66762 | NCT06580314 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT04858334 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT04858334 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT04858334 | Map |
| KY | Flaget Memorial Hospital | Bardstown40004 | NCT06580314 | Map |
| KY | Baptist Health Corbin | Corbin40701 | NCT06580314 | Map |
| KY | Commonwealth Cancer Center-Corbin | Corbin40701 | NCT06580314 | Map |
| KY | Baptist Health Lexington | Lexington40503 | NCT06580314 | Map |
| KY | Saint Joseph Hospital | Lexington40504 | NCT06580314 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT05564377 | Map |
| KY | Saint Joseph Hospital East | Lexington40509 | NCT06580314 | Map |
| KY | Saint Joseph Radiation Oncology Resource Center | Lexington40504 | NCT06580314 | Map |
| KY | University of Kentucky | Lexington40536 | NCT05568550 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05554328 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT05564377 | Map |
| KY | Saint Joseph London | London40741 | NCT06580314 | Map |
| KY | Baptist Health Louisville | Louisville40207 | NCT06580314 | Map |
| KY | James Graham Brown Cancer Center ( Site 0058) | Louisville40202 | NCT03486873 | Map |
| KY | The James Graham Brown Cancer Center at University of Louisville | Louisville40202 | NCT06580314 | Map |
| KY | UofL Health Medical Center Northeast | Louisville40245 | NCT06580314 | Map |
| KY | Saint Joseph Mount Sterling | Mount Sterling40353 | NCT06580314 | Map |
| KY | Baptist Health Paducah | Paducah42003 | NCT06580314 | Map |
| KY | Mercy Health-Paducah Cancer Center ( Site 0084) | Paducah42003 | NCT03486873 | Map |
| LA | LSU Health Baton Rouge-North Clinic | Baton Rouge70805 | NCT06580314 | Map |
| LA | Mary Bird Perkins Cancer Center | Baton Rouge70809 | NCT04858334 | Map |
| LA | Our Lady of The Lake | Baton Rouge70808 | NCT06580314 | Map |
| LA | Our Lady of the Lake Medical Oncology | Baton Rouge70817 | NCT06580314 | Map |
| LA | Our Lady of the Lake Physician Group | Baton Rouge70808 | NCT06580314 | Map |
| LA | Women's Cancer Care ( Site 0088) | Covington70433 | NCT03486873 | Map |
| LA | Ochsner | Jefferson70121 | NCT06785636 | Map |
| LA | West Jefferson Medical Center | Marrero70072 | NCT06580314 | Map |
| LA | East Jefferson General Hospital | Metairie70006 | NCT06580314 | Map |
| LA | LSU Healthcare Network / Metairie Multi-Specialty Clinic | Metairie70006 | NCT06580314 | Map |
| LA | Ochsner Baptist Medical Center | New Orleans70115 | NCT05554328 | Map |
| LA | Ochsner Baptist Medical Center | New Orleans70115 | NCT06580314 | Map |
| LA | Ochsner Clinic Foundation ( Site 0021) | New Orleans70121 | NCT06966700 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT05554328 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT05564377 | Map |
| LA | Ochsner Medical Center Jefferson | New Orleans70121 | NCT06580314 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT06580314 | Map |
| LA | Louisiana State University Health Sciences Shreveport ( Site 0053) | Shreveport71103 | NCT06966700 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT02693535 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT05554328 | Map |
| ME | Harold Alfond Center for Cancer Care | Augusta04330 | NCT05564377 | Map |
| ME | Jackson Laboratory - Maine Cancer Genomics Initiative | Augusta04330 | NCT02693535 | Map |
| ME | Waldo County General Hospital | Belfast04915 | NCT02693535 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Biddeford | Biddeford04005 | NCT02693535 | Map |
| ME | Lafayette Family Cancer Center-EMMC | Brewer04412 | NCT05554328 | Map |
| ME | Lafayette Family Cancer Center-EMMC | Brewer04412 | NCT05564377 | Map |
| ME | Northern Light Cancer Care | Brewer04412 | NCT02693535 | Map |
| ME | Raish Peavey Haskell Children's Cancer and Treatment Center | Brewer04412 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -Brunswick | Brunswick04011 | NCT02693535 | Map |
| ME | New England Cancer Specialist | Kennebunk04043 | NCT02693535 | Map |
| ME | York Hopsital Oncology & Infusion Care in Kittery | Kittery03904 | NCT02693535 | Map |
| ME | Stephens Memorial Hospital | Norway04268 | NCT02693535 | Map |
| ME | Penobscot Bay Medical Center | Rockport04856 | NCT02693535 | Map |
| ME | SMHC Cancer Care and Blood Disorders -Sandford | Sanford04073 | NCT02693535 | Map |
| ME | Maine Children's Cancer Program | Scarborough04074 | NCT02693535 | Map |
| ME | Maine Medical Partner's Women's Health | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05554328 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT05564377 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT06580314 | Map |
| ME | New England Cancer Specialist | Scarborough04074 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care -South Portland | South Portland04106 | NCT02693535 | Map |
| ME | MaineHealth Cancer Care and IV Therapy - South Portland | South Portland04106 | NCT05564377 | Map |
| ME | New England Cancer Specialist | Topsham04086 | NCT02693535 | Map |
| ME | York Hospital Oncology & Infusion Care in Wells | Wells04090 | NCT02693535 | Map |
| ME | New England Cancer Specialists ( Site 0051) | Westbrook04092 | NCT06966700 | Map |
| ME | York Hospital Oncology & Infusion Care in York | York Village03909 | NCT02693535 | Map |
| MD | Johns Hopkins Hospital | Baltimore21287 | NCT06785636 | Map |
| MD | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore21287 | NCT05498272 | Map |
| MD | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore21228 | NCT03786796 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT06580314 | Map |
| MD | MedStar Franklin Square Medical Center ( Site 0046) | Baltimore21237 | NCT03486873 | Map |
| MD | Mercy Medical Center - Baltimore ( Site 0015) | Baltimore21202 | NCT06966700 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore21287 | NCT06245889 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore21287 | NCT06245889 | Map |
| MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 0056) | Baltimore21287 | NCT03486873 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT05554328 | Map |
| MD | University of Maryland/Greenebaum Cancer Center | Baltimore21201 | NCT05564377 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05554328 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT05564377 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT04086485 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT05554328 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT05564377 | Map |
| MD | Walter Reed National Military Medical Center | Bethesda20889-5600 | NCT06580314 | Map |
| MD | Maryland Oncology Hematology (MOH) ( Site 8000) | Columbia21044 | NCT03486873 | Map |
| MD | UPMC Western Maryland | Cumberland21502 | NCT05554328 | Map |
| MD | UPMC Western Maryland | Cumberland21502 | NCT05564377 | Map |
| MD | Christiana Care - Union Hospital | Elkton21921 | NCT06580314 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05463848 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06488378 | Map |
| MA | Brigham and Women's Hospital | Boston02215 | NCT06488378 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05463848 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05564377 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT04585958 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT06488378 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT05463848 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05554328 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05564377 | Map |
| MA | Baystate Medical Center | Springfield01199 | NCT05554328 | Map |
| MA | Baystate Medical Center | Springfield01199 | NCT05564377 | Map |
| MA | Baystate Medical Center | Springfield01199 | NCT06580314 | Map |
| MA | Tufts Medical Center Cancer Center Stoneham | Stoneham02180 | NCT05554328 | Map |
| MA | Tufts Medical Center Cancer Center Stoneham | Stoneham02180 | NCT05564377 | Map |
| MI | MyMichigan Medical Center Gratiot | Alma48801 | NCT06580314 | Map |
| MI | MyMichigan Medical Center Alpena | Alpena49707 | NCT06580314 | Map |
| MI | Trinity Health Ann Arbor Hospital | Ann Arbor48106 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05554328 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT05564377 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT04858334 | Map |
| MI | Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor48106 | NCT06580314 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05554328 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT05564377 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT04858334 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT06580314 | Map |
| MI | VA Ann Arbor Healthcare System, Ann Arbor, MI | Ann Arbor48105 | NCT04038502 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT05564377 | Map |
| MI | Bronson Battle Creek | Battle Creek49017 | NCT06580314 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05554328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT05564377 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT04858334 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton48114 | NCT06580314 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05554328 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT05564377 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT04858334 | Map |
| MI | Trinity Health Medical Center - Brighton | Brighton48114 | NCT06580314 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT05554328 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT05564377 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT06580314 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05554328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT05564377 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT04858334 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton48188 | NCT06580314 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05554328 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT05564377 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT04858334 | Map |
| MI | Trinity Health Medical Center - Canton | Canton48188 | NCT06580314 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05554328 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT05564377 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT04858334 | Map |
| MI | Chelsea Hospital | Chelsea48118 | NCT06580314 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05554328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT05564377 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT04858334 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea48118 | NCT06580314 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT04858334 | Map |
| MI | Hematology Oncology Consultants-Clarkston | Clarkston48346 | NCT06580314 | Map |
| MI | Newland Medical Associates-Clarkston | Clarkston48346 | NCT06580314 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05554328 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT05564377 | Map |
| MI | Corewell Health Dearborn Hospital | Dearborn48124 | NCT04858334 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT02693535 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT04858334 | Map |
| MI | Henry Ford Health Saint John Hospital | Detroit48236 | NCT06580314 | Map |
| MI | Karmanos Cancer Institute | Detroit48201 | NCT06785636 | Map |
| MI | Karmanos Cancer Institute ( Site 0047) | Detroit48201 | NCT03486873 | Map |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT04858334 | — |
| MI | Henry Ford River District Hospital | East China Township48054 | NCT06580314 | — |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT05564377 | Map |
| MI | OSF Saint Francis Hospital and Medical Group | Escanaba49829 | NCT06580314 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05554328 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT05564377 | Map |
| MI | Corewell Health Farmington Hills Hospital | Farmington Hills48336 | NCT04858334 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05554328 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT05564377 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT04858334 | Map |
| MI | Cancer Hematology Centers - Flint | Flint48503 | NCT06580314 | Map |
| MI | Genesee Hematology Oncology PC | Flint48503 | NCT06580314 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT02693535 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05554328 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT05564377 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT04858334 | Map |
| MI | Genesys Hurley Cancer Institute | Flint48503 | NCT06580314 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05554328 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT05564377 | Map |
| MI | Hurley Medical Center | Flint48503 | NCT06580314 | Map |
| MI | MyMichigan Medical Center Gladwin | Gladwin48624 | NCT06580314 | Map |
| MI | Cancer Research Consortium of West Michigan | Grand Rapids49503 | NCT02693535 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT05564377 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Butterworth Hospital | Grand Rapids49503 | NCT06580314 | Map |
| MI | Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital | Grand Rapids49503 | NCT06580314 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT05564377 | Map |
| MI | Trinity Health Grand Rapids Hospital | Grand Rapids49503 | NCT06580314 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT04858334 | Map |
| MI | Henry Ford Saint John Hospital - Academic | Grosse Pointe Woods48236 | NCT06580314 | Map |
| MI | Henry Ford Saint John Hospital - Breast | Grosse Pointe Woods48236 | NCT06580314 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT04858334 | Map |
| MI | Henry Ford Saint John Hospital - Van Elslander | Grosse Pointe Woods48236 | NCT06580314 | Map |
| MI | Beacon Kalamazoo | Kalamazoo49048 | NCT05564377 | Map |
| MI | Beacon Kalamazoo | Kalamazoo49048 | NCT06580314 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT05564377 | Map |
| MI | Beacon Kalamazoo Cancer Center | Kalamazoo49009 | NCT06580314 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT05564377 | Map |
| MI | Bronson Methodist Hospital | Kalamazoo49007 | NCT06580314 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT05564377 | Map |
| MI | West Michigan Cancer Center | Kalamazoo49007 | NCT06580314 | Map |
| MI | Herbert-Herman Cancer Center, Sparrow Hospital | Lansing48912 | NCT01042379 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT02693535 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05554328 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT05564377 | Map |
| MI | University of Michigan Health - Sparrow Lansing | Lansing48912 | NCT06580314 | Map |
| MI | Trinity Health Livonia Hospital | Livonia48154 | NCT02693535 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05554328 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT05564377 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT04858334 | Map |
| MI | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia48154 | NCT06580314 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT05554328 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT05564377 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT04858334 | Map |
| MI | Henry Ford Saint John Hospital - Macomb Medical | Macomb48044 | NCT06580314 | Map |
| MI | Henry Ford Warren Hospital - Breast Macomb | Macomb48044 | NCT06580314 | Map |
| MI | MyMichigan Medical Center Midland | Midland48670 | NCT06580314 | Map |
| MI | MyMichigan Medical Center Mount Pleasant | Mount Pleasant48858 | NCT06580314 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT05564377 | Map |
| MI | Trinity Health Muskegon Hospital | Muskegon49444 | NCT06580314 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT05564377 | Map |
| MI | Corewell Health Lakeland Hospitals - Niles Hospital | Niles49120 | NCT06580314 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT05564377 | Map |
| MI | Cancer and Hematology Centers of Western Michigan - Norton Shores | Norton Shores49444 | NCT06580314 | Map |
| MI | Henry Ford Health Providence Novi Hospital | Novi48374 | NCT04858334 | Map |
| MI | Hope Cancer Center | Pontiac48341 | NCT06580314 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT05564377 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT04858334 | Map |
| MI | Michigan Healthcare Professionals Pontiac | Pontiac48341 | NCT06580314 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT04858334 | Map |
| MI | Newland Medical Associates-Pontiac | Pontiac48341 | NCT06580314 | Map |
| MI | Trinity Health Oakland Hospital | Pontiac48341 | NCT02693535 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05554328 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT05564377 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT04858334 | Map |
| MI | Trinity Health Saint Joseph Mercy Oakland Hospital | Pontiac48341 | NCT06580314 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT05564377 | Map |
| MI | Corewell Health Reed City Hospital | Reed City49677 | NCT06580314 | Map |
| MI | Corewell Health Children's | Royal Oak48073 | NCT05564377 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05554328 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT05564377 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT04858334 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT02693535 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT05564377 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT04858334 | Map |
| MI | MyMichigan Medical Center Saginaw | Saginaw48601 | NCT06580314 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT05564377 | Map |
| MI | Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center | Saint Joseph49085 | NCT06580314 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT05564377 | Map |
| MI | Corewell Health Lakeland Hospitals - Saint Joseph Hospital | Saint Joseph49085 | NCT06580314 | Map |
| MI | Henry Ford Health Providence Southfield Hospital | Southfield48075 | NCT04858334 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT05564377 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT04858334 | Map |
| MI | MyMichigan Medical Center Tawas | Tawas City48764 | NCT06580314 | Map |
| MI | Michigan Cancer Research Consortium | Traverse City48341 | NCT02693535 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT05564377 | Map |
| MI | Munson Medical Center | Traverse City49684 | NCT06580314 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05554328 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT05564377 | Map |
| MI | Corewell Health Beaumont Troy Hospital | Troy48085 | NCT04858334 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT02693535 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT04858334 | Map |
| MI | Henry Ford Health Warren Hospital | Warren48093 | NCT06580314 | Map |
| MI | Henry Ford Madison Heights Hospital - Breast | Warren48093 | NCT06580314 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT04858334 | Map |
| MI | Henry Ford Warren Hospital - GLCMS | Warren48093 | NCT06580314 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT05564377 | Map |
| MI | University of Michigan Health - West | Wyoming49519 | NCT06580314 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05554328 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT05564377 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT04858334 | Map |
| MI | Huron Gastroenterology PC | Ypsilanti48106 | NCT06580314 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05554328 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT05564377 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT04858334 | Map |
| MI | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti48197 | NCT06580314 | Map |
| MN | Riverwood Healthcare Center | Aitkin56431 | NCT06580314 | Map |
| MN | Essentia Health - Baxter Clinic | Baxter56425 | NCT06580314 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT05564377 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT04858334 | Map |
| MN | Sanford Joe Lueken Cancer Center | Bemidji56601 | NCT06580314 | Map |
| MN | Essentia Health Saint Joseph's Medical Center | Brainerd56401 | NCT06580314 | Map |
| MN | Minnesota Oncology - Burnsville | Burnsville55337 | NCT06580314 | Map |
| MN | Cambridge Medical Center | Cambridge55008 | NCT06580314 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05554328 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT05564377 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT04858334 | Map |
| MN | Mercy Hospital | Coon Rapids55433 | NCT06580314 | Map |
| MN | Essentia Health - Saint Joseph's Crosslake Clinic | Crosslake56442 | NCT06580314 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05554328 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT05564377 | Map |
| MN | Essentia Health - Deer River Clinic | Deer River56636 | NCT06580314 | Map |
| MN | Essentia Health Saint Mary's - Detroit Lakes Clinic | Detroit Lakes56501 | NCT06580314 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05554328 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT05564377 | Map |
| MN | Essentia Health Cancer Center | Duluth55805 | NCT06580314 | Map |
| MN | Essentia Health Saint Mary's Medical Center | Duluth55805 | NCT06580314 | Map |
| MN | Miller-Dwan Hospital | Duluth55805 | NCT06580314 | Map |
| MN | Saint Luke's Hospital of Duluth | Duluth55805 | NCT04858334 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05554328 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT05564377 | Map |
| MN | Fairview Southdale Hospital | Edina55435 | NCT06580314 | Map |
| MN | Essentia Health - Ely Clinic | Ely55731 | NCT06580314 | Map |
| MN | Essentia Health - Fosston | Fosston56542 | NCT06580314 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05554328 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT05564377 | Map |
| MN | Essentia Health Hibbing Clinic | Hibbing55746 | NCT06580314 | Map |
| MN | Essentia Health - International Falls Clinic | International Falls56649 | NCT06580314 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05554328 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT05564377 | Map |
| MN | Fairview Clinics and Surgery Center Maple Grove | Maple Grove55369 | NCT06580314 | Map |
| MN | Minnesota Oncology Hematology PA-Maplewood | Maplewood55109 | NCT06580314 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT05564377 | Map |
| MN | Saint John's Hospital - Healtheast | Maplewood55109 | NCT06580314 | Map |
| MN | Avera Cancer Institute at Marshall | Marshall56258 | NCT06580314 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05554328 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT05564377 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT04858334 | Map |
| MN | Abbott-Northwestern Hospital | Minneapolis55407 | NCT06580314 | Map |
| MN | Health Partners Inc | Minneapolis55454 | NCT06580314 | Map |
| MN | Hennepin County Medical Center | Minneapolis55415 | NCT06580314 | Map |
| MN | Minneapolis VA Health Care System, Minneapolis, MN | Minneapolis55417-2309 | NCT04038502 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT01042379 | Map |
| MN | University of Minnesota/Masonic Cancer Center | Minneapolis55455 | NCT06580314 | Map |
| MN | Monticello Cancer Center | Monticello55362 | NCT06580314 | Map |
| MN | Essentia Health - Moose Lake Clinic | Moose Lake55767 | NCT06580314 | Map |
| MN | New Ulm Medical Center | New Ulm56073 | NCT06580314 | Map |
| MN | Essentia Health - Park Rapids | Park Rapids56470 | NCT06580314 | Map |
| MN | Essentia Health - Saint Joseph's Pequot Lakes Clinic | Pequot Lakes56472 | NCT06580314 | Map |
| MN | Essentia Health - Saint Joseph's Pine River Clinic | Pine River56474 | NCT06580314 | Map |
| MN | Fairview Northland Medical Center | Princeton55371 | NCT06580314 | Map |
| MN | North Memorial Medical Health Center | Robbinsdale55422 | NCT06580314 | Map |
| MN | Exelixis Clinical Site #14 | Rochester55905 | NCT05932862 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT01042379 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05554328 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT05564377 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT04633239 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT04585958 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06580314 | Map |
| MN | Mayo Clinic in Rochester, Minnesota ( Site 0002) | Rochester55905 | NCT03486873 | Map |
| MN | Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center | Saint Louis Park55416 | NCT01042379 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05554328 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT05564377 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT04858334 | Map |
| MN | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park55416 | NCT06580314 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05554328 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT05564377 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT04858334 | Map |
| MN | Regions Hospital | Saint Paul55101 | NCT06580314 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05554328 | Map |
| MN | United Hospital | Saint Paul55102 | NCT05564377 | Map |
| MN | United Hospital | Saint Paul55102 | NCT04858334 | Map |
| MN | United Hospital | Saint Paul55102 | NCT06580314 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05554328 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT05564377 | Map |
| MN | Essentia Health Sandstone | Sandstone55072 | NCT06580314 | Map |
| MN | Saint Francis Regional Medical Center | Shakopee55379 | NCT06580314 | Map |
| MN | Essentia Health - Saint Joseph's Staples Clinic | Staples56479 | NCT06580314 | Map |
| MN | Lakeview Hospital | Stillwater55082 | NCT06580314 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05554328 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT05564377 | Map |
| MN | Essentia Health Virginia Clinic | Virginia55792 | NCT06580314 | Map |
| MN | Ridgeview Medical Center | Waconia55387 | NCT06580314 | Map |
| MN | Rice Memorial Hospital | Willmar56201 | NCT06580314 | Map |
| MN | Minnesota Oncology Hematology PA-Woodbury | Woodbury55125 | NCT06580314 | Map |
| MN | Fairview Lakes Medical Center | Wyoming55092 | NCT06580314 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT05564377 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus39705 | NCT04858334 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT05564377 | Map |
| MS | Baptist Cancer Center-Grenada | Grenada38901 | NCT04858334 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT05564377 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Union County | New Albany38652 | NCT04858334 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT05564377 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Oxford | Oxford38655 | NCT04858334 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT05564377 | Map |
| MS | Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven38671 | NCT04858334 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT04858334 | Map |
| MO | Mercy Oncology and Hematology - Clayton-Clarkson | Ballwin63011 | NCT06580314 | Map |
| MO | Central Care Cancer Center - Bolivar | Bolivar65613 | NCT06580314 | Map |
| MO | Cox Cancer Center Branson | Branson65616 | NCT06580314 | Map |
| MO | Mercy Cancer Center - Cape Girardeau | Cape Girardeau63703 | NCT06580314 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05554328 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT05564377 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT04858334 | Map |
| MO | Saint Francis Medical Center | Cape Girardeau63703 | NCT06580314 | Map |
| MO | Saint Luke's Hospital | Chesterfield63017 | NCT05564377 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT05564377 | Map |
| MO | MU Health - University Hospital/Ellis Fischel Cancer Center | Columbia65212 | NCT06580314 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT05564377 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05554328 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT05564377 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT04858334 | Map |
| MO | Parkland Health Center - Farmington | Farmington63640 | NCT06580314 | Map |
| MO | Freeman Health System | Joplin64804 | NCT06580314 | Map |
| MO | Mercy Hospital Joplin | Joplin64804 | NCT06580314 | Map |
| MO | Kansas City VA Medical Center, Kansas City, MO | Kansas City64128 | NCT04038502 | Map |
| MO | Saint Luke's Cancer Institute ( Site 0059) | Kansas City64111 | NCT06966700 | Map |
| MO | Saint Luke's Hospital of Kansas City | Kansas City64111 | NCT04858334 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT04858334 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT04858334 | Map |
| MO | Saint Luke's East - Lee's Summit | Lee's Summit64086 | NCT04858334 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT04858334 | Map |
| MO | Lake Regional Hospital | Osage Beach65065 | NCT06580314 | Map |
| MO | Mercy Clinic-Rolla-Cancer and Hematology | Rolla65401 | NCT06580314 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT05564377 | Map |
| MO | Phelps Health Delbert Day Cancer Institute | Rolla65401 | NCT06580314 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT05564377 | Map |
| MO | Heartland Regional Medical Center | Saint Joseph64506 | NCT06580314 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05554328 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT05564377 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT04858334 | Map |
| MO | Sainte Genevieve County Memorial Hospital | Sainte Genevieve63670 | NCT06580314 | Map |
| MO | CoxHealth South Hospital | Springfield65807 | NCT06580314 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT05564377 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT04858334 | Map |
| MO | Mercy Hospital Springfield | Springfield65804 | NCT06580314 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT05564377 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT04858334 | Map |
| MO | Mercy Hospital Saint Louis | St Louis63141 | NCT06580314 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT05564377 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT04858334 | Map |
| MO | Mercy Hospital South | St Louis63128 | NCT06580314 | Map |
| MO | Mercy Infusion Center - Chippewa | St Louis63109 | NCT06580314 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05554328 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT05564377 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT04858334 | Map |
| MO | Missouri Baptist Medical Center | St Louis63131 | NCT06580314 | Map |
| MO | Siteman Cancer Center | St Louis63108 | NCT06785636 | Map |
| MO | Siteman Cancer Center at Christian Hospital | St Louis63136 | NCT05564377 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05564377 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05554328 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05564377 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT06580314 | Map |
| MO | Washington University School of Medicine in St. Louis | St Louis63110 | NCT06915025 | Map |
| MO | Washington University Siteman Cancer Center ( Site 0031) | St Louis63110 | NCT06966700 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05554328 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT05564377 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT04858334 | Map |
| MO | Missouri Baptist Sullivan Hospital | Sullivan63080 | NCT06580314 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05554328 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT05564377 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT04858334 | Map |
| MO | BJC Outpatient Center at Sunset Hills | Sunset Hills63127 | NCT06580314 | Map |
| MO | Mercy Hospital Washington | Washington63090 | NCT06580314 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05554328 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT05564377 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT04858334 | Map |
| MT | Community Hospital of Anaconda | Anaconda59711 | NCT06580314 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05554328 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT05564377 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT04858334 | Map |
| MT | Billings Clinic Cancer Center | Billings59101 | NCT06580314 | Map |
| MT | Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003) | Billings59102 | NCT06797635 | Map |
| MT | Intermountain Health West End Clinic | Billings59106 | NCT06580314 | Map |
| MT | Saint Vincent Frontier Cancer Center | Billings59102 | NCT06580314 | Map |
| MT | Saint Vincent Healthcare | Billings59101 | NCT06580314 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05554328 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT05564377 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT04858334 | Map |
| MT | Bozeman Health Deaconess Hospital | Bozeman59715 | NCT06580314 | Map |
| MT | Saint James Community Hospital and Cancer Treatment Center | Butte59701 | NCT06580314 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05554328 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT05564377 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT04858334 | Map |
| MT | Benefis Sletten Cancer Institute | Great Falls59405 | NCT06580314 | Map |
| MT | Great Falls Clinic | Great Falls59405 | NCT06580314 | Map |
| MT | Hi-Line Sletten Cancer Center | Havre59501 | NCT06580314 | Map |
| MT | Benefis Helena Specialty Center | Helena59601 | NCT06580314 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05554328 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT05564377 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT04858334 | Map |
| MT | Logan Health Medical Center | Kalispell59901 | NCT06580314 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05554328 | Map |
| MT | Community Medical Center | Missoula59804 | NCT05564377 | Map |
| MT | Community Medical Center | Missoula59804 | NCT04858334 | Map |
| MT | Community Medical Center | Missoula59804 | NCT06580314 | Map |
| MT | Saint Patrick Hospital - Community Hospital | Missoula59802 | NCT06580314 | Map |
| NE | CHI Health Saint Francis | Grand Island68803 | NCT06580314 | Map |
| NE | CHI Health Good Samaritan | Kearney68847 | NCT06580314 | Map |
| NE | Cancer Partners of Nebraska ( Site 0068) | Lincoln68516 | NCT06966700 | Map |
| NE | Alegent Health Bergan Mercy Medical Center | Omaha68124 | NCT06580314 | Map |
| NE | Alegent Health Immanuel Medical Center | Omaha68122 | NCT06580314 | Map |
| NE | Alegent Health Lakeside Hospital | Omaha68130 | NCT06580314 | Map |
| NE | Creighton University Medical Center | Omaha68131 | NCT06580314 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT06785636 | Map |
| NE | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha68114 | NCT04858334 | Map |
| NE | Nebraska Cancer Specialists/Oncology Hematology West PC - MECC | Omaha68114 | NCT06580314 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT04858334 | Map |
| NE | Nebraska Methodist Hospital | Omaha68114 | NCT06580314 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT02693535 | Map |
| NV | Alliance for Childhood Diseases/Cure 4 the Kids Foundation | Las Vegas89135 | NCT05564377 | Map |
| NV | Comprehensive Cancer Centers of Nevada ( Site 0043) | Las Vegas89169 | NCT03486873 | Map |
| NV | Optum Care Cancer Center ( Site 0050) | Las Vegas89102 | NCT06966700 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05554328 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT05564377 | Map |
| NV | OptumCare Cancer Care at Charleston | Las Vegas89102 | NCT04858334 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05554328 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT05564377 | Map |
| NV | OptumCare Cancer Care at Fort Apache | Las Vegas89183 | NCT04858334 | Map |
| NV | Summerlin Hospital Medical Center | Las Vegas89144 | NCT05564377 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT04858334 | Map |
| NV | Renown Regional Medical Center ( Site 0041) | Reno89502 | NCT06966700 | Map |
| NH | NH Oncology - Hematology, PA | Concord03103 | NCT02693535 | Map |
| NH | Dartmouth Cancer Center | Lebanon03756 | NCT05900895 | Map |
| NH | Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center | Lebanon03756 | NCT04858334 | Map |
| NH | Solinsky Center for Cancer Care | Manchester03103 | NCT02693535 | Map |
| NH | New England Cancer Specialist | Portsmouth03801 | NCT02693535 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT04858334 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT06580314 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT04683679 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT05188508 | Map |
| NJ | Summit Medical Group | Berkeley Heights07922 | NCT06580314 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT04858334 | Map |
| NJ | Cooper Hospital University Medical Center | Camden08103 | NCT06580314 | Map |
| NJ | Hunterdon Medical Center | Flemington08822 | NCT05564377 | Map |
| NJ | Summit Health - Florham Park Campus | Florham Park07932 | NCT06580314 | Map |
| NJ | Hackensack Univ Medical Center (HUMC) ( Site 0007) | Hackensack07601 | NCT06966700 | Map |
| NJ | The Cancer Institute of New Jersey Hamilton | Hamilton08690 | NCT06580314 | Map |
| NJ | Jersey City Medical Center | Jersey City07302 | NCT05554328 | Map |
| NJ | Jersey City Medical Center | Jersey City07302 | NCT06580314 | Map |
| NJ | Monmouth Medical Center Southern Campus | Lakewood08701 | NCT05554328 | Map |
| NJ | Monmouth Medical Center Southern Campus | Lakewood08701 | NCT05564377 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT05564377 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05554328 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT05564377 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05554328 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT05564377 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT04858334 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT06580314 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT04683679 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT05188508 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT04858334 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT06580314 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT04683679 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT05188508 | Map |
| NJ | Cancer Institute of New Jersey ( Site 0025) | New Brunswick08901 | NCT03486873 | Map |
| NJ | Exelixis Clinical Site #9 | New Brunswick08901 | NCT05932862 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05554328 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT05564377 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT01042379 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT06580314 | Map |
| NJ | Rutgers Cancer Institute of New Jersey ( Site 0076) | New Brunswick08901 | NCT06966700 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT05554328 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT05564377 | Map |
| NJ | Sidney Kimmel Cancer Center Washington Township | Sewell08080 | NCT06580314 | Map |
| NJ | Robert Wood Johnson University Hospital Somerset | Somerville08876 | NCT05564377 | Map |
| NJ | Robert Wood Johnson University Hospital Somerset | Somerville08876 | NCT06580314 | Map |
| NJ | Holy Name Medical Center /ID# 279017 | Teaneck07666 | NCT07024784 | Map |
| NJ | Community Medical Center | Toms River08755 | NCT05564377 | Map |
| NJ | MD Anderson Cancer Center at Cooper-Voorhees | Voorhees Township08043 | NCT04858334 | Map |
| NM | Lovelace Medical Center - Saint Joseph Square | Albuquerque87102 | NCT02693535 | Map |
| NM | Presbyterian Kaseman Hospital | Albuquerque87110 | NCT02693535 | Map |
| NM | The University of New Mexico Comprehensive Cancer Center | Albuquerque87131 | NCT02693535 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05554328 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT05564377 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT04858334 | Map |
| NM | University of New Mexico Cancer Center | Albuquerque87106 | NCT06580314 | Map |
| NM | Memorial Medical Center | Las Cruces88011 | NCT02693535 | Map |
| NM | Presbyterian Rust Medical Center | Rio Rancho87124 | NCT02693535 | Map |
| NY | NYU Langone Hospital - Brooklyn | Brooklyn11220 | NCT06580314 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05554328 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT05564377 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT04858334 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT01042379 | Map |
| NY | Roswell Park Cancer Institute | Buffalo14263 | NCT06580314 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05554328 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT05564377 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT04858334 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT06580314 | Map |
| NY | Memorial Sloan Kettering Commack (Limited Protocol Activities) | Commack11725 | NCT04683679 | Map |
| NY | Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities) | Commack11725 | NCT05188508 | Map |
| NY | Glens Falls Hospital | Glens Falls12801 | NCT06580314 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05554328 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT05564377 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT04858334 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT06580314 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT04683679 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT05188508 | Map |
| NY | Northwell Health Monter Cancer Center | Lake Success11042 | NCT02693535 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT04858334 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05564377 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT04858334 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT06580314 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT02693535 | Map |
| NY | Cohen Children's Medical Center | New Hyde Park11040 | NCT02693535 | Map |
| NY | Bellevue Hospital Center | New York10016 | NCT06580314 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT05498272 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT01042379 | Map |
| NY | Exelixis Clinical Site #5 | New York10029 | NCT05932862 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center / NYU Langone Health | New York10016 | NCT01042379 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05564377 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT04858334 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT06580314 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032) | New York10016 | NCT03486873 | Map |
| NY | Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY | New York10010 | NCT04038502 | Map |
| NY | Manhattan Eye, Ear, and Throat Hospital | New York10065 | NCT02693535 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05463848 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05498272 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05554328 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05564377 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04711824 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT04858334 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06580314 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT04683679 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT05188508 | Map |
| NY | Mount Sinai Chelsea | New York10011 | NCT06580314 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT05564377 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT06580314 | Map |
| NY | Mount Sinai West | New York10019 | NCT06580314 | Map |
| NY | Staten Island University Hospital | New York10305 | NCT02693535 | Map |
| NY | Queens Cancer Center | Rego Park11374 | NCT02693535 | Map |
| NY | Rochester General Hospital | Rochester14621 | NCT04858334 | Map |
| NY | Unity Park Ridge Campus | Rochester14626 | NCT04858334 | Map |
| NY | University of Rochester | Rochester14642 | NCT06580314 | Map |
| NY | University of Rochester Wilmot Cancer Institute | Rochester14642 | NCT01042379 | Map |
| NY | Phelps Hospital | Sleepy Hollow10591 | NCT02693535 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05554328 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT05564377 | Map |
| NY | State University of New York Upstate Medical University | Syracuse13210 | NCT06580314 | Map |
| NY | Montefiore Medical Center | The Bronx10467 | NCT01042379 | Map |
| NY | Montefiore Medical Center - Moses Campus | The Bronx10467 | NCT05564377 | Map |
| NY | Montefiore Medical Center-Einstein Campus | The Bronx10461 | NCT05564377 | Map |
| NY | Montefiore Medical Center-Weiler Hospital | The Bronx10461 | NCT05564377 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT04858334 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT06580314 | Map |
| NY | Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale11553 | NCT04683679 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT05188508 | Map |
| NY | Wilmot Cancer Institute at Webster | Webster14580 | NCT06580314 | Map |
| NY | White Plains Hospital-Center for Cancer Care ( Site 0069) | White Plains10601 | NCT03486873 | Map |
| NC | Cone Health MedCenter Asheboro | Asheboro27205 | NCT05554328 | Map |
| NC | Cone Health MedCenter Asheboro | Asheboro27205 | NCT05564377 | Map |
| NC | Hope Women's Cancer Centers-Asheville | Asheville28816 | NCT05554328 | Map |
| NC | Mission Hospital | Asheville28801 | NCT05554328 | Map |
| NC | Cone Health Cancer Center at Alamance Regional | Burlington27215 | NCT05554328 | Map |
| NC | Cone Health Cancer Center at Alamance Regional | Burlington27215 | NCT05564377 | Map |
| NC | WakeMed Cancer Care - Waverly Hematology & Medical Oncology ( Site 0074) | Cary27518 | NCT03486873 | Map |
| NC | Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT02693535 | Map |
| NC | UNC Lineberger Comprehensive Cancer Center | Chapel Hill27599 | NCT06580314 | Map |
| NC | University of North Carolina at Chapel Hill | Chapel Hill27899 | NCT04711824 | Map |
| NC | University of North Carolina at Chapel Hill ( Site 0040) | Chapel Hill27514 | NCT03486873 | Map |
| NC | Atrium Health's Levine Cancer Institute | Charlotte28277 | NCT02693535 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT05564377 | Map |
| NC | Southeastern Medical Oncology Center-Clinton | Clinton28328 | NCT04858334 | Map |
| NC | Duke Cancer Center ( Site 0028) | Durham27710 | NCT03486873 | Map |
| NC | Duke Cancer Institute | Durham27710 | NCT04711824 | Map |
| NC | Duke University medical center | Durham27710 | NCT06785636 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05554328 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05564377 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06580314 | Map |
| NC | Durham VA Medical Center, Durham, NC | Durham27705-3875 | NCT04038502 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT05564377 | Map |
| NC | Southeastern Medical Oncology Center-Goldsboro | Goldsboro27534 | NCT04858334 | Map |
| NC | Cone Health Cancer Center | Greensboro27403 | NCT05554328 | Map |
| NC | Cone Health Cancer Center | Greensboro27403 | NCT05564377 | Map |
| NC | Cone Health Cancer Center at Drawbridge Parkway | Greensboro27410 | NCT05554328 | Map |
| NC | Cone Health Cancer Center at Drawbridge Parkway | Greensboro27410 | NCT05564377 | Map |
| NC | Hayworth Cancer Center | High Point27262 | NCT05564377 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT05564377 | Map |
| NC | Southeastern Medical Oncology Center-Jacksonville | Jacksonville28546 | NCT04858334 | Map |
| NC | Duke Women's Cancer Care Raleigh | Raleigh27607 | NCT05554328 | Map |
| NC | Duke Women's Cancer Care Raleigh | Raleigh27607 | NCT05564377 | Map |
| NC | Duke Women's Cancer Care Raleigh | Raleigh27607 | NCT06580314 | Map |
| NC | Annie Penn Memorial Hospital | Reidsville27320 | NCT05554328 | Map |
| NC | Annie Penn Memorial Hospital | Reidsville27320 | NCT05564377 | Map |
| NC | Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT01042379 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT05564377 | Map |
| NC | Wake Forest University Health Sciences | Winston-Salem27157 | NCT04633239 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05554328 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT05564377 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT04858334 | Map |
| ND | Sanford Bismarck Medical Center | Bismarck58501 | NCT06580314 | Map |
| ND | Sanford Health- Bismarck | Bismarck58501 | NCT02693535 | Map |
| ND | Essentia Health Cancer Center-South University Clinic | Fargo58103 | NCT06580314 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05554328 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT05564377 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT04858334 | Map |
| ND | Sanford Broadway Medical Center | Fargo58122 | NCT06580314 | Map |
| ND | Sanford Health- Fargo | Fargo58122 | NCT02693535 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05554328 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT05564377 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT04858334 | Map |
| ND | Sanford Roger Maris Cancer Center | Fargo58122 | NCT06580314 | Map |
| ND | Altru Health System ( Site 0057) | Grand Forks58201 | NCT06966700 | Map |
| ND | Essentia Health - Jamestown Clinic | Jamestown58401 | NCT06580314 | Map |
| OH | OhioHealth O'Bleness Hospital | Athens45701 | NCT05564377 | Map |
| OH | OhioHealth O'Bleness Hospital | Athens45701 | NCT06580314 | Map |
| OH | UH Seidman Cancer Center at UH Avon Health Center | Avon44011 | NCT05554328 | Map |
| OH | UH Seidman Cancer Center at UH Avon Health Center | Avon44011 | NCT05564377 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT05554328 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT05564377 | Map |
| OH | UHHS-Chagrin Highlands Medical Center | Beachwood44122 | NCT06580314 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT05554328 | Map |
| OH | Strecker Cancer Center-Belpre | Belpre45714 | NCT05564377 | Map |
| OH | Aultman Health Foundation | Canton44710 | NCT05554328 | Map |
| OH | Aultman Health Foundation | Canton44710 | NCT05564377 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05554328 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT05564377 | Map |
| OH | Miami Valley Hospital South | Centerville45459 | NCT04858334 | Map |
| OH | Geauga Hospital | Chardon44024 | NCT06580314 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT05554328 | Map |
| OH | Adena Regional Medical Center | Chillicothe45601 | NCT05564377 | Map |
| OH | Bethesda North Hospital | Cincinnati45242 | NCT06580314 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT05564377 | Map |
| OH | Good Samaritan Hospital - Cincinnati | Cincinnati45220 | NCT06580314 | Map |
| OH | Good Samaritan Hospital-TriHealth Cancer institute ( Site 0027) | Cincinnati45220 | NCT06966700 | Map |
| OH | TriHealth Cancer Institute-Anderson | Cincinnati45255 | NCT06580314 | Map |
| OH | TriHealth Cancer Institute-Westside | Cincinnati45247 | NCT06580314 | Map |
| OH | University of Cincinnati | Cincinnati45229 | NCT05498272 | Map |
| OH | University of Cincinnati Medical Center | Cincinnati45219 | NCT02693535 | Map |
| OH | University of Cincinnati Medical Center. /ID# 278925 | Cincinnati45219 | NCT07024784 | Map |
| OH | Call for Information (Investigational Site 2091) | Cleveland44195 | NCT02861573 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05554328 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT05564377 | Map |
| OH | Case Western Reserve University | Cleveland44106 | NCT06580314 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT04711824 | Map |
| OH | Cleveland Clinic | Cleveland44106 | NCT01042379 | Map |
| OH | Cleveland Clinic Cancer Center/Fairview Hospital | Cleveland44111 | NCT06580314 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT05564377 | Map |
| OH | Cleveland Clinic Foundation | Cleveland44195 | NCT06580314 | Map |
| OH | Exelixis Clinical Site #7 | Cleveland44106 | NCT05932862 | Map |
| OH | University Hospitals Cleveland Medical Center ( Site 0043) | Cleveland44106 | NCT06353386 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT05564377 | Map |
| OH | Columbus Oncology and Hematology Associates Inc | Columbus43214 | NCT06580314 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT05564377 | Map |
| OH | Doctors Hospital | Columbus43228 | NCT06580314 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT05564377 | Map |
| OH | Grant Medical Center | Columbus43215 | NCT06580314 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT05554328 | Map |
| OH | Mount Carmel East Hospital | Columbus43213 | NCT05564377 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05554328 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT05564377 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04633239 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06580314 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT05554328 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT05564377 | Map |
| OH | Riverside Methodist Hospital | Columbus43214 | NCT06580314 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT05554328 | Map |
| OH | The Mark H Zangmeister Center | Columbus43219 | NCT05564377 | Map |
| OH | The Ohio State University | Columbus43210 | NCT06785636 | Map |
| OH | The Ohio State University, Stefanie Spielman Comprehensive Breast Center | Columbus43212 | NCT01042379 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT05554328 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT05564377 | Map |
| OH | Miami Valley Hospital | Dayton45409 | NCT04858334 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05554328 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT05564377 | Map |
| OH | Miami Valley Hospital North | Dayton45415 | NCT04858334 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT05564377 | Map |
| OH | Premier Blood and Cancer Center | Dayton45409 | NCT04858334 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT05564377 | Map |
| OH | Delaware Health Center-Grady Cancer Center | Delaware43015 | NCT06580314 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT05564377 | Map |
| OH | Grady Memorial Hospital | Delaware43015 | NCT06580314 | Map |
| OH | Columbus Oncology and Hematology Associates | Dublin43016 | NCT05564377 | Map |
| OH | Columbus Oncology and Hematology Associates | Dublin43016 | NCT06580314 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT05554328 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT05564377 | Map |
| OH | Dublin Methodist Hospital | Dublin43016 | NCT06580314 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05554328 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT05564377 | Map |
| OH | Atrium Medical Center-Middletown Regional Hospital | Franklin45005-1066 | NCT04858334 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05554328 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT05564377 | Map |
| OH | Miami Valley Cancer Care and Infusion | Greenville45331 | NCT04858334 | Map |
| OH | Kettering Health | Kettering45429 | NCT02693535 | Map |
| OH | Kettering Medical Center | Kettering45429 | NCT05564377 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT05554328 | Map |
| OH | Fairfield Medical Center | Lancaster43130 | NCT05564377 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT05554328 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT05564377 | Map |
| OH | OhioHealth Mansfield Hospital | Mansfield44903 | NCT06580314 | Map |
| OH | Marietta Memorial Hospital | Marietta45750 | NCT05554328 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT05564377 | Map |
| OH | OhioHealth Marion General Hospital | Marion43302 | NCT06580314 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT05554328 | Map |
| OH | Memorial Hospital | Marysville43040 | NCT05564377 | Map |
| OH | Taylor Cancer Research Center | Maumee43537 | NCT06785636 | Map |
| OH | Hillcrest Hospital Cancer Center | Mayfield Heights44124 | NCT06580314 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT05554328 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT05564377 | Map |
| OH | UH Seidman Cancer Center at Lake Health Mentor Campus | Mentor44060 | NCT06580314 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT05554328 | Map |
| OH | Knox Community Hospital | Mount Vernon43050 | NCT05564377 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT05554328 | Map |
| OH | Licking Memorial Hospital | Newark43055 | NCT05564377 | Map |
| OH | Mercy Health - Perrysburg Hospital | Perrysburg43551 | NCT05554328 | Map |
| OH | Mercy Health - Perrysburg Hospital | Perrysburg43551 | NCT05564377 | Map |
| OH | OhioHealth Pickerington Methodist Hospital | Pickerington43147 | NCT05554328 | Map |
| OH | OhioHealth Pickerington Methodist Hospital | Pickerington43147 | NCT05564377 | Map |
| OH | OhioHealth Pickerington Methodist Hospital | Pickerington43147 | NCT06580314 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT05554328 | Map |
| OH | Southern Ohio Medical Center | Portsmouth45662 | NCT05564377 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT05554328 | Map |
| OH | Springfield Regional Cancer Center | Springfield45504 | NCT05564377 | Map |
| OH | Springfield Regional Medical Center | Springfield45504 | NCT05554328 | Map |
| OH | Springfield Regional Medical Center | Springfield45504 | NCT05564377 | Map |
| OH | ProMedica Flower Hospital | Sylvania43560 | NCT06580314 | Map |
| OH | Mercy Health - Saint Anne Hospital | Toledo43623 | NCT05554328 | Map |
| OH | Mercy Health - Saint Anne Hospital | Toledo43623 | NCT05564377 | Map |
| OH | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital | Toledo43606 | NCT06580314 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05554328 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT05564377 | Map |
| OH | Upper Valley Medical Center | Troy45373 | NCT04858334 | Map |
| OH | West Chester Hospital | West Chester45069 | NCT02693535 | Map |
| OH | OhioHealth Westerville Medical Campus/Westerville Cancer Center | Westerville43082 | NCT05554328 | Map |
| OH | OhioHealth Westerville Medical Campus/Westerville Cancer Center | Westerville43082 | NCT05564377 | Map |
| OH | OhioHealth Westerville Medical Campus/Westerville Cancer Center | Westerville43082 | NCT06580314 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT05554328 | Map |
| OH | Saint Ann's Hospital | Westerville43081 | NCT05564377 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT05554328 | Map |
| OH | UH Seidman Cancer Center at Saint John Medical Center | Westlake44145 | NCT06580314 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT05554328 | Map |
| OH | Genesis Healthcare System Cancer Care Center | Zanesville43701 | NCT05564377 | Map |
| OK | Exelixis Clinical Site #13 | Oklahoma City73104 | NCT05932862 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT04858334 | Map |
| OK | Mercy Hospital Oklahoma City | Oklahoma City73120 | NCT06580314 | Map |
| OK | OU Health - Stephenson Cancer Center /ID# 277656 | Oklahoma City73104 | NCT07024784 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05554328 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT05564377 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04633239 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06580314 | Map |
| OK | Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0082) | Tulsa74146 | NCT03486873 | Map |
| OR | Saint Charles Health System | Bend97701 | NCT06580314 | Map |
| OR | Clackamas Radiation Oncology Center | Clackamas97015 | NCT06580314 | Map |
| OR | Bay Area Hospital | Coos Bay97420 | NCT06580314 | Map |
| OR | Providence Hood River Memorial Hospital | Hood River97031 | NCT06580314 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05554328 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT05564377 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT04858334 | Map |
| OR | Providence Newberg Medical Center | Newberg97132 | NCT06580314 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05554328 | Map |
| OR | Saint Alphonsus Cancer Care Center-Ontario | Ontario97914 | NCT05564377 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05554328 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT05564377 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT04858334 | Map |
| OR | Providence Willamette Falls Medical Center | Oregon City97045 | NCT06580314 | Map |
| OR | Call for Information (Investigational Site 2094) | Portland97239 | NCT02861573 | Map |
| OR | Legacy Good Samaritan Hospital and Medical Center | Portland97210 | NCT06580314 | Map |
| OR | OHSU Knight Cancer Institute | Portland97239 | NCT04005690 | Map |
| OR | Oregon Health & Science Institute (OHSU) | Portland97239 | NCT01042379 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05554328 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT05564377 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT04858334 | Map |
| OR | Oregon Health and Science University | Portland97239 | NCT06580314 | Map |
| OR | Providence Cancer Institute | Portland97213 | NCT06915025 | Map |
| OR | Providence Health & Services | Portland97213 | NCT02693535 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05554328 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT05564377 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT04858334 | Map |
| OR | Providence Portland Medical Center | Portland97213 | NCT06580314 | Map |
| OR | Providence Portland Medical Center /ID# 277727 | Portland97213 | NCT07024784 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05554328 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT05564377 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT04858334 | Map |
| OR | Providence Saint Vincent Medical Center | Portland97225 | NCT06580314 | Map |
| OR | VA Portland Health Care System, Portland, OR | Portland97239 | NCT04038502 | Map |
| OR | Saint Charles Health System-Redmond | Redmond97756 | NCT06580314 | Map |
| OR | Northwest Cancer Specialists (Compass Oncology) ( Site 8003) | Tigard97223 | NCT06797635 | Map |
| OR | Legacy Meridian Park Hospital | Tualatin97062 | NCT06580314 | Map |
| PA | Lehigh Valley Health Network (Data Collection Only) | Allentown18103 | NCT05188508 | Map |
| PA | Lehigh Valley Hospital - Cedar Crest | Allentown18103 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05554328 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT05564377 | Map |
| PA | Lehigh Valley Hospital-Cedar Crest | Allentown18103 | NCT06580314 | Map |
| PA | Saint Luke's Cancer Center - Allentown | Allentown18104 | NCT06580314 | Map |
| PA | UPMC Altoona | Altoona16601 | NCT05554328 | Map |
| PA | UPMC Altoona | Altoona16601 | NCT05564377 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05554328 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT05564377 | Map |
| PA | Lehigh Valley Hospital - Muhlenberg | Bethlehem18017 | NCT06580314 | Map |
| PA | Lehigh Valley Hospital- Muhlenberg | Bethlehem18017 | NCT02693535 | Map |
| PA | Saint Luke's University Hospital-Bethlehem Campus | Bethlehem18015 | NCT06580314 | Map |
| PA | St. Luke's University Health Network ( Site 0017) | Bethlehem18015 | NCT03486873 | Map |
| PA | Bryn Mawr Hospital | Bryn Mawr19010 | NCT05554328 | Map |
| PA | Bryn Mawr Hospital | Bryn Mawr19010 | NCT05564377 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT06580314 | Map |
| PA | Chambersburg Hospital | Chambersburg17201 | NCT06580314 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT02693535 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT05554328 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT05564377 | Map |
| PA | Pocono Medical Center | East Stroudsburg18301 | NCT06580314 | Map |
| PA | Saint Luke's Hospital-Anderson Campus | Easton18045 | NCT06580314 | Map |
| PA | Ephrata Cancer Center | Ephrata17522 | NCT06580314 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05554328 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT05564377 | Map |
| PA | Adams Cancer Center | Gettysburg17325 | NCT06580314 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05554328 | Map |
| PA | UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg15601 | NCT05564377 | Map |
| PA | WellSpan Medical Oncology and Hematology | Hanover17331 | NCT06580314 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT02693535 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT05564377 | Map |
| PA | Lehigh Valley Hospital-Hazleton | Hazleton18201 | NCT06580314 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT06580314 | Map |
| PA | Sechler Family Cancer Center | Lebanon17042 | NCT06580314 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05554328 | Map |
| PA | UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion | Mechanicsburg17050 | NCT05564377 | Map |
| PA | Riddle Memorial Hospital | Media19063 | NCT05554328 | Map |
| PA | Riddle Memorial Hospital | Media19063 | NCT05564377 | Map |
| PA | Riddle Memorial Hospital | Media19063 | NCT04858334 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT05554328 | Map |
| PA | UPMC Hillman Cancer Center - Monroeville | Monroeville15146 | NCT05564377 | Map |
| PA | Paoli Memorial Hospital | Paoli19301 | NCT05554328 | Map |
| PA | Paoli Memorial Hospital | Paoli19301 | NCT05564377 | Map |
| PA | Paoli Memorial Hospital | Paoli19301 | NCT04858334 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT02693535 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05554328 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05564377 | Map |
| PA | Fox Chase Cancer Center ( Site 0042) | Philadelphia19111 | NCT03486873 | Map |
| PA | Jefferson Torresdale Hospital | Philadelphia19114 | NCT06580314 | Map |
| PA | Penn Medicine Abramson Cancer Center | Philadelphia19104 | NCT05498272 | Map |
| PA | Pennsylvania Hospital | Philadelphia19107 | NCT05554328 | Map |
| PA | Pennsylvania Hospital | Philadelphia19107 | NCT06580314 | Map |
| PA | Philadelphia MultiService Center, Philadelphia, PA | Philadelphia19106 | NCT04038502 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05554328 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT05564377 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT04633239 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06580314 | Map |
| PA | University of Pennsylvania ( Site 0010) | Philadelphia19104 | NCT03486873 | Map |
| PA | University of Pennsylvania (U Penn) | Philadelphia19104 | NCT01042379 | Map |
| PA | University of Pennsylvania Abramson Cancer Center | Philadelphia19104 | NCT05238922 | Map |
| PA | University of Pennsylvania Health System, Perelman Center for Advanced Medicine | Philadelphia19104 | NCT05887609 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT04858334 | Map |
| PA | University of Pennsylvania/Abramson Cancer Center | Philadelphia19104 | NCT06580314 | Map |
| PA | Call for Information (Investigational Site 0008) | Pittsburgh15232 | NCT02861573 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05554328 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05564377 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT04585958 | Map |
| PA | UPMC Hillman Cancer Center ( Site 0008) | Pittsburgh15232 | NCT03486873 | Map |
| PA | UPMC Magee-Women's Hospital | Pittsburgh15213 | NCT05887609 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT05554328 | Map |
| PA | UPMC-Magee Womens Hospital | Pittsburgh15213 | NCT05564377 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05554328 | Map |
| PA | UPMC-Passavant Hospital | Pittsburgh15237 | NCT05564377 | Map |
| PA | Saint Luke's Hospital - Upper Bucks Campus | Quakertown18951 | NCT06580314 | Map |
| PA | Guthrie Medical Group PC-Robert Packer Hospital | Sayre18840 | NCT05564377 | Map |
| PA | Saint Luke's Hospital - Monroe Campus | Stroudsburg18360 | NCT06580314 | Map |
| PA | Chester County Hospital | West Chester19380 | NCT06580314 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT05554328 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT05564377 | Map |
| PA | Asplundh Cancer Pavilion | Willow Grove19090 | NCT06580314 | Map |
| PA | Lankenau Medical Center | Wynnewood19096 | NCT05554328 | Map |
| PA | Lankenau Medical Center | Wynnewood19096 | NCT05564377 | Map |
| PA | Lankenau Medical Center | Wynnewood19096 | NCT04858334 | Map |
| PA | WellSpan Health-York Cancer Center | York17403 | NCT06580314 | Map |
| PA | WellSpan Health-York Hospital | York17403 | NCT06580314 | Map |
| RI | Roger Williams Medical Center | Providence02908 | NCT05564377 | Map |
| RI | Women & Infants Hospital /ID# 277930 | Providence02905 | NCT07024784 | Map |
| RI | Women and Infants Hospital | Providence02905 | NCT05554328 | Map |
| RI | Women and Infants Hospital | Providence02905 | NCT05564377 | Map |
| RI | Women and Infants Hospital | Providence02905 | NCT06580314 | Map |
| SC | SC Cancer Specialists at St. Joseph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | St. Joseph's/Candler Smith | Bluffton29910 | NCT02693535 | Map |
| SC | Summit Cancer Care at St. Josph's/Candler Bluffton | Bluffton29910 | NCT02693535 | Map |
| SC | Prisma Health Cancer Institute - Spartanburg | Boiling Springs29316 | NCT05564377 | Map |
| SC | Medical University of South Carolina-Hollings Cancer Center ( Site 0016) | Charleston29425 | NCT06966700 | Map |
| SC | Prisma Health Richland Hospital | Columbia29203 | NCT05564377 | Map |
| SC | Prisma Health Cancer Institute - Easley | Easley29640 | NCT05564377 | Map |
| SC | Gibbs Cancer Center-Gaffney | Gaffney29341 | NCT06580314 | Map |
| SC | BI-LO Charities Children's Cancer Center | Greenville29605 | NCT05564377 | Map |
| SC | Prisma Health Cancer Institute - Butternut | Greenville29605 | NCT05564377 | Map |
| SC | Prisma Health Cancer Institute - Eastside | Greenville29615 | NCT05564377 | Map |
| SC | Prisma Health Cancer Institute - Faris | Greenville29605 | NCT05564377 | Map |
| SC | Saint Francis Cancer Center | Greenville29607 | NCT05564377 | Map |
| SC | Saint Francis Health System ( Site 0089) | Greenville29607 | NCT03486873 | Map |
| SC | Saint Francis Hospital | Greenville29601 | NCT05564377 | Map |
| SC | St Francis Cancer Center ( Site 0093) | Greenville29607 | NCT06966700 | Map |
| SC | Gibbs Cancer Center-Pelham | Greer29651 | NCT06580314 | Map |
| SC | Prisma Health Cancer Institute - Greer | Greer29650 | NCT05564377 | Map |
| SC | South Carolina Cancer Specialists | Hilton Head Island29926 | NCT02693535 | Map |
| SC | Call for Information (Investigational Site 0019) | Myrtle Beach29572 | NCT02861573 | Map |
| SC | Prisma Health Cancer Institute - Seneca | Seneca29672 | NCT05564377 | Map |
| SC | Spartanburg Medical Center | Spartanburg29303 | NCT06580314 | Map |
| SC | SMC Center for Hematology Oncology Union | Union29379 | NCT06580314 | Map |
| SD | Avera Cancer Institute-Aberdeen | Aberdeen57401 | NCT04858334 | Map |
| SD | Avera Cancer Institute-Aberdeen | Aberdeen57401 | NCT06580314 | Map |
| SD | Avera Cancer Institute - Mitchell | Mitchell57301 | NCT06580314 | Map |
| SD | Avera Cancer Institute at Pierre | Pierre57501 | NCT04858334 | Map |
| SD | Avera Cancer Institute at Pierre | Pierre57501 | NCT06580314 | Map |
| SD | Rapid City Regional Hospital | Rapid City57701 | NCT05564377 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT04858334 | Map |
| SD | Avera Cancer Institute | Sioux Falls57105 | NCT06580314 | Map |
| SD | Avera McKennan Hospital ( Site 0002) | Sioux Falls57105 | NCT06966700 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05554328 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT05564377 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT04858334 | Map |
| SD | Sanford Cancer Center Oncology Clinic | Sioux Falls57104 | NCT06580314 | Map |
| SD | Sanford Cancer Center Oncology Clinic and Pharmacy | Sioux Falls57104 | NCT02693535 | Map |
| SD | Sanford Clinical Research | Sioux Falls57104 | NCT01042379 | Map |
| SD | Sanford Health | Sioux Falls57104 | NCT06915025 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05554328 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT05564377 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT04858334 | Map |
| SD | Sanford USD Medical Center - Sioux Falls | Sioux Falls57117-5134 | NCT06580314 | Map |
| SD | Avera Cancer Institute - Yankton ( Site 0089) | Yankton57078 | NCT06966700 | Map |
| SD | Avera Cancer Institute at Yankton | Yankton57078 | NCT06580314 | Map |
| TN | Erlanger Health | Chattanooga37403 | NCT06915025 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT05564377 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Collierville | Collierville38017 | NCT04858334 | Map |
| TN | Vanderbilt-Ingram Cancer Center at Franklin | Franklin37067 | NCT06580314 | Map |
| TN | Vanderbilt-Ingram Cancer Center Cool Springs | Franklin37067 | NCT06580314 | Map |
| TN | Call for Information (Investigational Site 2090) | Germantown38138 | NCT02861573 | Map |
| TN | Exelixis Clinical Site #11 | Germantown38138 | NCT05932862 | Map |
| TN | Regional Cancer Center at Johnson City Medical Center | Johnson City37604 | NCT05564377 | Map |
| TN | Ballad Health Cancer Care - Kingsport | Kingsport37660 | NCT05564377 | Map |
| TN | Tennessee Cancer Specialists ( Site 7001) | Knoxville37909 | NCT06966700 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT05564377 | Map |
| TN | Baptist Memorial Hospital and Cancer Center-Memphis | Memphis38120 | NCT04858334 | Map |
| TN | Exelixis Clinical Site #6 | Nashville37203 | NCT05932862 | Map |
| TN | Nashville General Hospital ( Site 0017) | Nashville37208 | NCT06966700 | Map |
| TN | SCRI Oncology Partners ( Site 7000) | Nashville37203 | NCT06797635 | Map |
| TN | SCRI Oncology Partners /ID# 279733 | Nashville37203 | NCT07024784 | Map |
| TN | Tennessee Oncology - Nashville / Sarah Cannon Research Institute | Nashville37203 | NCT02693535 | Map |
| TN | Vanderbilt Breast Center at One Hundred Oaks | Nashville37204 | NCT05564377 | Map |
| TN | Vanderbilt Breast Center at One Hundred Oaks | Nashville37204 | NCT06580314 | Map |
| TN | Vanderbilt Health One Hundred Oaks Diagnostic ( Site 0060) | Nashville37204 | NCT03486873 | Map |
| TN | Vanderbilt Ingram Cancer Center ( Site 0015) | Nashville37232 | NCT03486873 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT05564377 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT04633239 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT06580314 | Map |
| TN | Vanderbilt-Ingram Cancer Center ( Site 0038) | Nashville37232 | NCT06966700 | Map |
| TX | Hendrick Medical Center | Abilene79601 | NCT05564377 | Map |
| TX | Hendrick Medical Center ( Site 0009) | Abilene79601 | NCT06966700 | Map |
| TX | Exelixis Clinical Site #4 | Austin78758 | NCT05932862 | Map |
| TX | Texas Oncology - Central/South Texas ( Site 8001) | Austin78745 | NCT03486873 | Map |
| TX | Texas Oncology-Austin North /ID# 279958 | Austin78758 | NCT07024784 | Map |
| TX | MD Anderson in The Woodlands | Conroe77384 | NCT05554328 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT04858334 | Map |
| TX | Parkland Memorial Hospital | Dallas75235 | NCT06580314 | Map |
| TX | Texas Oncology - DFW ( Site 8000) | Dallas75246 | NCT06797635 | Map |
| TX | Texas Oncology-Baylor Sammons Cancer Center ( Site 0062) | Dallas75246 | NCT03486873 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75390 | NCT06785636 | Map |
| TX | UT Southwestern Simmons Cancer Center - RedBird | Dallas75237 | NCT04858334 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05554328 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT05564377 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT04858334 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Dallas | Dallas75390 | NCT06580314 | Map |
| TX | Texas Oncology - Northeast Texas ( Site 8002) | Flower Mound75028 | NCT06966700 | Map |
| TX | JPS Oncology and Infusion Center ( Site 0083) | Fort Worth76104 | NCT06966700 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT04858334 | Map |
| TX | UT Southwestern/Simmons Cancer Center-Fort Worth | Fort Worth76104 | NCT06580314 | Map |
| TX | Exelixis Clinical Site #1 | Houston77030 | NCT05932862 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT06580314 | Map |
| TX | Houston Methodist Hospital ( Site 0022) | Houston77030 | NCT06797635 | Map |
| TX | Houston Methodist West Hospital | Houston77094 | NCT06580314 | Map |
| TX | Kelsey-Seybold Clinic ( Site 0042) | Houston77025 | NCT06966700 | Map |
| TX | Kelsey-Seybold Clinic ( Site 0088) | Houston77025 | NCT06966700 | Map |
| TX | Lyndon Baines Johnson General Hospital | Houston77026-1967 | NCT05554328 | Map |
| TX | Lyndon Baines Johnson General Hospital | Houston77026-1967 | NCT05564377 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05554328 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05564377 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04090567 | Map |
| TX | MD Anderson Cancer Center | Houston77030 | NCT06525298 | Map |
| TX | MD Anderson West Houston | Houston77079 | NCT05554328 | Map |
| TX | Memorial Hermann Texas Medical Center | Houston77030 | NCT06580314 | Map |
| TX | Methodist Willowbrook Hospital | Houston77070 | NCT06580314 | Map |
| TX | Oncology Consultants P.A. ( Site 0073) | Houston77030 | NCT06966700 | Map |
| TX | Oncology Consultants, P.A | Houston77030 | NCT06785636 | Map |
| TX | The University of Texas M. D. Anderson Cancer Center | Houston77030 | NCT07382544 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT02693535 | Map |
| TX | University of Texas MD Anderson Cancer Center ( Site 0007) | Houston77030 | NCT03486873 | Map |
| TX | MD Anderson League City | League City77573 | NCT05554328 | Map |
| TX | Texas Tech University Health Sciences Center ( Site 0087) | Lubbock79430 | NCT06966700 | Map |
| TX | Houston Methodist Saint John Hospital | Nassau Bay77058 | NCT06580314 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT04858334 | Map |
| TX | UT Southwestern Clinical Center at Richardson/Plano | Richardson75080 | NCT06580314 | Map |
| TX | Exelixis Clinical Site #3 | San Antonio78229 | NCT05932862 | Map |
| TX | South Texas Accelerated Research Therapeutics, LLC (START) ( Site 0001) | San Antonio78229 | NCT03486873 | Map |
| TX | Texas Oncology - San Antonio ( Site 8004) | San Antonio78240 | NCT06966700 | Map |
| TX | MD Anderson in Sugar Land | Sugar Land77478 | NCT05554328 | Map |
| TX | Scott and White Memorial Hospital | Temple76508 | NCT05564377 | Map |
| TX | Houston Methodist The Woodlands Hospital | The Woodlands77385 | NCT06580314 | Map |
| UT | Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center | Cedar City84720 | NCT02693535 | Map |
| UT | Farmington Health Center | Farmington84025 | NCT04858334 | Map |
| UT | Intermountain Medical Center ( Site 0074) | Murray84107 | NCT06966700 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05568550 | Map |
| UT | Huntsman Cancer Institute, University of Utah | Salt Lake City84112 | NCT01042379 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT04858334 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT06580314 | Map |
| UT | Intermountain Healthcare | Salt Lake City84107 | NCT02693535 | Map |
| UT | University of Utah Sugarhouse Health Center | Salt Lake City84106 | NCT04858334 | Map |
| UT | University of Utah Sugarhouse Health Center | Salt Lake City84106 | NCT06580314 | Map |
| UT | South Jordan Health Center | South Jordan84009 | NCT06580314 | Map |
| UT | Dixie Regional Medical Center-River Road Campus | St. George84770 | NCT02693535 | Map |
| VT | Dartmouth Cancer Center - North | Saint Johnsbury05819 | NCT04858334 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05554328 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05564377 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT04633239 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT06580314 | Map |
| VA | University of Virginia Health System ( Site 0035) | Charlottesville22908 | NCT03486873 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22042 | NCT02693535 | Map |
| VA | Inova Schar Cancer Institute | Fairfax22031 | NCT05564377 | Map |
| VA | NEXT Oncology - Virginia | Fairfax22031 | NCT06785636 | Map |
| VA | Next Virginia /ID# 279684 | Fairfax22031 | NCT07024784 | Map |
| VA | Virginia Cancer Institute | Fairfax22031 | NCT05238922 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT05564377 | Map |
| VA | Bon Secours Cancer Institute at St. Francis ( Site 0048) | Midlothian23114 | NCT06966700 | Map |
| VA | Virginia Oncology Associates (VOA) ( Site 8001) | Norfolk23502 | NCT06797635 | Map |
| VA | Henrico Doctor's Hospital | Richmond23229 | NCT05554328 | Map |
| VA | Henrico Doctor's Hospital | Richmond23229 | NCT05564377 | Map |
| VA | VCU Health Adult Outpatient Pavillion ( Site 0080) | Richmond23219 | NCT03486873 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05554328 | Map |
| VA | VCU Massey Cancer Center at Stony Point | Richmond23235 | NCT05564377 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05554328 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT05564377 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06580314 | Map |
| VA | Virginia Cancer Institute | Richmond23229 | NCT05554328 | Map |
| VA | Blue Ridge Cancer Care ( Site 0067) | Roanoke24014 | NCT03486873 | Map |
| VA | Carilion Roanoke Memorial Hospital | Roanoke24033 | NCT05554328 | Map |
| VA | Carilion Roanoke Memorial Hospital | Roanoke24033 | NCT05564377 | Map |
| VA | Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005) | Roanoke24014 | NCT06966700 | Map |
| VA | VCU Community Memorial Health Center | South Hill23970 | NCT05554328 | Map |
| VA | VCU Community Memorial Health Center | South Hill23970 | NCT05564377 | Map |
| WA | Providence Regional Cancer System-Aberdeen | Aberdeen98520 | NCT06580314 | Map |
| WA | PeaceHealth Saint Joseph Medical Center | Bellingham98225 | NCT06580314 | Map |
| WA | Northwest Medical Specialties | Bonney Lake98391 | NCT02693535 | Map |
| WA | Providence Regional Cancer System-Centralia | Centralia98531 | NCT06580314 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05554328 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT05564377 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT04858334 | Map |
| WA | Swedish Cancer Institute-Edmonds | Edmonds98026 | NCT06580314 | Map |
| WA | Providence Regional Cancer Partnership | Everett98201 | NCT06580314 | Map |
| WA | Northwest Medical Specialties | Federal Way98003 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Gig Harbor98332 | NCT02693535 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05554328 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT05564377 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT04858334 | Map |
| WA | Swedish Cancer Institute-Issaquah | Issaquah98029 | NCT06580314 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT04858334 | Map |
| WA | Kadlec Clinic Hematology and Oncology | Kennewick99336 | NCT06580314 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05554328 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT05564377 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT04858334 | Map |
| WA | Providence Regional Cancer System-Lacey | Lacey98503 | NCT06580314 | Map |
| WA | PeaceHealth Saint John Medical Center | Longview98632 | NCT06580314 | Map |
| WA | Skagit Regional Health Cancer Care Center | Mount Vernon98274 | NCT06580314 | Map |
| WA | Northwest Medical Specialties | Olympia98502 | NCT02693535 | Map |
| WA | Northwest Medical Specialties | Puyallup98373 | NCT02693535 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05554328 | Map |
| WA | Valley Medical Center | Renton98055 | NCT05564377 | Map |
| WA | Valley Medical Center | Renton98055 | NCT04858334 | Map |
| WA | Call for Information (Investigational Site 0016) | Seattle98109 | NCT02861573 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT06580314 | Map |
| WA | Fred Hutchinson Cancer Center ( Site 0024) | Seattle98109 | NCT03486873 | Map |
| WA | Fred Hutchinson Cancer Center ( Site 0069) | Seattle98109 | NCT06966700 | Map |
| WA | Swedish Cancer Institute | Seattle98104 | NCT02693535 | Map |
| WA | Swedish Medical Center-Ballard Campus | Seattle98107 | NCT06580314 | Map |
| WA | Swedish Medical Center-Cherry Hill | Seattle98122-5711 | NCT06580314 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05554328 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT05564377 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT04858334 | Map |
| WA | Swedish Medical Center-First Hill | Seattle98122 | NCT06580314 | Map |
| WA | University of Washington Medical Center - Montlake | Seattle98195 | NCT06580314 | Map |
| WA | University of Washington Medical Center - Northwest | Seattle98133 | NCT06580314 | Map |
| WA | VA Puget Sound Health Care System Seattle Division, Seattle, WA | Seattle98108-1532 | NCT04038502 | Map |
| WA | PeaceHealth United General Medical Center | Sedro-Woolley98284 | NCT06580314 | Map |
| WA | Saint Michael Cancer Center | Silverdale98383 | NCT06580314 | Map |
| WA | Cancer Care Northwest - Spokane South | Spokane99202 | NCT06580314 | Map |
| WA | Cancer Care Northwest ( Site 0003) | Spokane99202 | NCT06966700 | Map |
| WA | Cancer Care Northwest-North Spokane | Spokane99218 | NCT06580314 | Map |
| WA | Cancer Care Northwest-Valley | Spokane99216 | NCT06580314 | Map |
| WA | Providence Sacred Heart Medical Center & Children's Hospital | Spokane99204 | NCT06915025 | Map |
| WA | Northwest Medical Specialties | Tacoma98405 | NCT02693535 | Map |
| WA | Northwest Medical Specialties, PLLC ( Site 0067) | Tacoma98405 | NCT06966700 | Map |
| WA | Legacy Salmon Creek Hospital | Vancouver98686 | NCT06580314 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT05554328 | Map |
| WA | Providence Saint Mary Regional Cancer Center | Walla Walla99362 | NCT06580314 | Map |
| WA | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima98902 | NCT05554328 | Map |
| WV | United Hospital Center | Bridgeport26330 | NCT04858334 | Map |
| WV | United Hospital Center | Bridgeport26330 | NCT06580314 | Map |
| WV | West Virginia University Charleston Division | Charleston25304 | NCT05564377 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT05554328 | Map |
| WV | Edwards Comprehensive Cancer Center | Huntington25701 | NCT05564377 | Map |
| WV | WVUH-Berkely Medical Center | Martinsburg25401 | NCT06580314 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT05554328 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT05564377 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT04858334 | Map |
| WV | West Virginia University Healthcare | Morgantown26506 | NCT06580314 | Map |
| WV | Camden Clark Medical Center | Parkersburg26101 | NCT04858334 | Map |
| WV | Camden Clark Medical Center | Parkersburg26101 | NCT06580314 | Map |
| WV | Princeton Community Hospital | Princeton24740 | NCT06580314 | Map |
| WV | Wheeling Hospital/Schiffler Cancer Center | Wheeling26003 | NCT06580314 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT05564377 | Map |
| WI | ThedaCare Regional Cancer Center | Appleton54911 | NCT04858334 | Map |
| WI | ThedaCare Regional Medical Center - Appleton | Appleton54911 | NCT05564377 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05554328 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT05564377 | Map |
| WI | Duluth Clinic Ashland | Ashland54806 | NCT06580314 | Map |
| WI | Northwest Wisconsin Cancer Center | Ashland54806 | NCT06580314 | Map |
| WI | ThedaCare Cancer Care - Berlin | Berlin54923 | NCT05564377 | Map |
| WI | Aurora Cancer Care - Burlington | Burlington53105 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT05554328 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT05564377 | Map |
| WI | Aurora Cancer Care-Southern Lakes VLCC | Burlington53105 | NCT06580314 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT05554328 | Map |
| WI | Aurora Saint Luke's South Shore | Cudahy53110 | NCT06580314 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT05564377 | Map |
| WI | Marshfield Medical Center-EC Cancer Center | Eau Claire54701 | NCT04858334 | Map |
| WI | Aurora Health Care - Germantown Health Center | Germantown53022 | NCT02693535 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT05554328 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT05564377 | Map |
| WI | Aurora Health Care Germantown Health Center | Germantown53022 | NCT06580314 | Map |
| WI | Aurora Cancer Care - Grafton | Grafton53024 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05554328 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT05564377 | Map |
| WI | Aurora Cancer Care-Grafton | Grafton53024 | NCT06580314 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT02693535 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05554328 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT05564377 | Map |
| WI | Aurora BayCare Medical Center | Green Bay54311 | NCT06580314 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05554328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT05564377 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT04858334 | Map |
| WI | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay54303 | NCT06580314 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05554328 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT05564377 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT04858334 | Map |
| WI | Saint Vincent Hospital Cancer Center Green Bay | Green Bay54301 | NCT06580314 | Map |
| WI | Essentia Health-Hayward Clinic | Hayward54843 | NCT06580314 | Map |
| WI | Tamarack Health Hayward Medical Center | Hayward54843 | NCT06580314 | Map |
| WI | Mercyhealth Hospital and Cancer Center - Janesville | Janesville53548 | NCT05564377 | Map |
| WI | Mercyhealth Hospital and Cancer Center - Janesville | Janesville53548 | NCT04858334 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Johnson Creek | Johnson Creek53038 | NCT04858334 | Map |
| WI | Aurora Cancer Care - Kenosha South | Kenosha53142 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT05554328 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT05564377 | Map |
| WI | Aurora Cancer Care-Kenosha South | Kenosha53142 | NCT06580314 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05554328 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT05564377 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT04858334 | Map |
| WI | Gundersen Lutheran Medical Center | La Crosse54601 | NCT06580314 | Map |
| WI | University of Wisconsin - Carbone Cancer Center - University Hospital | Madison53792 | NCT05887609 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05554328 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT05564377 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT04858334 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05554328 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT05564377 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT04858334 | Map |
| WI | University of Wisconsin-Madison ( Site 0024) | Madison53792 | NCT06966700 | Map |
| WI | William S. Middleton Memorial Veterans Hospital, Madison, WI | Madison53705-2254 | NCT04038502 | Map |
| WI | Aurora Bay Area Medical Center | Marinette54143 | NCT02693535 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05554328 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT05564377 | Map |
| WI | Aurora Bay Area Medical Group-Marinette | Marinette54143 | NCT06580314 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT05564377 | Map |
| WI | Marshfield Medical Center-Marshfield | Marshfield54449 | NCT04858334 | Map |
| WI | Aurora Cancer Care Milwaukee | Milwaukee53209 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT05554328 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT05564377 | Map |
| WI | Aurora Cancer Care-Milwaukee | Milwaukee53209 | NCT06580314 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05554328 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT05564377 | Map |
| WI | Aurora Saint Luke's Medical Center | Milwaukee53215 | NCT06580314 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53223 | NCT02693535 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05554328 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT05564377 | Map |
| WI | Aurora Sinai Medical Center | Milwaukee53233 | NCT06580314 | Map |
| WI | Aurora St. Luke's Medical Center | Milwaukee53215 | NCT02693535 | Map |
| WI | Aurora West Allis Medical Center | Milwaukee53227 | NCT02693535 | Map |
| WI | Froedtert and The Medical College of Wisconsin | Milwaukee53226 | NCT06915025 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT06580314 | Map |
| WI | MEDICAL COLLEGE OF WISCONSIN-Cancer Center Clinical Trials Office ( Site 0020) | Milwaukee53226 | NCT06353386 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT05564377 | Map |
| WI | Marshfield Medical Center - Minocqua | Minocqua54548 | NCT04858334 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT05564377 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT04858334 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT06580314 | Map |
| WI | ThedaCare Regional Medical Center - Neenah | Neenah54956 | NCT05564377 | Map |
| WI | ThedaCare Cancer Care - New London | New London54961 | NCT05564377 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05554328 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT05564377 | Map |
| WI | Cancer Center of Western Wisconsin | New Richmond54017 | NCT06580314 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT05564377 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT04858334 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT06580314 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05554328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT05564377 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT04858334 | Map |
| WI | Saint Vincent Hospital Cancer Center at Oconto Falls | Oconto Falls54154 | NCT06580314 | Map |
| WI | ThedaCare Cancer Care - Oshkosh | Oshkosh54904 | NCT05564377 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05554328 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT05564377 | Map |
| WI | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh54904 | NCT06580314 | Map |
| WI | Aurora Cancer Care - Racine | Racine53406 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT05554328 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT05564377 | Map |
| WI | Aurora Cancer Care-Racine | Racine53406 | NCT06580314 | Map |
| WI | Marshfield Medical Center-Rice Lake | Rice Lake54868 | NCT05564377 | Map |
| WI | ThedaCare Cancer Care - Shawano | Shawano54166 | NCT05564377 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05554328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT05564377 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT04858334 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sheboygan | Sheboygan53081 | NCT06580314 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT05564377 | Map |
| WI | Sheboygan Physicians Group | Sheboygan53081 | NCT06580314 | Map |
| WI | Vince Lombardi Cancer Center | Sheboygan53081 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05554328 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT05564377 | Map |
| WI | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan53081 | NCT06580314 | Map |
| WI | Essentia Health-Spooner Clinic | Spooner54801 | NCT06580314 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT05564377 | Map |
| WI | Marshfield Medical Center-River Region at Stevens Point | Stevens Point54482 | NCT04858334 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05554328 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT05564377 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT04858334 | Map |
| WI | Saint Vincent Hospital Cancer Center at Sturgeon Bay | Sturgeon Bay54235-1495 | NCT06580314 | Map |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT02693535 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05554328 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT05564377 | — |
| WI | Aurora Medical Center in Summit | Summit53066 | NCT06580314 | — |
| WI | Essentia Health Saint Mary's Hospital - Superior | Superior54880 | NCT06580314 | Map |
| WI | Vince Lombardi Cancer Clinic - Two Rivers | Two Rivers54241 | NCT02693535 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05554328 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT05564377 | Map |
| WI | Vince Lombardi Cancer Clinic-Two Rivers | Two Rivers54241 | NCT06580314 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT04858334 | Map |
| WI | ProHealth Waukesha Memorial Hospital | Waukesha53188 | NCT06580314 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT05564377 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT04858334 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT06580314 | Map |
| WI | ThedaCare Cancer Care - Waupaca | Waupaca54981 | NCT05564377 | Map |
| WI | Aurora Cancer Care - Milwaukee West | Wauwatosa53226 | NCT02693535 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05554328 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT05564377 | Map |
| WI | Aurora Cancer Care-Milwaukee West | Wauwatosa53226 | NCT06580314 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05554328 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT05564377 | Map |
| WI | Aurora West Allis Medical Center | West Allis53227 | NCT06580314 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT05564377 | Map |
| WI | Marshfield Medical Center - Weston | Weston54476 | NCT04858334 | Map |
| WY | Memorial Hospital of Laramie County | Cheyenne82001 | NCT06580314 | Map |
| WY | Billings Clinic-Cody | Cody82414 | NCT06580314 | Map |
Olaparib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | no longer available | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 2 | 1 | 4 | 1 | 1 | 9 | ||||||
| P1 | 16 | 12 | 42 | 10 | 4 | 1 | 1 | 2 | 88 | |||
| P1/P2 | 13 | 10 | 6 | 5 | 1 | 5 | 40 | |||||
| P2 | 39 | 55 | 2 | 49 | 17 | 10 | 6 | 28 | 206 | |||
| P2/P3 | 2 | 2 | 4 | |||||||||
| P3 | 6 | 15 | 16 | 1 | 1 | 1 | 1 | 41 | ||||
| P4 | 1 | 2 | 2 | 1 | 6 | |||||||
| N/A | 2 | 6 | 1 | 1 | 3 | 1 | 1 | 15 |
Recruiting Olaparib clinical trials (93)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT03486873 | MK-3475Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | P3 | Solid Tumors | 3,500 | Aug 2018 |
| NCT07486687 | PLANETPembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy | P3 | Triple Negative Breast Cancer (TNBC), Early Setting | 1,000 | Apr 2026 |
| NCT06797635 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | P2 | Breast Neoplasms | 372 | Mar 2025 |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | P3 | Fallopian Tube Endometrioid Adenocarcinoma | 880 | Mar 2025 |
| NCT06966700 | MK-2870-032A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | P3 | Breast Neoplasms | 2,400 | Jun 2025 |
| NCT03150576 | PARTNERPlatinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer | P2/P3 | Breast Cancer | 780 | May 2016 |
| NCT06915025 | OVATION-3Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | P3 | Epithelial Ovarian Cancer | 500 | Jul 2025 |
| NCT07460180 | PROOVThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | P1/P2 | Ovarian Cancer | 55 | May 2025 |
| NCT07382544 | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | P1 | Advanced Cancer | 36 | Feb 2026 |
| NCT06712472 | RAINBO-REDRandomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer | P3 | Endometrial Cancer | 554 | Jun 2024 |
| NCT01042379 | I-SPYI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | P2 | Breast Neoplasms | 5,000 | Mar 2010 |
| NCT07151911 | ROYALReal wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients | — | Breast Cancer | 100 | Aug 2024 |
| NCT05522491 | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer | P2 | Solid Tumor | 30 | Sep 2026 |
| NCT02813135 | ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | Pediatric Cancer | 472 | Aug 2016 |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | P2 | Ovary Cancer | 53 | Oct 2023 |
| NCT05255653 | RAINBORefining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features | P2/P3 | Endometrial Cancer | 1,615 | Nov 2021 |
| NCT05332561 | COGNITION-GUIDEGenomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | P2 | Early-stage Breast Cancer | 240 | Jun 2023 |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | P2 | Ovarian Cancer | 20 | Feb 2025 |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | P2 | Advanced Malignant Solid Neoplasm | 2,900 | Apr 2023 |
| NCT06245889 | NeoADAPTPET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | P2 | Triple Negative Breast Cancer | 30 | May 2024 |
| NCT07005583 | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer | P2 | Triple-Negative Breast Cancer (TNBC) | 46 | Jun 2025 |
| NCT06607692 | LUPARPEDStudy in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). | P1/P2 | Solid Tumor Cancer | 25 | Sep 2024 |
| NCT05932862 | ISM3091A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | P1 | Advanced Solid Tumor | 429 | Apr 2024 |
| NCT06856499 | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | P1 | Endometrioid Ovarian Cancer | 50 | Dec 2025 |
| NCT05568550 | Pembro With Radiation With or Without Olaparib | P2 | Prostate Cancer | 64 | Jul 2023 |
| NCT06298084 | ICARUSBREAST02Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | P1/P2 | Breast Cancer Metastatic | 152 | Mar 2024 |
| NCT03740893 | PHOENIXPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer | P2 | Breast Neoplasm | 119 | Oct 2019 |
| NCT06785636 | P300A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC | P1/P2 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | 120 | Feb 2025 |
| NCT07113964 | HRDQL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) | P2 | Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency | 79 | Aug 2025 |
| NCT06488378 | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | P1 | Breast Cancer | 20 | Aug 2024 |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | P1/P2 | Gastric Cancer (GC) | 626 | Apr 2026 |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | P1 | Metastatic Solid Tumor | 110 | Aug 2025 |
| NCT06353386 | MK-5684Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | P1/P2 | Prostatic Neoplasms, Castration-Resistant | 220 | May 2024 |
| NCT07407452 | QL1706Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer | P2 | Ovarian Cancers | 50 | Feb 2026 |
| NCT07187674 | The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel | N/A | Triple Negative Breast Cancer (TNBC) | 20 | Dec 2025 |
| NCT06201234 | ELEMENTEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer | P2 | Hormone Receptor Positive HER-2 Negative Breast Cancer | 176 | Dec 2024 |
| NCT05900895 | PHOEBEEstradiol Plus Olaparib for Breast Cancer (PHOEBE) | P1 | Metastatic Breast Cancer | 6 | Jul 2024 |
| NCT02693535 | TAPURTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | Lymphoma, Non-Hodgkin | 4,200 | Mar 2016 |
| NCT06686745 | Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors | P1 | Advanced Solid Tumors | 130 | Dec 2024 |
| NCT07090369 | LumOnatePhase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer | P1 | Metastatic Castrate Resistant Prostate Cancer (mCRPC) | 20 | Nov 2025 |
| NCT06650709 | NEOCATSNEoadjuvant Olaparib Combination OvArian Cancer Targeted Study | P2 | Ovarian Cancer Stage IV | 40 | Nov 2024 |
| NCT06217757 | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | P1/P2 | Lung Cancer | 45 | Apr 2024 |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | P2 | Recurrent Endometrial Carcinoma | 165 | Apr 2023 |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | P2 | Triple Negative Breast Neoplasms | 23 | Jul 2024 |
| NCT05898399 | POLKAStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | P1/P2 | Advanced Solid Tumor | 181 | Jun 2023 |
| NCT06441747 | MEDI4736Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | P2 | Cholangiocarcinoma | 40 | Sep 2024 |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | P2 | Platinum-sensitive Ovarian Cancer | 150 | Feb 2025 |
| NCT02861573 | MK-3475Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | P1/P2 | Metastatic Castration-Resistant Prostate Cancer | 1,200 | Nov 2016 |
| NCT05128734 | TNBCTemozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | P2 | Breast Cancer Triple Negative | 40 | Apr 2026 |
| NCT04644289 | WoOWoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | P2 | Epithelial Ovarian Cancer | 60 | May 2022 |
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | P2 | Mesothelioma | 56 | Feb 2021 |
| NCT04550104 | CONCORDEA Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC | P1 | Non Small Cell Lung Cancer | 200 | Mar 2021 |
| NCT03786796 | ORCHIDStudy of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | P2 | Renal Cell Carcinoma | 20 | Jun 2019 |
| NCT07024784 | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | P2 | Gynecologic Cancers | 377 | Jul 2025 |
| NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | Early P1 | Locally Advanced Pancreatic Ductal Adenocarcinoma | 90 | Aug 2019 |
| NCT06160843 | POLARPembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma | P2 | Relapsed Peripheral T-Cell Lymphoma | 24 | Jul 2024 |
| NCT06177171 | HRDOlaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | P1 | BRCA1 Mutation | 18 | Feb 2024 |
| NCT05255471 | MITO 35BMITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. | P3 | Ovarian Cancer | 200 | Jan 2022 |
| NCT05093231 | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | P2 | Pancreatic Cancer | 20 | Feb 2025 |
| NCT04086485 | GEP-NETLu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | P1/P2 | Gastroenteropancreatico Tumors | 56 | Oct 2022 |
| NCT06525298 | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | P1/P2 | Advanced Solid Tumor | 144 | Sep 2024 |
| NCT05524935 | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | P2 | Uveal Melanoma | 37 | Oct 2022 |
| NCT04090567 | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | P2 | Advanced Breast Carcinoma | 60 | Jul 2020 |
| NCT02925234 | DRUPThe Drug Rediscovery Protocol (DRUP Trial) | P2 | Cancer | 1,550 | Aug 2016 |
| NCT05432518 | Pilot Trial for Treatment of Recurrent Glioblastoma | Early P1 | Glioblastoma | 10 | Jun 2023 |
| NCT04858334 | APOLLOAPOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | P2 | Pancreatic Acinar Cell Carcinoma | 152 | Jun 2021 |
| NCT02029001 | MOST plusAdapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment | P2 | Malignant Solid Neoplasms | 900 | Mar 2014 |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | P1 | Solid Tumors | 604 | Jul 2022 |
| NCT04038502 | COBRACarboplatin or Olaparib for BRcA Deficient Prostate Cancer | P2 | Metastatic Castrate Resistant Prostate Cancer | 100 | Oct 2019 |
| NCT05623319 | THORPembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) | P2 | SCLC,Extensive Stage | 60 | Mar 2023 |
| NCT05568212 | NSCLCRandomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | P2 | Non-small-cell Lung Cancer Patients | 176 | May 2022 |
| NCT06739395 | Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | P2 | Solid Tumor | 300 | Nov 2024 |
| NCT07371104 | Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | P1 | Cancer | 40 | Apr 2026 |
| NCT05463848 | Surgical Pembro +/- Olaparib w TMZ for rGBM | P2 | Glioblastoma | 78 | Oct 2022 |
| NCT05188508 | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | P2 | Glioma | 57 | Jan 2022 |
| NCT04683679 | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | P2 | Triple Negative Breast Cancer | 34 | Apr 2021 |
| NCT03297606 | CAPTURCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | P2 | Lymphoma, Non-Hodgkin | 720 | Mar 2018 |
| NCT05870423 | PRRT-PARPiImproving Peptide Receptor Radionuclide Therapy With PARP Inhibitors | P1 | Neuroendocrine Tumors | 24 | Jun 2022 |
| NCT06419179 | GUIDANCEMaintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | P2 | Small Cell Lung Carcinoma | 29 | Oct 2024 |
| NCT05498272 | NePtuneStudy of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | P2 | Prostate Cancer | 32 | Feb 2023 |
| NCT06783127 | COROSClinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer | — | Prostate Cancer | 3,000 | Jan 2023 |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | P1 | Metastatic Malignant Solid Neoplasm | 55 | May 2021 |
| NCT03772561 | MEDIPACPhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies | P1 | Solid Tumor, Adult | 40 | Dec 2018 |
| NCT05222971 | OPTIMUMOlaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy | P2 | Biliary Tract Cancer | 62 | Apr 2022 |
| NCT04711824 | SOLARAStudy of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | P1/P2 | Breast Cancer | 41 | Mar 2022 |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | P1 | Recurrent Ovarian High Grade Serous Adenocarcinoma | 42 | Jul 2021 |
| NCT04361370 | OPEB-01Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer | P2 | Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer | 44 | Oct 2020 |
| NCT06078787 | PALBOLAOlaparib in PALB2 Advanced Pancreatic Cancer | P2 | Advanced Pancreatic Cancer | 16 | Aug 2023 |
| NCT04592211 | GEJPembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | P1/P2 | Gastric Cancer Stage IV | 71 | Oct 2021 |
| NCT07069335 | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer | P1 | Ovarian Cancer | 24 | Jun 2025 |
| NCT05536128 | Post-CDKEvaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | P2 | Advanced Breast Cancer | 64 | Dec 2022 |
| NCT05078671 | PROACTIVEPharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness | P4 | Cancer | 160 | Dec 2021 |
| NCT03991832 | SOLIDStudy of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | P2 | Glioma | 58 | Dec 2019 |
Olaparib clinical trials by indication
Ovarian Cancer (37)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07460180 | PROOV | P1/P2 | recruiting | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer |
| NCT04742075 | DOVACC | P2 | active not recruiting | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer |
| NCT05952453 | — | P2 | recruiting | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro |
| NCT06120972 | — | P2 | withdrawn | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency |
| NCT04931342 | BOUQUET | P2 | active not recruiting | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors |
| NCT05255471 | MITO 35B | P3 | recruiting | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. |
| NCT04884360 | MONO-OLA1 | P3 | active not recruiting | D9319C00001- 1L OC Mono Global RCT |
| NCT02571725 | — | P1/P2 | active not recruiting | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer |
| + 29 more, see All trials below. | ||||
Breast Cancer (17)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03150576 | PARTNER | P2/P3 | recruiting | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer |
| NCT02810743 | Subito | P3 | active not recruiting | Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer |
| NCT06112379 | — | P3 | active not recruiting | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer |
| NCT07151911 | ROYAL | N/A | recruiting | Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients |
| NCT02624973 | PETREMAC | P2 | active not recruiting | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial |
| NCT02032823 | OlympiA | P3 | active not recruiting | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer |
| NCT06488378 | — | P1 | recruiting | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer |
| NCT05203445 | TNBC | P2 | active not recruiting | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer |
| + 9 more, see All trials below. | ||||
Prostate Cancer (11)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05568550 | — | P2 | recruiting | Pembro With Radiation With or Without Olaparib |
| NCT03787680 | — | P2 | active not recruiting | Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) |
| NCT05498272 | NePtune | P2 | recruiting | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations |
| NCT06783127 | COROS | N/A | recruiting | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer |
| NCT04748042 | ADT | P2 | active not recruiting | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) |
| NCT05167175 | — | P2 | unknown | The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation |
| NCT05501548 | — | P2 | terminated | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer |
| NCT05262608 | PROspect | P2 | unknown | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation |
| + 3 more, see All trials below. | ||||
Metastatic Castration-resistant Prostate Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06909825 | — | P2 | active not recruiting | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| NCT03732820 | — | P3 | active not recruiting | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer |
| NCT05457257 | — | P4 | active not recruiting | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations |
| NCT05171816 | — | P3 | active not recruiting | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) |
| NCT05700669 | — | P1/P2 | completed | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors |
| NCT01972217 | — | P2 | completed | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. |
| NCT02987543 | — | P3 | completed | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) |
| NCT04556617 | — | P1/P2 | terminated | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Advanced Solid Tumor (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05932862 | ISM3091 | P1 | recruiting | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors |
| NCT05898399 | POLKA | P1/P2 | recruiting | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) |
| NCT06525298 | — | P1/P2 | recruiting | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors |
| NCT06545942 | — | P1 | active not recruiting | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors |
| NCT05933265 | — | P1/P2 | active not recruiting | Study of LP-184 in Patients With Advanced Solid Tumors |
| NCT06130254 | MRTX849 | P1 | terminated | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers |
| NCT06560632 | POLAR | P1 | terminated | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors |
| NCT05252390 | — | P1 | terminated | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors |
Advanced Malignant Solid Neoplasm (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05564377 | — | P2 | recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
| NCT02498613 | — | P2 | active not recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors |
| NCT03155620 | — | P2 | active not recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
| NCT04197713 | AZD1775 | P1 | active not recruiting | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study |
| NCT03842228 | COD | P1 | active not recruiting | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations |
| NCT03212274 | — | P2 | active not recruiting | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations |
| NCT02419495 | KPT-330 | P1 | terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies |
| NCT03233204 | — | P2 | completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
Solid Tumours (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04236414 | — | P1 | completed | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours |
| NCT01921140 | — | P1 | completed | To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours |
| NCT02093351 | — | P1 | completed | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer |
| NCT01851265 | — | P1 | completed | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours |
| NCT01894243 | — | P1 | completed | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment |
| NCT01929603 | — | P1 | completed | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours |
| NCT01900028 | — | P1 | completed | To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours |
| NCT01894256 | — | P1 | completed | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function |
Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06116578 | NeoSarc | P2 | withdrawn | Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab |
| NCT02925234 | DRUP | P2 | recruiting | The Drug Rediscovery Protocol (DRUP Trial) |
| NCT07371104 | — | P1 | recruiting | Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer |
| NCT05078671 | PROACTIVE | P4 | recruiting | Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness |
| NCT04801966 | TAILOR | N/A | terminated | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study |
| NCT04774406 | — | N/A | completed | Arterial Hypertension Related to PARP Inhibitors (ArteRIB) |
| NCT01813474 | — | P1 | completed | Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies |
Breast Neoplasms (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06797635 | — | P2 | recruiting | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) |
| NCT06966700 | MK-2870-032 | P3 | recruiting | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) |
| NCT01042379 | I-SPY | P2 | recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
| NCT03594396 | — | P1/P2 | active not recruiting | Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer |
| NCT00494234 | ICEBERG 1 | P2 | completed | Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer |
Metastatic Breast Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05900895 | PHOEBE | P1 | recruiting | Estradiol Plus Olaparib for Breast Cancer (PHOEBE) |
| NCT03344965 | — | P2 | active not recruiting | Olaparib In Metastatic Breast Cancer |
| NCT05629429 | — | P2 | unknown | Olaparib Maintenance Therapy in Metastatic Breast Cancer |
| NCT02299999 | SAFIR02_Breast | P2 | active not recruiting | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer |
| NCT03685331 | HOPE | P1 | completed | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer |
Epithelial Ovarian Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06915025 | OVATION-3 | P3 | recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
| NCT04644289 | WoO | P2 | recruiting | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC |
| NCT04015739 | BOLD | P2 | unknown | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse |
| NCT03106987 | OReO | P3 | completed | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. |
Triple Negative Breast Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06245889 | NeoADAPT | P2 | recruiting | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC |
| NCT04683679 | — | P2 | recruiting | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer |
| NCT05174832 | — | P2 | unknown | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients |
| NCT03167619 | DORA | P2 | completed | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) |
Gastric Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05379972 | — | P2 | completed | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers |
| NCT05411679 | — | P2 | withdrawn | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
| NCT01063517 | — | P2 | completed | Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients |
| NCT01924533 | — | P3 | completed | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. |
Advanced Breast Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05536128 | Post-CDK | P2 | recruiting | Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor |
| NCT03182634 | plasmaMATCH | P2 | unknown | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial |
| NCT03205761 | COMETABreast | P2 | completed | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer |
| NCT03931551 | OPHELIA | P2 | terminated | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer |
Solid Tumor (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05522491 | — | P2 | not yet recruiting | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer |
| NCT06739395 | — | P2 | recruiting | Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion |
| NCT03057145 | — | P1 | completed | Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors |
Advanced Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07382544 | — | P1 | recruiting | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss |
| NCT02684318 | — | P1/P2 | unknown | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors |
| NCT02338622 | ComPAKT | P1 | completed | Trial of Olaparib in Combination With AZD5363 (ComPAKT) |
Pancreatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05093231 | — | P2 | recruiting | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer |
| NCT02511223 | 10 | P2 | completed | Efficacy and Safety of PARPi to Treat Pancreatic Cancer |
| NCT01296763 | — | P1 | completed | Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer |
Advanced Solid Tumors (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06686745 | — | P1 | recruiting | Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors |
| NCT05240898 | — | P1 | completed | A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors |
| NCT06331559 | — | P1 | terminated | Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors |
Endometrial Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06712472 | RAINBO-RED | P3 | recruiting | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer |
| NCT05255653 | RAINBO | P2/P3 | recruiting | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features |
| NCT05320757 | — | Early P1 | completed | Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients |
Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06217757 | — | P1/P2 | recruiting | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC |
| NCT05245994 | MEDI4736 | P2 | unknown | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese |
| NCT04939662 | SUKSES-B2 | P2 | completed | Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects |
Breast Cancer Metastatic (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06298084 | ICARUSBREAST02 | P1/P2 | recruiting | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd |
| NCT03742245 | — | P1 | active not recruiting | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
| NCT02000622 | OlympiAD | P3 | completed | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. |
Anatomic Stage IV Breast Cancer AJCC v8 (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05807126 | — | P1 | withdrawn | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations |
| NCT03801369 | AMTEC IIT | P2 | terminated | AMTEC IIT: Phase 2 Multiarm Study in TNBC |
| NCT03544125 | — | P1 | completed | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer |
Glioblastoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05432518 | — | Early P1 | recruiting | Pilot Trial for Treatment of Recurrent Glioblastoma |
| NCT05463848 | — | P2 | recruiting | Surgical Pembro +/- Olaparib w TMZ for rGBM |
| NCT04614909 | — | Early P1 | completed | Study of Pamiparib in Newly Diagnosed and rGBM |
Castration-Resistant Prostate Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03317392 | — | P1/P2 | active not recruiting | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis |
| NCT03516812 | — | P2 | completed | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer |
| NCT04951492 | — | P2 | terminated | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma |
Solid Tumors (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03486873 | MK-3475 | P3 | recruiting | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) |
| NCT05238922 | — | P1 | recruiting | Study of INCB123667 in Subjects With Advanced Solid Tumors |
| NCT04123366 | MK-7339 | P2 | active not recruiting | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) |
Ovarian Neoplasms (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05440578 | — | N/A | unknown | First-line Olaparib Combined With Bevacizumab Maintenance Therapy |
| NCT05153603 | — | N/A | unknown | Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting |
| NCT03314740 | BAROCCO | P2 | completed | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib |
Metastatic Castration-Resistant Prostate Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02861573 | MK-3475 | P1/P2 | recruiting | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) |
| NCT03568656 | — | P1/P2 | completed | Study to Evaluate CCS1477 in Advanced Tumours |
| NCT05005728 | — | P2 | completed | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer |
Non Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04550104 | CONCORDE | P1 | recruiting | A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC |
| NCT02679963 | PIPSeN | P2 | terminated | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer |
| NCT01513174 | GOAL | P1/P2 | completed | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone |
Metastatic Pancreatic Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04548752 | — | P2 | active not recruiting | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations |
| NCT04348045 | MAZEPPA | P2 | active not recruiting | Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. |
| NCT02677038 | — | P2 | completed | Olaparib in Treating Patients With Stage IV Pancreatic Cancer |
Cervical Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04487587 | COMICE | P2 | active not recruiting | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer |
| NCT04483544 | — | P2 | terminated | Pembrolizumab and Olaparib in Cervical Cancer Patients |
| NCT04641728 | — | P2 | unknown | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer |
Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04624204 | LS-SCLC | P3 | active not recruiting | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) |
| NCT02446704 | — | P1/P2 | unknown | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy |
| NCT03009682 | SUKSES-B | P2 | completed | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations |
Colorectal Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04166435 | — | P2 | completed | TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer |
| NCT00535353 | — | P1 | completed | AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer |
| NCT00912743 | MSI | P2 | completed | Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status |
Squamous Cell Carcinoma of the Head and Neck (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02882308 | OPHELIA | P2 | completed | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. |
| NCT02686008 | — | P1 | withdrawn | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC |
| NCT01758731 | — | P1 | completed | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History |
Cholangiocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06441747 | MEDI4736 | P2 | recruiting | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) |
| NCT04306367 | — | P2 | completed | Study of Pembrolizumab and Olaparib in Bile Duct Cancer |
Triple Negative Breast Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05485766 | — | P2 | recruiting | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer |
| NCT04191135 | TNBC | P2 | completed | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) |
Renal Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03786796 | ORCHID | P2 | recruiting | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations |
| NCT05949424 | OPTI-DOSE | P4 | unknown | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults |
Pancreatic Acinar Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04858334 | APOLLO | P2 | recruiting | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation |
| NCT05286827 | — | P2 | terminated | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma |
Anatomic Stage III Breast Cancer AJCC v8 (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02849496 | — | P2 | active not recruiting | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer |
| NCT05967286 | — | P2 | withdrawn | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial |
Ovary Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05887609 | — | P2 | recruiting | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib |
| NCT04532645 | OVAL-1 | N/A | completed | Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK |
Carcinoma, Ovarian Epithelial (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06121401 | IOLANTHE | P4 | active not recruiting | First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients |
| NCT05158062 | — | P2 | unknown | Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer |
Advanced Breast Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04090567 | — | P2 | recruiting | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
| NCT05238831 | ACT | Early P1 | withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial |
Metastatic Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04753879 | — | P2 | active not recruiting | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. |
| NCT05659914 | MEDI4736 | P2 | active not recruiting | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations |
High Grade Serous Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03462342 | CAPRI | P2 | completed | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer |
| NCT05358639 | — | P1 | active not recruiting | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC |
Malignant Neoplasm of Breast (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03162627 | — | P1 | active not recruiting | Selumetinib and Olaparib in Solid Tumors |
| NCT05033756 | COMPRENDO | P2 | active not recruiting | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO |
Metastatic Colorectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05201612 | PEMBROLA | P2 | unknown | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). |
| NCT04456699 | MK-7339 | P3 | completed | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) |
Glioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05188508 | — | P2 | recruiting | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma |
| NCT03991832 | SOLID | P2 | recruiting | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors |
Bladder Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04579133 | — | P2 | terminated | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy |
| NCT03534492 | NEODURVARIB | P2 | completed | Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) |
Mesothelioma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04515836 | — | P2 | recruiting | Olaparib in Patients With HRD Malignant Mesothelioma |
| NCT03531840 | — | P2 | completed | Olaparib in People With Malignant Mesothelioma |
Extensive Stage Lung Small Cell Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04728230 | — | P1/P2 | active not recruiting | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial |
| NCT02899728 | — | P2 | terminated | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer |
Pulmonary Arterial Hypertension (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03782818 | OPTION | P1/P2 | terminated | Olaparib for PAH: a Multicenter Clinical Trial |
| NCT03251872 | OPTION-p | Early P1 | terminated | Olaparib for PAH: a Pilot Study |
Soft Tissue Sarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03784014 | MULTISARC | P3 | completed | Molecular Profiling of Advanced Soft-tissue Sarcomas |
| NCT02398058 | TOMAS | P1 | completed | Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) |
Endometrial Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03745950 | UTOLA | P2 | completed | UTOLA: UTerin OLAparib |
| NCT02506816 | Polen | N/A | completed | Preoperative Olaparib Endometrial Carcinoma Study (POLEN) |
Advanced Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03737643 | DUO-O | P3 | active not recruiting | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients |
| NCT03161132 | ROLANDO | P2 | completed | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin |
Lymphoma, Non-Hodgkin (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02693535 | TAPUR | P2 | recruiting | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
| NCT03297606 | CAPTUR | P2 | recruiting | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) |
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02282020 | SOLO3 | P3 | completed | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments |
| NCT02983799 | — | P2 | completed | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status |
Fallopian Tube Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02345265 | — | P2 | active not recruiting | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer |
| NCT01116648 | — | P1/P2 | active not recruiting | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer |
Fallopian Tube Clear Cell Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02502266 | — | P2/P3 | active not recruiting | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer |
| NCT02446600 | — | P3 | active not recruiting | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
Ovarian (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02734004 | MEDIOLA | P1/P2 | active not recruiting | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. |
| NCT01078662 | — | P2 | completed | Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats |
Advanced Solid Tumours (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02588105 | AToM | P1 | completed | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer |
| NCT02430311 | — | P1 | completed | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. |
Triple Negative Breast Cancer (TNBC), Early Setting (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07486687 | PLANET | P3 | not yet recruiting | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy |
Gastric Cancer (GC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07453394 | — | P1/P2 | not yet recruiting | QLS5132 Combination Therapy in Advanced Solid Tumors |
Breast Cancer Triple Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05128734 | TNBC | P2 | not yet recruiting | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) |
Ovarian Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07407452 | QL1706 | P2 | not yet recruiting | Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer |
Triple Negative Breast Cancer (TNBC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07187674 | — | N/A | not yet recruiting | The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel |
Endometrioid Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06856499 | — | P1 | recruiting | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer |
Metastatic Castrate Resistant Prostate Cancer (mCRPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07090369 | LumOnate | P1 | not yet recruiting | Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer |
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07113964 | HRD | P2 | not yet recruiting | QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) |
Metastatic Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07156253 | — | P1 | recruiting | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors |
Gynecologic Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07024784 | — | P2 | recruiting | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies |
Triple-Negative Breast Cancer (TNBC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07005583 | — | P2 | not yet recruiting | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer |
Early Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06829199 | MK-5890 | P2 | withdrawn | A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) |
Fallopian Tube Endometrioid Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06580314 | — | P3 | recruiting | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer |
Platinum-sensitive Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06686030 | — | P2 | recruiting | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer |
mCRPC (Metastatic Castration-resistant Prostate Cancer) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06785636 | P300 | P1/P2 | recruiting | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC |
Advanced or Recurrent Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06746116 | DUoENDE | P3 | active not recruiting | A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain |
Hormone Receptor Positive HER-2 Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06201234 | ELEMENT | P2 | recruiting | Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer |
Ovarian Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06650709 | NEOCATS | P2 | not yet recruiting | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study |
Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06419179 | GUIDANCE | P2 | enrolling by invitation | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) |
Solid Tumor Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06607692 | LUPARPED | P1/P2 | recruiting | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). |
Relapsed Peripheral T-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06160843 | POLAR | P2 | recruiting | Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma |
Prostatic Neoplasms, Castration-Resistant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06353386 | MK-5684 | P1/P2 | recruiting | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) |
BRCA1 Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06177171 | HRD | P1 | recruiting | Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors |
TNBC - Triple-Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05209529 | — | P2 | withdrawn | Chemo-free BRCA-targeted Neoadjuvant Strategy |
Extensive-stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05975944 | — | P1/P2 | unknown | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer |
Advanced Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06078787 | PALBOLA | P2 | recruiting | Olaparib in PALB2 Advanced Pancreatic Cancer |
Early-stage Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05332561 | COGNITION-GUIDE | P2 | recruiting | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) |
Locally Advanced Pancreatic Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05411094 | — | P1 | suspended | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer |
Recurrent Endometrial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05554328 | — | P2 | recruiting | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial |
Locally Advanced Uterine Corpus Leiomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05432791 | — | P2/P3 | active not recruiting | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working |
SCLC,Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05623319 | THOR | P2 | recruiting | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) |
Uveal Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05524935 | — | P2 | recruiting | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma |
Recurrent Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05482074 | — | P2 | withdrawn | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 |
Gastroenteropancreatico Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04086485 | GEP-NET | P1/P2 | recruiting | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05405309 | CORONADO CLL | P1/P2 | terminated | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia |
Esophagogastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05268510 | — | P2 | completed | Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma |
Squamous Cell Carcinoma of Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05366166 | — | P2 | active not recruiting | Pembrolizumab Plus Olaparib in LA-HNSCC |
Platinum-Refractory Fallopian Tube Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05295589 | — | P2 | withdrawn | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy |
Neuroendocrine Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05870423 | PRRT-PARPi | P1 | recruiting | Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors |
Healthy Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06360445 | — | P1 | completed | Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects |
Non-small-cell Lung Cancer Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05568212 | NSCLC | P2 | recruiting | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab |
Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05222971 | OPTIMUM | P2 | recruiting | Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy |
HER2-negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05340413 | RADIOLA | P2 | completed | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. |
Endometrial Carcinosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05156268 | — | P2 | completed | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma |
Gastric Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04592211 | GEJ | P1/P2 | recruiting | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer |
Recurrent Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04643379 | — | P2 | active not recruiting | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma |
EGFR-Mutated Non-Small-Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04538378 | LYNPARZA | P2 | terminated | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors |
Recurrent Ovarian High Grade Serous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04633239 | — | P1 | recruiting | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer |
Fallopian Tube Mucinous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04739800 | — | P2 | active not recruiting | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
Metastatic Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04585958 | — | P1 | recruiting | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer |
Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05860530 | — | N/A | completed | Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers |
Biochemically Recurrent Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04336943 | — | P2 | terminated | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load |
Advanced Adrenal Gland Pheochromocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04394858 | — | P2 | active not recruiting | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer |
Metastatic Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04633902 | HR | P2 | unknown | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
Stomach Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04410887 | LIGC | P1/P2 | unknown | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) |
Metastatic Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04666740 | — | P2 | active not recruiting | A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy |
Osteosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04417062 | — | P2 | active not recruiting | Olaparib With Ceralasertib in Recurrent Osteosarcoma |
Advanced Bladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03375307 | — | P2 | active not recruiting | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes |
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04361370 | OPEB-01 | P2 | enrolling by invitation | Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer |
Fallopian Tube Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03924245 | — | P1 | terminated | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers |
Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03953898 | IDH | P2 | active not recruiting | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation |
Advanced Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04209686 | — | P2 | active not recruiting | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma |
Renal Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03741426 | WIRE | P2 | unknown | WIRE - Novel Treatments in Renal Cell Cancer |
Lung Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04380636 | NSCLC | P3 | active not recruiting | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) |
Bile Duct Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04298021 | — | P2 | unknown | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer |
Bile Duct Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04042831 | — | P2 | active not recruiting | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations |
Advanced Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03838744 | TOMAS2 | P2 | completed | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. |
Endometrial Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04269200 | DUO-E | P3 | active not recruiting | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer |
Clinical Trial, Phase I (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04375267 | LuPARP | P1 | completed | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03878524 | SMMART | P1 | terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04076579 | — | P2 | completed | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma |
Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04169841 | GUIDE2REPAIR | P2 | active not recruiting | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03878095 | — | P2 | active not recruiting | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors |
Fallopian Tube Endometrioid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04034927 | — | P2 | active not recruiting | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer |
High Grade Serous Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04261465 | NUVOLA | P2 | unknown | NUVOLA TRIAL Open-label Multicentre Study |
Gynaecological Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04065269 | ATARI | P2 | active not recruiting | ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss |
Breast Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03740893 | PHOENIX | P2 | recruiting | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer |
Metastatic Castrate Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04038502 | COBRA | P2 | recruiting | Carboplatin or Olaparib for BRcA Deficient Prostate Cancer |
Recurrent Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03259503 | — | P1 | completed | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant |
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04053322 | DOLAF | P2 | active not recruiting | Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. |
Stage III Uterine Corpus Leiomyosarcoma AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03880019 | — | P2 | active not recruiting | A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma |
Locally Advanced Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04005690 | — | Early P1 | recruiting | Targeted Pathway Inhibition in Patients With Pancreatic Cancer |
Metastatic Castration Resistant Prostate Cancer (mCRPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03874884 | LuPARP | P1 | active not recruiting | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer |
BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04091204 | MITO 31 | P2 | unknown | Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study |
Oesophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03829345 | SOLAR | P2 | unknown | A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer |
Carcinoma, Squamous Cell, Non-small-cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03976362 | MK-3475 | P3 | completed | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) |
Carcinoma, Nonsquamous Non-small-cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03976323 | NSCLC | P3 | completed | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) |
BRCA-Mutated Ovarian Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03943173 | — | Early P1 | active not recruiting | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery |
Small Cell Lung Cancer Extensive Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03923270 | — | P1 | active not recruiting | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer |
Metastatic Malignant Neoplasm in the Chest Wall (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03955640 | — | P1 | terminated | Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences |
Prostatic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03834519 | KEYLYNK-010 | P3 | completed | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) |
Mismatch Repair Proficient Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03851614 | DAPPER | P2 | active not recruiting | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors |
Recurrent IDH (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03561870 | OLAGLI | P2 | completed | Olaparib in Recurrent IDH-mutant Glioma |
Advanced Cancers Harbouring Mutations in HRG (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03967938 | 1-2018 BSMO | P2 | active not recruiting | Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes |
Ovarian Neoplasm Epithelial (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04780945 | FAB | P2 | terminated | Functional Analysis of BRCAness |
Breast Inflammatory Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03598257 | — | P2 | active not recruiting | Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer |
Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03682289 | AZD6738 | P2 | active not recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors |
Breast Cancer Organoids (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03925233 | — | N/A | unknown | Breast Cancer Treatment Based on Organ-like Culture |
Non-small Cell Lung Cancer NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03775486 | ORION | P2 | active not recruiting | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) |
Advanced Solid Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03742895 | MK-7339 | P2 | active not recruiting | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) |
Recurrent Fallopian Tube Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03579316 | — | P2 | active not recruiting | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Solid Tumor, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03772561 | MEDIPAC | P1 | recruiting | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies |
Advanced Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03579784 | MEDI4736 | P2 | unknown | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer |
Platinum-resistant Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03699449 | AMBITION | P2 | unknown | An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) |
Cancers With DNA Repair-Deficiency (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03127215 | NCT-PMO-1603 | P2 | completed | Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03428607 | — | P2 | completed | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] |
Relapsed Ovarian Cancers Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04152941 | RETROLA | N/A | completed | Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients |
Endometrial Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03660826 | — | P2 | active not recruiting | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone |
Prostate Adenocarcinoma Without Neuroendocrine Differentiation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03570476 | — | P2 | terminated | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer |
Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03532880 | — | P1 | completed | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer |
Cancer of Unknown Primary Site (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03498521 | CUPISCO | P2 | completed | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site |
Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03575078 | — | P1 | withdrawn | ARQ761 + PARP Inhibitor in Refractory Solid Tumors |
Relapsed Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03534453 | L-MOCA | P3 | completed | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
Carcinosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03570437 | COPELIA | P2 | unknown | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? |
Malignant Solid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03553108 | IVIVC | P1 | completed | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. |
Metastatic Urothelial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03448718 | — | P2 | completed | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations |
Urinary Bladder Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03459846 | BAYOU | P2 | active not recruiting | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) |
Metastatic Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03330847 | — | P2 | active not recruiting | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. |
Metastatic Esophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03008278 | — | P1/P2 | completed | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery |
Prostate Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03434158 | IMANOL | P2 | completed | Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) |
Non-Germline BRCA Mutated Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03402841 | OPINION | P3 | completed | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients |
HER2-ve Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03286842 | — | P3 | completed | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03334617 | HUDSON | P2 | active not recruiting | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy |
Recurrent Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02974621 | — | P2 | active not recruiting | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma |
Prostate Cancer Aggressiveness (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03263650 | — | P2 | active not recruiting | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC |
Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03022409 | DDR | P1 | completed | A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). |
Malignant Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03212742 | OLA-TMZ-RTE-01 | P1/P2 | active not recruiting | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients |
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02893917 | — | P2 | active not recruiting | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer |
Breast Neoplasms, Triple-Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03109080 | RadioPARP | P1 | completed | Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) |
Malignant Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03205176 | — | P1 | completed | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas |
BRCA1 Gene Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02953457 | — | P2 | completed | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation |
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02898207 | — | P1 | completed | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer |
Oral Squamous Cell Carcinoma (OSCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03085147 | — | P1/P2 | active not recruiting | A Dye for the Detection of Cancer of the Tongue and Mouth |
Prostate (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03047135 | — | P2 | active not recruiting | Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
Recurrent Platinum Resistant Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02889900 | CONCERTO | P2 | completed | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer |
Prostate Cancer Metastatic Castration-Resistant (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03012321 | — | P2 | active not recruiting | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects |
Rare Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03239015 | — | P2 | unknown | Efficacy and Safety of Precision Therapy in Refractory Tumor |
Muscle Invasive Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02546661 | BISCAY | P1 | active not recruiting | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer |
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02937818 | — | P2 | completed | A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer |
Recurrent Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02755844 | ENDOLA | P1/P2 | completed | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients |
Ovarian Epithelial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02822157 | CLIO | P2 | unknown | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer |
Pediatric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02813135 | ESMART | P1/P2 | recruiting | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors |
Platinum Sensitive Relapsed Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02392676 | — | P3 | withdrawn | Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations |
Urothelial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02769962 | — | P1/P2 | completed | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer |
Soft-tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02787642 | RADIOSARP | P1 | completed | A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma |
Primary Peritoneal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02485990 | — | P1 | terminated | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) |
Head and Neck Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02308072 | ORCA-2 | P1 | completed | Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer |
BRCA or HRR+ Mutated Ovarian Cancer Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02476968 | ORZORA | P4 | completed | To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer |
Neoplasms, Germ Cell and Embryonal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02533765 | — | P2 | completed | Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor |
Refractory Solid Tumours (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02511795 | — | P1 | completed | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors |
Colorectal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02484404 | MEDI4736 | P1/P2 | active not recruiting | Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... |
Germline BRCA1/2 Mutations and (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02184195 | POLO | P3 | completed | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
BRCA1 Mutation Carrier (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02208375 | — | P1 | active not recruiting | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian |
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02264678 | — | P1 | active not recruiting | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents |
Laryngeal Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02229656 | — | P1 | unknown | Olaparib and Radiotherapy in Head and Neck Cancer |
Non-small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02117167 | SAFIR02_Lung | P2 | completed | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients |
Malignant Solid Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02029001 | MOST plus | P2 | recruiting | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01788332 | PIN | P2 | unknown | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) |
Locally Advanced Malignant Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02227082 | — | P1 | completed | Olaparib and Radiotherapy in Inoperable Breast Cancer |
Platinum Sensitive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01874353 | — | P3 | active not recruiting | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
Newly Diagnosed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01844986 | SOLO-1 | P3 | active not recruiting | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. |
Carcinoma of the Oesophagus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01460888 | ROCOCO | P1 | unknown | Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus |
Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01858168 | — | P1 | completed | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma |
Stage III Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01650376 | — | P1/P2 | unknown | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer |
Adenocarcinoma of the Prostate (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01682772 | TOPARP | P2 | unknown | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer |
Ewing's Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01583543 | — | P2 | completed | Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma |
NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01562210 | olaparib | P1 | completed | Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC |
Brain and Central Nervous System Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01390571 | — | P1 | completed | Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma |
PSR Ovarian Cancer With a BRCA Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03063710 | — | N/A | no longer available | Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan |
Carcinoma, Squamous Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01491139 | ORCA | P1 | withdrawn | Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck |
Olaparib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| IOLANTHE | NCT06121401 | P4 | active not recruiting | Carcinoma, Ovarian Epithelial | 190 | — |
| PROACTIVE | NCT05078671 | P4 | recruiting | Cancer | 160 | PMID 37806255 |
| OPTI-DOSE | NCT05949424 | P4 | unknown | Renal Cell Carcinoma | 30 | — |
| SOLI | NCT04330040 | P4 | completed | Ovarian Cancer | 202 | — |
| ORZORA | NCT02476968 | P4 | completed | BRCA or HRR+ Mutated Ovarian Cancer Patients | 181 | — |
| MK-3475 | NCT03486873 | P3 | recruiting | Solid Tumors | 3,500 | PMID 37348035 |
| PLANET | NCT07486687 | P3 | not yet recruiting | Triple Negative Breast Cancer (TNBC), Early Setting | 1,000 | — |
| MK-2870-032 | NCT06966700 | P3 | recruiting | Breast Neoplasms | 2,400 | — |
| Subito | NCT02810743 | P3 | active not recruiting | Breast Cancer | 174 | — |
| OVATION-3 | NCT06915025 | P3 | recruiting | Epithelial Ovarian Cancer | 500 | — |
| RAINBO-RED | NCT06712472 | P3 | recruiting | Endometrial Cancer | 554 | — |
| NSCLC | NCT04380636 | P3 | active not recruiting | Lung Neoplasms | 870 | PMID 35618629 |
| OlympiA | NCT02032823 | P3 | active not recruiting | Breast Cancer | 1,837 | PMID 34081848 |
| DUoENDE | NCT06746116 | P3 | active not recruiting | Advanced or Recurrent Endometrial Cancer | 45 | — |
| SOLO-1 | NCT01844986 | P3 | active not recruiting | Newly Diagnosed | 450 | PMID 30345884 |
| MITO 35B | NCT05255471 | P3 | recruiting | Ovarian Cancer | 200 | PMID 35318277 |
| LS-SCLC | NCT04624204 | P3 | active not recruiting | Small Cell Lung Cancer | 672 | PMID 35613997 |
| MONO-OLA1 | NCT04884360 | P3 | active not recruiting | Ovarian Cancer | 366 | — |
| ROSY-O | NCT04421963 | P3 | active not recruiting | Ovarian Cancer | 185 | — |
| DUO-E | NCT04269200 | P3 | active not recruiting | Endometrial Neoplasms | 805 | PMID 41943281 |
| DUO-O | NCT03737643 | P3 | active not recruiting | Advanced Ovarian Cancer | 1,407 | PMID 37185961 |
| MK-3475 | NCT03740165 | P3 | completed | Ovarian Cancer | 1,367 | — |
| MK-3475 | NCT03976362 | P3 | completed | Carcinoma, Squamous Cell, Non-small-cell Lung | 851 | PMID 39477187 |
| NSCLC | NCT03976323 | P3 | completed | Carcinoma, Nonsquamous Non-small-cell Lung | 1,003 | PMID 39521434 |
| MULTISARC | NCT03784014 | P3 | completed | Soft Tissue Sarcoma | 603 | PMID 34740331 |
| OlympiAD | NCT02000622 | P3 | completed | Breast Cancer Metastatic | 302 | PMID 28578601 |
| L-MOCA | NCT03534453 | P3 | completed | Relapsed Ovarian Cancer | 229 | PMID 38755585 |
| KEYLYNK-010 | NCT03834519 | P3 | completed | Prostatic Neoplasms | 793 | PMID 37290035 |
| ICON9 | NCT03278717 | P3 | unknown | Ovarian Cancer | 330 | PMID 33097567 |
| MK-7339 | NCT04456699 | P3 | completed | Metastatic Colorectal Cancer | 335 | PMID 38749110 |
| POLO | NCT02184195 | P3 | completed | Germline BRCA1/2 Mutations and | 154 | PMID 33364840 |
| SOLO3 | NCT02282020 | P3 | completed | Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | 266 | PMID 39668137 |
| PAOLA-1 | NCT02477644 | P3 | completed | Ovarian Cancer | 806 | PMID 31851799 |
| OPINION | NCT03402841 | P3 | completed | Non-Germline BRCA Mutated Ovarian Cancer | 279 | PMID 31553234 |
| OReO | NCT03106987 | P3 | completed | Epithelial Ovarian Cancer | 220 | PMID 37797734 |
| I-SPY | NCT01042379 | P2 | recruiting | Breast Neoplasms | 5,000 | PMID 21796368 |
| MK-5890 | NCT06829199 | P2 | withdrawn | Early Triple Negative Breast Cancer | 0 | — |
| COGNITION-GUIDE | NCT05332561 | P2 | recruiting | Early-stage Breast Cancer | 240 | — |
| DOVACC | NCT04742075 | P2 | active not recruiting | Ovarian Cancer | 188 | — |
| NeoADAPT | NCT06245889 | P2 | recruiting | Triple Negative Breast Cancer | 30 | PMID 32101663 |
| PETREMAC | NCT02624973 | P2 | active not recruiting | Breast Cancer | 200 | PMID 33242536 |
| NeoSarc | NCT06116578 | P2 | withdrawn | Cancer | 0 | — |
| PHOENIX | NCT03740893 | P2 | recruiting | Breast Neoplasm | 119 | — |
| HRD | NCT07113964 | P2 | not yet recruiting | Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency | 79 | — |
| QL1706 | NCT07407452 | P2 | not yet recruiting | Ovarian Cancers | 50 | — |
| ELEMENT | NCT06201234 | P2 | recruiting | Hormone Receptor Positive HER-2 Negative Breast Cancer | 176 | PMID 35584336 |
| TAPUR | NCT02693535 | P2 | recruiting | Lymphoma, Non-Hodgkin | 4,200 | PMID 36753688 |
| NEOCATS | NCT06650709 | P2 | not yet recruiting | Ovarian Cancer Stage IV | 40 | — |
| MEDI4736 | NCT06441747 | P2 | recruiting | Cholangiocarcinoma | 40 | — |
| TNBC | NCT05128734 | P2 | not yet recruiting | Breast Cancer Triple Negative | 40 | — |
| WoO | NCT04644289 | P2 | recruiting | Epithelial Ovarian Cancer | 60 | — |
| BOUQUET | NCT04931342 | P2 | active not recruiting | Ovarian Cancer | 176 | — |
| ORCHID | NCT03786796 | P2 | recruiting | Renal Cell Carcinoma | 20 | — |
| AZD6738 | NCT03682289 | P2 | active not recruiting | Clear Cell Renal Cell Carcinoma | 83 | PMID 41686845 |
| POLAR | NCT06160843 | P2 | recruiting | Relapsed Peripheral T-Cell Lymphoma | 24 | — |
| DRUP | NCT02925234 | P2 | recruiting | Cancer | 1,550 | PMID 37424386 |
| APOLLO | NCT04858334 | P2 | recruiting | Pancreatic Acinar Cell Carcinoma | 152 | PMID 37222189 |
| MOST plus | NCT02029001 | P2 | recruiting | Malignant Solid Neoplasms | 900 | PMID 37444551 |
| COBRA | NCT04038502 | P2 | recruiting | Metastatic Castrate Resistant Prostate Cancer | 100 | — |
| DOLAF | NCT04053322 | P2 | active not recruiting | ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | 172 | PMID 40986529 |
| GUIDE2REPAIR | NCT04169841 | P2 | active not recruiting | Immunotherapy | 270 | PMID 32778095 |
| THOR | NCT05623319 | P2 | recruiting | SCLC,Extensive Stage | 60 | — |
| NSCLC | NCT05568212 | P2 | recruiting | Non-small-cell Lung Cancer Patients | 176 | PMID 18500231 |
| IDH | NCT03953898 | P2 | active not recruiting | Acute Myeloid Leukemia | 14 | — |
| TNBC | NCT05203445 | P2 | active not recruiting | Breast Cancer | 6 | — |
| CAPTUR | NCT03297606 | P2 | recruiting | Lymphoma, Non-Hodgkin | 720 | — |
| DAPPER | NCT03851614 | P2 | active not recruiting | Mismatch Repair Proficient Colorectal Cancer | 90 | — |
| GUIDANCE | NCT06419179 | P2 | enrolling by invitation | Small Cell Lung Carcinoma | 29 | — |
| NePtune | NCT05498272 | P2 | recruiting | Prostate Cancer | 32 | PMID 36710203 |
| OlympiaN | NCT05498155 | P2 | active not recruiting | Breast Cancer | 50 | — |
| BAYOU | NCT03459846 | P2 | active not recruiting | Urinary Bladder Neoplasms | 154 | PMID 35737919 |
| OPTIMUM | NCT05222971 | P2 | recruiting | Biliary Tract Cancer | 62 | PMID 20375404 |
| ORION | NCT03775486 | P2 | active not recruiting | Non-small Cell Lung Cancer NSCLC | 401 | PMID 37390980 |
| HUDSON | NCT03334617 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 528 | PMID 38351187 |
| OPEB-01 | NCT04361370 | P2 | enrolling by invitation | Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer | 44 | PMID 33559413 |
| ATARI | NCT04065269 | P2 | active not recruiting | Gynaecological Cancers | 174 | PMID 34904813 |
| PALBOLA | NCT06078787 | P2 | recruiting | Advanced Pancreatic Cancer | 16 | — |
| MK-7339 | NCT03742895 | P2 | active not recruiting | Advanced Solid Neoplasms | 329 | — |
| MK-7339 | NCT04123366 | P2 | active not recruiting | Solid Tumors | 300 | PMID 35567913 |
| MEDI4736 | NCT05659914 | P2 | active not recruiting | Metastatic Pancreatic Cancer | 40 | — |
| ADT | NCT04748042 | P2 | active not recruiting | Prostate Cancer | 21 | — |
| COMICE | NCT04487587 | P2 | active not recruiting | Cervical Cancer | 79 | — |
| COMPRENDO | NCT05033756 | P2 | active not recruiting | Malignant Neoplasm of Breast | 11 | — |
| MITO 35a | NCT05233982 | P2 | unknown | Ovarian Cancer | 200 | — |
| Post-CDK | NCT05536128 | P2 | recruiting | Advanced Breast Cancer | 64 | — |
| MAZEPPA | NCT04348045 | P2 | active not recruiting | Metastatic Pancreatic Adenocarcinoma | 307 | — |
| 1-2018 BSMO | NCT03967938 | P2 | active not recruiting | Advanced Cancers Harbouring Mutations in HRG | 540 | — |
| NEO | NCT02489006 | P2 | unknown | Ovarian Cancer | 71 | — |
| SAFIR02_Breast | NCT02299999 | P2 | active not recruiting | Metastatic Breast Cancer | 1,460 | PMID 32067679 |
| WIRE | NCT03741426 | P2 | unknown | Renal Cell Cancer | 60 | PMID 34794412 |
| TNBC | NCT04191135 | P2 | completed | Triple Negative Breast Neoplasms | 462 | PMID 41405563 |
| STROBE | NCT06377267 | P2 | unknown | Ovarian Cancer | 100 | — |
| CAPRI | NCT03462342 | P2 | completed | High Grade Serous Carcinoma | 123 | — |
| PEMBROLA | NCT05201612 | P2 | unknown | Metastatic Colorectal Cancer | 40 | — |
| SOLID | NCT03991832 | P2 | recruiting | Glioma | 58 | — |
| RADIOLA | NCT05340413 | P2 | completed | HER2-negative Breast Cancer | 65 | — |
| HR | NCT04633902 | P2 | unknown | Metastatic Melanoma | 41 | — |
| FAB | NCT04780945 | P2 | terminated | Ovarian Neoplasm Epithelial | 27 | — |
| MEDI4736 | NCT03579784 | P2 | unknown | Advanced Gastric Cancer | 40 | — |
| AMTEC IIT | NCT03801369 | P2 | terminated | Anatomic Stage IV Breast Cancer AJCC v8 | 24 | — |
| TOMAS2 | NCT03838744 | P2 | completed | Advanced Soft Tissue Sarcoma | 130 | PMID 36110934 |
| CUPISCO | NCT03498521 | P2 | completed | Cancer of Unknown Primary Site | 529 | PMID 39096924 |
| UTOLA | NCT03745950 | P2 | completed | Endometrial Carcinoma | 147 | — |
| PROspect | NCT05262608 | P2 | unknown | Prostate Cancer | 30 | — |
| LYNPARZA | NCT04538378 | P2 | terminated | EGFR-Mutated Non-Small-Cell Lung Carcinoma | 4 | — |
| BOLD | NCT04015739 | P2 | unknown | Epithelial Ovarian Cancer | 74 | — |
| OCTOVA | NCT03117933 | P2 | completed | Ovarian Cancer | 139 | PMID 33452192 |
| SAFIR02_Lung | NCT02117167 | P2 | completed | Non-small Cell Lung Cancer Metastatic | 999 | PMID 26410619 |
| NCT-PMO-1603 | NCT03127215 | P2 | completed | Cancers With DNA Repair-Deficiency | 102 | — |
| MEDI4736 | NCT05245994 | P2 | unknown | Lung Cancer | 60 | — |
| plasmaMATCH | NCT03182634 | P2 | unknown | Advanced Breast Cancer | 1,150 | PMID 32919527 |
| SUKSES-B2 | NCT04939662 | P2 | completed | Lung Cancer | 25 | — |
| ANLOLA | NCT04566952 | P2 | unknown | Ovarian Cancer | 68 | — |
| MITO 31 | NCT04091204 | P2 | unknown | BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | 200 | — |
| CLIO | NCT02822157 | P2 | unknown | Ovarian Epithelial Cancer | 160 | — |
| OLAPem | NCT04417192 | P2 | completed | Ovarian Cancer | 30 | — |
| COPELIA | NCT03570437 | P2 | unknown | Carcinosarcoma | 124 | — |
| ROLANDO | NCT03161132 | P2 | completed | Advanced Ovarian Cancer | 32 | PMID 34329939 |
| ICEBERG 1 | NCT00494234 | P2 | completed | Breast Neoplasms | 54 | PMID 20609467 |
| COMETABreast | NCT03205761 | P2 | completed | Advanced Breast Cancer | 11 | — |
| NUVOLA | NCT04261465 | P2 | unknown | High Grade Serous Ovarian Cancer | 35 | PMID 34131041 |
| AMBITION | NCT03699449 | P2 | unknown | Platinum-resistant Recurrent Ovarian Cancer | 104 | PMID 31671191 |
| DORA | NCT03167619 | P2 | completed | Triple Negative Breast Cancer | 45 | PMID 38236575 |
| IMANOL | NCT03434158 | P2 | completed | Prostate Cancer Metastatic | 16 | — |
| PIPSeN | NCT02679963 | P2 | terminated | Non Small Cell Lung Cancer | 180 | PMID 38097741 |
| OPHELIA | NCT03931551 | P2 | terminated | Advanced Breast Cancer | 5 | — |
| SOLAR | NCT03829345 | P2 | unknown | Oesophageal Cancer | 54 | — |
| NOBROLA | NCT03367689 | P2 | terminated | Breast Cancer | 7 | PMID 39520738 |
| 337 | NCT03432897 | P2 | terminated | Prostate Cancer | 1 | PMID 33084183 |
| OLAGLI | NCT03561870 | P2 | completed | Recurrent IDH | 35 | PMID 38855053 |
| 10 | NCT02511223 | P2 | completed | Pancreatic Cancer | 24 | — |
| BAROCCO | NCT03314740 | P2 | completed | Ovarian Neoplasms | 123 | PMID 35170751 |
| CONCERTO | NCT02889900 | P2 | completed | Recurrent Platinum Resistant Ovarian Cancer | 62 | — |
| SUKSES-B | NCT03009682 | P2 | completed | Small Cell Lung Cancer | 15 | — |
| DUETTE | NCT04239014 | P2 | withdrawn | Ovarian Cancer | 0 | PMID 32878963 |
| NEODURVARIB | NCT03534492 | P2 | completed | Bladder Cancer | 29 | — |
| TOPARP | NCT01682772 | P2 | unknown | Adenocarcinoma of the Prostate | 148 | PMID 31806540 |
| OPHELIA | NCT02882308 | P2 | completed | Squamous Cell Carcinoma of the Head and Neck | 41 | PMID 33714009 |
| PIN | NCT01788332 | P2 | unknown | Non-small Cell Lung Cancer | 70 | PMID 35990583 |
| MSI | NCT00912743 | P2 | completed | Colorectal Cancer | 33 | — |
Terminated and withdrawn Olaparib trials (52)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06829199withdrawnA Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- NCT05209529withdrawnChemo-free BRCA-targeted Neoadjuvant Strategy
- NCT06120972withdrawnUpfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
- NCT06116578withdrawnStudy Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
- NCT05411094suspendedTesting the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
- NCT05482074withdrawnOlaparib in Unresectable/Metastatic Melanoma With BRCA1/2
- NCT05807126withdrawnTesting the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
- NCT05238831withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial
- NCT06130254terminatedPhase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
- NCT04729387terminatedAlpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
- NCT06560632terminatedPhase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors
- NCT05286827terminatedOlaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
- NCT06331559terminatedStudy of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
- NCT04336943terminatedDurvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
- NCT05967286withdrawnOlaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
- NCT05405309terminatedRP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
- NCT05411679withdrawnEP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
- NCT04780945terminatedFunctional Analysis of BRCAness
- NCT03801369terminatedAMTEC IIT: Phase 2 Multiarm Study in TNBC
- NCT04483544terminatedPembrolizumab and Olaparib in Cervical Cancer Patients
- NCT03782818terminatedOlaparib for PAH: a Multicenter Clinical Trial
- NCT05501548terminatedPhase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
- NCT02419495terminatedPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- NCT05252390terminatedNUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
- NCT06065059terminatedStudy to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
- NCT04826198terminatedSafety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
- NCT04538378terminatedOlaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
- NCT04951492terminatedOlaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
- NCT03810105terminatedA Study of Olaparib and Durvalumab in Prostate Cancer
- NCT04377087terminatedDelayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
- NCT05295589withdrawnComparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
- NCT04801966terminatedSafety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study
- NCT04556617terminatedPLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- NCT02679963terminatedTrial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer
- NCT03931551terminatedOlaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer
- NCT03924245terminatedOlaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
- NCT03367689terminatedA Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent
- NCT03432897terminatedBrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes
- NCT03955640terminatedHyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
- NCT04579133terminatedNeoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
- NCT04239014withdrawnA Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
- NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- NCT02899728terminatedOlaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
- NCT02485990terminatedStudy of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
- NCT03251872terminatedOlaparib for PAH: a Pilot Study
- NCT02686008withdrawnPharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
- NCT03570476terminatedOlaparib Before Surgery in Treating Participants With Localized Prostate Cancer
- NCT02392676withdrawnOlaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
- NCT03575078withdrawnARQ761 + PARP Inhibitor in Refractory Solid Tumors
- NCT02561832terminatedA Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
- NCT01661868withdrawnOlaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
- NCT01491139withdrawnPhase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
All Olaparib trials (409)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT03486873 | MK-3475 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | P3 | recruiting | 3,500 | Merck Sharp & Dohme LLC | Aug 2018 |
| NCT07486687 | PLANET | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy | P3 | not yet recruiting | 1,000 | The Netherlands Cancer Institute | Apr 2026 |
| NCT06797635 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | P2 | recruiting | 372 | Merck Sharp & Dohme LLC | Mar 2025 | |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | P3 | recruiting | 880 | NRG Oncology | Mar 2025 | |
| NCT06966700 | MK-2870-032 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | P3 | recruiting | 2,400 | Merck Sharp & Dohme LLC | Jun 2025 |
| NCT03150576 | PARTNER | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer | P2/P3 | recruiting | 780 | Cambridge University Hospitals NHS Foundation Trust | May 2016 |
| NCT02810743 | Subito | Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | P3 | active not recruiting | 174 | The Netherlands Cancer Institute | Jan 2017 |
| NCT06915025 | OVATION-3 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | P3 | recruiting | 500 | Imunon | Jul 2025 |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | P3 | active not recruiting | 1,902 | AstraZeneca | Nov 2023 | |
| NCT07460180 | PROOV | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | P1/P2 | recruiting | 55 | The Netherlands Cancer Institute | May 2025 |
| NCT07382544 | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | P1 | recruiting | 36 | M.D. Anderson Cancer Center | Feb 2026 | |
| NCT06712472 | RAINBO-RED | Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer | P3 | recruiting | 554 | Gustave Roussy, Cancer Campus, Grand Paris | Jun 2024 |
| NCT01042379 | I-SPY | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | P2 | recruiting | 5,000 | QuantumLeap Healthcare Collaborative | Mar 2010 |
| NCT07151911 | ROYAL | Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients | — | recruiting | 100 | Azienda Ospedaliero-Universitaria di Modena | Aug 2024 |
| NCT05522491 | Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer | P2 | not yet recruiting | 30 | Hebei Medical University Fourth Hospital | Sep 2026 | |
| NCT06829199 | MK-5890 | A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) | P2 | withdrawn | 0 | Merck Sharp & Dohme LLC | Mar 2025 |
| NCT02813135 | ESMART | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | recruiting | 472 | Gustave Roussy, Cancer Campus, Grand Paris | Aug 2016 |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | P2 | recruiting | 53 | University of Colorado, Denver | Oct 2023 | |
| NCT05255653 | RAINBO | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features | P2/P3 | recruiting | 1,615 | Leiden University Medical Center | Nov 2021 |
| NCT05332561 | COGNITION-GUIDE | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | P2 | recruiting | 240 | German Cancer Research Center | Jun 2023 |
| NCT04742075 | DOVACC | Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer | P2 | active not recruiting | 188 | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Dec 2021 |
| NCT05952453 | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro | P2 | recruiting | 20 | University of Alabama at Birmingham | Feb 2025 | |
| NCT05366166 | Pembrolizumab Plus Olaparib in LA-HNSCC | P2 | active not recruiting | 45 | UNC Lineberger Comprehensive Cancer Center | Sep 2022 | |
| NCT05209529 | Chemo-free BRCA-targeted Neoadjuvant Strategy | P2 | withdrawn | 0 | European Organisation for Research and Treatment of Cancer - EORTC | Feb 2024 | |
| NCT05564377 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | P2 | recruiting | 2,900 | National Cancer Institute (NCI) | Apr 2023 | |
| NCT06245889 | NeoADAPT | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | P2 | recruiting | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2024 |
| NCT02624973 | PETREMAC | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial | P2 | active not recruiting | 200 | Haukeland University Hospital | Apr 2016 |
| NCT07005583 | Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer | P2 | not yet recruiting | 46 | Tianjin Medical University Cancer Institute and Hospital | Jun 2025 | |
| NCT06607692 | LUPARPED | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). | P1/P2 | recruiting | 25 | Fundación de investigación HM | Sep 2024 |
| NCT06120972 | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | P2 | withdrawn | 0 | Alexander B Olawaiye, MD | Jan 2024 | |
| NCT05932862 | ISM3091 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | P1 | recruiting | 429 | Exelixis | Apr 2024 |
| NCT06856499 | Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer | P1 | recruiting | 50 | University of Colorado, Denver | Dec 2025 | |
| NCT04380636 | NSCLC | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | P3 | active not recruiting | 870 | Merck Sharp & Dohme LLC | Jul 2020 |
| NCT05568550 | Pembro With Radiation With or Without Olaparib | P2 | recruiting | 64 | Zin W Myint | Jul 2023 | |
| NCT06116578 | NeoSarc | Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab | P2 | withdrawn | 0 | Gustave Roussy, Cancer Campus, Grand Paris | Jan 2025 |
| NCT06298084 | ICARUSBREAST02 | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | P1/P2 | recruiting | 152 | Gustave Roussy, Cancer Campus, Grand Paris | Mar 2024 |
| NCT03740893 | PHOENIX | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer | P2 | recruiting | 119 | Institute of Cancer Research, United Kingdom | Oct 2019 |
| NCT02032823 | OlympiA | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | P3 | active not recruiting | 1,837 | AstraZeneca | Apr 2014 |
| NCT06785636 | P300 | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC | P1/P2 | recruiting | 120 | Pathos AI, Inc. | Feb 2025 |
| NCT07113964 | HRD | QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) | P2 | not yet recruiting | 79 | The First Affiliated Hospital with Nanjing Medical University | Aug 2025 |
| NCT06488378 | Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | P1 | recruiting | 20 | Dana-Farber Cancer Institute | Aug 2024 | |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | P1/P2 | not yet recruiting | 626 | Qilu Pharmaceutical Co., Ltd. | Apr 2026 | |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | P1 | recruiting | 110 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Aug 2025 | |
| NCT06353386 | MK-5684 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | P1/P2 | recruiting | 220 | Merck Sharp & Dohme LLC | May 2024 |
| NCT07407452 | QL1706 | Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer | P2 | not yet recruiting | 50 | Jiangsu Cancer Institute & Hospital | Feb 2026 |
| NCT07187674 | The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel | N/A | not yet recruiting | 20 | Harbin Medical University | Dec 2025 | |
| NCT06201234 | ELEMENT | Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer | P2 | recruiting | 176 | GBG Forschungs GmbH | Dec 2024 |
| NCT05900895 | PHOEBE | Estradiol Plus Olaparib for Breast Cancer (PHOEBE) | P1 | recruiting | 6 | Mary D Chamberlin | Jul 2024 |
| NCT02693535 | TAPUR | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | P2 | recruiting | 4,200 | American Society of Clinical Oncology | Mar 2016 |
| NCT06686745 | Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors | P1 | recruiting | 130 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Dec 2024 | |
| NCT07090369 | LumOnate | Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer | P1 | not yet recruiting | 20 | Peter MacCallum Cancer Centre, Australia | Nov 2025 |
| NCT06746116 | DUoENDE | A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain | P3 | active not recruiting | 45 | AstraZeneca | Dec 2024 |
| NCT06650709 | NEOCATS | NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study | P2 | not yet recruiting | 40 | British Columbia Cancer Agency | Nov 2024 |
| NCT06217757 | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | P1/P2 | recruiting | 45 | Sichuan University | Apr 2024 | |
| NCT04643379 | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | P2 | active not recruiting | 30 | Washington University School of Medicine | Aug 2021 | |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | P2 | recruiting | 165 | National Cancer Institute (NCI) | Apr 2023 | |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | P2 | recruiting | 23 | Okayama University | Jul 2024 | |
| NCT05898399 | POLKA | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | P1/P2 | recruiting | 181 | Artios Pharma Ltd | Jun 2023 |
| NCT04209686 | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | P2 | active not recruiting | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2020 | |
| NCT06441747 | MEDI4736 | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | P2 | recruiting | 40 | Australasian Gastro-Intestinal Trials Group | Sep 2024 |
| NCT03787680 | Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | P2 | active not recruiting | 49 | University of Michigan Rogel Cancer Center | Oct 2019 | |
| NCT01844986 | SOLO-1 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. | P3 | active not recruiting | 450 | AstraZeneca | Aug 2013 |
| NCT06686030 | Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer | P2 | recruiting | 150 | Akeso | Feb 2025 | |
| NCT02861573 | MK-3475 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | P1/P2 | recruiting | 1,200 | Merck Sharp & Dohme LLC | Nov 2016 |
| NCT05128734 | TNBC | Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | P2 | not yet recruiting | 40 | AHS Cancer Control Alberta | Apr 2026 |
| NCT05411094 | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | P1 | suspended | 18 | National Cancer Institute (NCI) | May 2023 | |
| NCT04644289 | WoO | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | P2 | recruiting | 60 | AGO Research GmbH | May 2022 |
| NCT04931342 | BOUQUET | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | P2 | active not recruiting | 176 | Hoffmann-La Roche | Oct 2021 |
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | P2 | recruiting | 56 | University of Chicago | Feb 2021 | |
| NCT04550104 | CONCORDE | A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC | P1 | recruiting | 200 | University of Leeds | Mar 2021 |
| NCT03786796 | ORCHID | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations | P2 | recruiting | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2019 |
| NCT03682289 | AZD6738 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | P2 | active not recruiting | 83 | Rahul Aggarwal | Jan 2019 |
| NCT04394858 | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer | P2 | active not recruiting | 46 | National Cancer Institute (NCI) | Mar 2021 | |
| NCT07024784 | A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies | P2 | recruiting | 377 | AbbVie | Jul 2025 | |
| NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | Early P1 | recruiting | 90 | OHSU Knight Cancer Institute | Aug 2019 | |
| NCT06160843 | POLAR | Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma | P2 | recruiting | 24 | National Cancer Centre, Singapore | Jul 2024 |
| NCT06177171 | HRD | Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors | P1 | recruiting | 18 | Varun Monga, MBBS | Feb 2024 |
| NCT05255471 | MITO 35B | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. | P3 | recruiting | 200 | National Cancer Institute, Naples | Jan 2022 |
| NCT05093231 | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | P2 | recruiting | 20 | Cambridge University Hospitals NHS Foundation Trust | Feb 2025 | |
| NCT04086485 | GEP-NET | Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | P1/P2 | recruiting | 56 | National Cancer Institute (NCI) | Oct 2022 |
| NCT06525298 | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | P1/P2 | recruiting | 144 | Eisbach Bio GmbH | Sep 2024 | |
| NCT05524935 | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | P2 | recruiting | 37 | H. Lee Moffitt Cancer Center and Research Institute | Oct 2022 | |
| NCT04728230 | Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial | P1/P2 | active not recruiting | 63 | M.D. Anderson Cancer Center | Jan 2021 | |
| NCT04090567 | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | P2 | recruiting | 60 | M.D. Anderson Cancer Center | Jul 2020 | |
| NCT02925234 | DRUP | The Drug Rediscovery Protocol (DRUP Trial) | P2 | recruiting | 1,550 | The Netherlands Cancer Institute | Aug 2016 |
| NCT05432518 | Pilot Trial for Treatment of Recurrent Glioblastoma | Early P1 | recruiting | 10 | AHS Cancer Control Alberta | Jun 2023 | |
| NCT06545942 | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | P1 | active not recruiting | 220 | MOMA Therapeutics | Aug 2024 | |
| NCT04858334 | APOLLO | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | P2 | recruiting | 152 | National Cancer Institute (NCI) | Jun 2021 |
| NCT02029001 | MOST plus | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment | P2 | recruiting | 900 | Centre Leon Berard | Mar 2014 |
| NCT02484404 | MEDI4736 | Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | P1/P2 | active not recruiting | 268 | National Cancer Institute (NCI) | Jun 2015 |
| NCT04624204 | LS-SCLC | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | P3 | active not recruiting | 672 | Merck Sharp & Dohme LLC | Dec 2020 |
| NCT06121401 | IOLANTHE | First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients | P4 | active not recruiting | 190 | Mario Negri Institute for Pharmacological Research | Sep 2023 |
| NCT05238922 | Study of INCB123667 in Subjects With Advanced Solid Tumors | P1 | recruiting | 604 | Incyte Corporation | Jul 2022 | |
| NCT04038502 | COBRA | Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | P2 | recruiting | 100 | VA Office of Research and Development | Oct 2019 |
| NCT04053322 | DOLAF | Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. | P2 | active not recruiting | 172 | UNICANCER | Aug 2019 |
| NCT04169841 | GUIDE2REPAIR | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment | P2 | active not recruiting | 270 | Centre Georges Francois Leclerc | Feb 2020 |
| NCT05623319 | THOR | Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) | P2 | recruiting | 60 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Mar 2023 |
| NCT04884360 | MONO-OLA1 | D9319C00001- 1L OC Mono Global RCT | P3 | active not recruiting | 366 | AstraZeneca | May 2021 |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | P1/P2 | active not recruiting | 50 | New Mexico Cancer Research Alliance | Feb 2016 | |
| NCT03943173 | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | Early P1 | active not recruiting | 15 | M.D. Anderson Cancer Center | Jun 2019 | |
| NCT03598257 | Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | P2 | active not recruiting | 300 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | P2 | active not recruiting | 85 | Fusion Pharmaceuticals Inc. | Feb 2025 | |
| NCT05568212 | NSCLC | Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab | P2 | recruiting | 176 | Fondazione Ricerca Traslazionale | May 2022 |
| NCT02893917 | Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | P2 | active not recruiting | 90 | National Cancer Institute (NCI) | Aug 2017 | |
| NCT06739395 | Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | P2 | recruiting | 300 | Tianjin Medical University Second Hospital | Nov 2024 | |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | P2 | withdrawn | 0 | Dana-Farber Cancer Institute | Oct 2022 | |
| NCT03047135 | Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis | P2 | active not recruiting | 51 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2017 | |
| NCT02498613 | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors | P2 | active not recruiting | 122 | National Cancer Institute (NCI) | Aug 2016 | |
| NCT04421963 | ROSY-O | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | P3 | active not recruiting | 185 | AstraZeneca | Aug 2020 |
| NCT04269200 | DUO-E | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer | P3 | active not recruiting | 805 | AstraZeneca | May 2020 |
| NCT07371104 | Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | P1 | recruiting | 40 | Daewoong Pharmaceutical Co. LTD. | Apr 2026 | |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | P2 | active not recruiting | 120 | National Cancer Institute (NCI) | Jun 2021 | |
| NCT03953898 | IDH | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | P2 | active not recruiting | 14 | National Cancer Institute (NCI) | Aug 2020 |
| NCT03660826 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | P2 | active not recruiting | 288 | National Cancer Institute (NCI) | Sep 2018 | |
| NCT02345265 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | P2 | active not recruiting | 70 | National Cancer Institute (NCI) | May 2016 | |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | P2/P3 | active not recruiting | 582 | National Cancer Institute (NCI) | May 2016 | |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | P3 | active not recruiting | 579 | National Cancer Institute (NCI) | Mar 2016 | |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | P1/P2 | active not recruiting | 155 | National Cancer Institute (NCI) | Apr 2010 | |
| NCT05463848 | Surgical Pembro +/- Olaparib w TMZ for rGBM | P2 | recruiting | 78 | L. Nicolas Gonzalez Castro, MD, PhD | Oct 2022 | |
| NCT04034927 | Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer | P2 | active not recruiting | 61 | National Cancer Institute (NCI) | Dec 2019 | |
| NCT03317392 | Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | P1/P2 | active not recruiting | 132 | National Cancer Institute (NCI) | Feb 2019 | |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | P3 | active not recruiting | 895 | AstraZeneca | Oct 2018 | |
| NCT05203445 | TNBC | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | P2 | active not recruiting | 6 | Memorial Sloan Kettering Cancer Center | Jan 2022 |
| NCT05188508 | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | P2 | recruiting | 57 | Memorial Sloan Kettering Cancer Center | Jan 2022 | |
| NCT04683679 | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | P2 | recruiting | 34 | Memorial Sloan Kettering Cancer Center | Apr 2021 | |
| NCT04666740 | A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy | P2 | active not recruiting | 63 | Memorial Sloan Kettering Cancer Center | Dec 2020 | |
| NCT03297606 | CAPTUR | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | P2 | recruiting | 720 | Canadian Cancer Trials Group | Mar 2018 |
| NCT05432791 | Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working | P2/P3 | active not recruiting | 74 | National Cancer Institute (NCI) | Mar 2023 | |
| NCT03012321 | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | P2 | active not recruiting | 70 | Northwestern University | Jan 2017 | |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | P2 | active not recruiting | 1,377 | National Cancer Institute (NCI) | Jul 2017 | |
| NCT05870423 | PRRT-PARPi | Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors | P1 | recruiting | 24 | Erasmus Medical Center | Jun 2022 |
| NCT03851614 | DAPPER | Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors | P2 | active not recruiting | 90 | University Health Network, Toronto | Apr 2019 |
| NCT06419179 | GUIDANCE | Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) | P2 | enrolling by invitation | 29 | University of Cologne | Oct 2024 |
| NCT05498272 | NePtune | Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | P2 | recruiting | 32 | Rana McKay, MD | Feb 2023 |
| NCT06783127 | COROS | Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer | — | recruiting | 3,000 | Santa Chiara Hospital | Jan 2023 |
| NCT05498155 | OlympiaN | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer | P2 | active not recruiting | 50 | AstraZeneca | Nov 2022 |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | P4 | active not recruiting | 43 | AstraZeneca | Jul 2022 | |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | P1 | recruiting | 55 | National Cancer Institute (NCI) | May 2021 | |
| NCT04197713 | AZD1775 | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study | P1 | active not recruiting | 13 | National Cancer Institute (NCI) | Jun 2020 |
| NCT03842228 | COD | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations | P1 | active not recruiting | 39 | National Cancer Institute (NCI) | Nov 2019 |
| NCT03923270 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | P1 | active not recruiting | 25 | H. Lee Moffitt Cancer Center and Research Institute | Jun 2019 | |
| NCT03579316 | Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | P2 | active not recruiting | 96 | M.D. Anderson Cancer Center | Dec 2018 | |
| NCT03772561 | MEDIPAC | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies | P1 | recruiting | 40 | National University Hospital, Singapore | Dec 2018 |
| NCT03459846 | BAYOU | A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) | P2 | active not recruiting | 154 | AstraZeneca | Mar 2018 |
| NCT03212742 | OLA-TMZ-RTE-01 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients | P1/P2 | active not recruiting | 91 | Centre Francois Baclesse | Sep 2017 |
| NCT01081951 | Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer | P2 | active not recruiting | 162 | AstraZeneca | Feb 2010 | |
| NCT05222971 | OPTIMUM | Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy | P2 | recruiting | 62 | Asan Medical Center | Apr 2022 |
| NCT03737643 | DUO-O | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | P3 | active not recruiting | 1,407 | AstraZeneca | Jan 2019 |
| NCT03375307 | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | P2 | active not recruiting | 60 | National Cancer Institute (NCI) | Nov 2020 | |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | P1 | withdrawn | 0 | National Cancer Institute (NCI) | Mar 2024 | |
| NCT03742245 | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | P1 | active not recruiting | 28 | The Methodist Hospital Research Institute | Jun 2019 | |
| NCT04711824 | SOLARA | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | P1/P2 | recruiting | 41 | Colette Shen | Mar 2022 |
| NCT03880019 | A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma | P2 | active not recruiting | 23 | National Cancer Institute (NCI) | Aug 2019 | |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | P1 | recruiting | 42 | National Cancer Institute (NCI) | Jul 2021 | |
| NCT03641755 | Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | P1 | active not recruiting | 10 | Dana-Farber Cancer Institute | Oct 2018 | |
| NCT04548752 | Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | P2 | active not recruiting | 88 | National Cancer Institute (NCI) | Feb 2021 | |
| NCT03775486 | ORION | Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) | P2 | active not recruiting | 401 | AstraZeneca | Dec 2018 |
| NCT02734004 | MEDIOLA | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | P1/P2 | active not recruiting | 264 | AstraZeneca | Mar 2016 |
| NCT03334617 | HUDSON | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy | P2 | active not recruiting | 528 | AstraZeneca | Dec 2017 |
| NCT03330847 | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. | P2 | active not recruiting | 273 | AstraZeneca | Mar 2018 | |
| NCT04361370 | OPEB-01 | Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer | P2 | enrolling by invitation | 44 | Yonsei University | Oct 2020 |
| NCT04065269 | ATARI | ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss | P2 | active not recruiting | 174 | Institute of Cancer Research, United Kingdom | Nov 2019 |
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | P2 | active not recruiting | 81 | National Cancer Institute (NCI) | Mar 2017 | |
| NCT04042831 | Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations | P2 | active not recruiting | 32 | Academic and Community Cancer Research United | Jun 2020 | |
| NCT03162627 | Selumetinib and Olaparib in Solid Tumors | P1 | active not recruiting | 90 | M.D. Anderson Cancer Center | Aug 2017 | |
| NCT06078787 | PALBOLA | Olaparib in PALB2 Advanced Pancreatic Cancer | P2 | recruiting | 16 | Azienda Ospedaliero-Universitaria di Modena | Aug 2023 |
| NCT03085147 | A Dye for the Detection of Cancer of the Tongue and Mouth | P1/P2 | active not recruiting | 23 | Memorial Sloan Kettering Cancer Center | Mar 2017 | |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | P1/P2 | active not recruiting | 64 | Lantern Pharma Inc. | Jun 2023 | |
| NCT03212274 | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | P2 | active not recruiting | 89 | National Cancer Institute (NCI) | Jan 2019 | |
| NCT02974621 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | P2 | active not recruiting | 70 | National Cancer Institute (NCI) | Dec 2017 | |
| NCT03878095 | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | P2 | active not recruiting | 24 | National Cancer Institute (NCI) | Jan 2020 | |
| NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | P2 | active not recruiting | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sep 2021 | |
| NCT03874884 | LuPARP | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer | P1 | active not recruiting | 70 | Peter MacCallum Cancer Centre, Australia | Jul 2019 |
| NCT03742895 | MK-7339 | Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) | P2 | active not recruiting | 329 | Merck Sharp & Dohme LLC | Dec 2018 |
| NCT03344965 | Olaparib In Metastatic Breast Cancer | P2 | active not recruiting | 114 | Beth Israel Deaconess Medical Center | Apr 2018 | |
| NCT03263650 | Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | P2 | active not recruiting | 96 | M.D. Anderson Cancer Center | Oct 2017 | |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | P1 | active not recruiting | 159 | M.D. Anderson Cancer Center | Nov 2014 | |
| NCT02264678 | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | P1 | active not recruiting | 354 | AstraZeneca | Oct 2014 | |
| NCT04123366 | MK-7339 | Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) | P2 | active not recruiting | 300 | Merck Sharp & Dohme LLC | Nov 2019 |
| NCT05659914 | MEDI4736 | Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations | P2 | active not recruiting | 40 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | Nov 2022 |
| NCT04417062 | Olaparib With Ceralasertib in Recurrent Osteosarcoma | P2 | active not recruiting | 63 | Dana-Farber Cancer Institute | Nov 2020 | |
| NCT05238831 | ACT | SMMART Adaptive Clinical Treatment (ACT) Trial | Early P1 | withdrawn | 0 | OHSU Knight Cancer Institute | Jan 2023 |
| NCT04592211 | GEJ | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | P1/P2 | recruiting | 71 | Yonsei University | Oct 2021 |
| NCT04748042 | ADT | Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | P2 | active not recruiting | 21 | University of Michigan Rogel Cancer Center | May 2021 |
| NCT07069335 | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer | P1 | recruiting | 24 | Boryung Pharmaceutical Co., Ltd | Jun 2025 | |
| NCT05171816 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | P3 | active not recruiting | 110 | AstraZeneca | Jun 2021 | |
| NCT05156268 | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | P2 | completed | 26 | Memorial Sloan Kettering Cancer Center | Jan 2022 | |
| NCT02308072 | ORCA-2 | Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer | P1 | completed | 16 | University College, London | Sep 2015 |
| NCT03740165 | MK-3475 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | P3 | completed | 1,367 | Merck Sharp & Dohme LLC | Dec 2018 |
| NCT06130254 | MRTX849 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | P1 | terminated | 1 | M.D. Anderson Cancer Center | Jan 2024 |
| NCT04487587 | COMICE | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer | P2 | active not recruiting | 79 | The Clatterbridge Cancer Centre NHS Foundation Trust | Oct 2018 |
| NCT05033756 | COMPRENDO | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO | P2 | active not recruiting | 11 | Institut fuer Frauengesundheit | Jul 2022 |
| NCT05233982 | MITO 35a | MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer | P2 | unknown | 200 | National Cancer Institute, Naples | Dec 2021 |
| NCT03976362 | MK-3475 | A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) | P3 | completed | 851 | Merck Sharp & Dohme LLC | Jun 2019 |
| NCT02546661 | BISCAY | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer | P1 | active not recruiting | 117 | AstraZeneca | Dec 2016 |
| NCT03976323 | NSCLC | Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | P3 | completed | 1,003 | Merck Sharp & Dohme LLC | Jun 2019 |
| NCT05379972 | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | P2 | completed | 9 | University of Colorado, Denver | Jan 2023 | |
| NCT03784014 | MULTISARC | Molecular Profiling of Advanced Soft-tissue Sarcomas | P3 | completed | 603 | Institut National de la Santé Et de la Recherche Médicale, France | Oct 2019 |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | P3 | terminated | 358 | Novartis Pharmaceuticals | Jul 2021 | |
| NCT05629429 | Olaparib Maintenance Therapy in Metastatic Breast Cancer | P2 | unknown | 300 | National Taiwan University Hospital | Feb 2023 | |
| NCT05536128 | Post-CDK | Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor | P2 | recruiting | 64 | Seoul National University Hospital | Dec 2022 |
| NCT05078671 | PROACTIVE | Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness | P4 | recruiting | 160 | Radboud University Medical Center | Dec 2021 |
| NCT04348045 | MAZEPPA | Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | P2 | active not recruiting | 307 | GERCOR - Multidisciplinary Oncology Cooperative Group | Dec 2020 |
| NCT03967938 | 1-2018 BSMO | Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes | P2 | active not recruiting | 540 | Universitair Ziekenhuis Brussel | Feb 2019 |
| NCT03594396 | Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer | P1/P2 | active not recruiting | 54 | Seoul National University Hospital | Jun 2018 | |
| NCT02489006 | NEO | A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | P2 | unknown | 71 | University Health Network, Toronto | Jul 2016 |
| NCT02299999 | SAFIR02_Breast | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | P2 | active not recruiting | 1,460 | UNICANCER | Apr 2014 |
| NCT01874353 | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | P3 | active not recruiting | 327 | AstraZeneca | Sep 2013 | |
| NCT02000622 | OlympiAD | Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. | P3 | completed | 302 | AstraZeneca | Mar 2014 |
| NCT01858168 | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma | P1 | completed | 49 | Massachusetts General Hospital | Jul 2013 | |
| NCT03685331 | HOPE | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | P1 | completed | 9 | Abramson Cancer Center at Penn Medicine | Oct 2020 |
| NCT03741426 | WIRE | WIRE - Novel Treatments in Renal Cell Cancer | P2 | unknown | 60 | CCTU- Cancer Theme | Jul 2020 |
| NCT05240898 | A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors | P1 | completed | 116 | Hoffmann-La Roche | Aug 2021 | |
| NCT04191135 | TNBC | Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) | P2 | completed | 462 | Merck Sharp & Dohme LLC | Dec 2019 |
| NCT03025035 | Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer | P2 | completed | 14 | Yuan Yuan | Sep 2017 | |
| NCT03259503 | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | P1 | completed | 50 | M.D. Anderson Cancer Center | Sep 2019 | |
| NCT06560632 | POLAR | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors | P1 | terminated | 26 | Repare Therapeutics | Sep 2024 |
| NCT06377267 | STROBE | Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) | P2 | unknown | 100 | Vall d'Hebron Institute of Oncology | Feb 2024 |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | P2 | terminated | 5 | National Cancer Institute (NCI) | Dec 2023 | |
| NCT06331559 | Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors | P1 | terminated | 13 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Mar 2024 | |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | P1/P2 | completed | 51 | National Cancer Institute (NCI) | Feb 2018 | |
| NCT03462342 | CAPRI | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer | P2 | completed | 123 | University of Pennsylvania | Mar 2018 |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | P1/P2 | completed | 220 | CellCentric Ltd. | Jul 2018 | |
| NCT05005728 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | P2 | completed | 72 | Xencor, Inc. | Oct 2021 | |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | P2 | terminated | 6 | University of Washington | Apr 2021 | |
| NCT05320757 | Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients | Early P1 | completed | 20 | The University of Hong Kong | Apr 2022 | |
| NCT04614909 | Study of Pamiparib in Newly Diagnosed and rGBM | Early P1 | completed | 50 | Nader Sanai | Jan 2021 | |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Oct 2023 | |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | P1 | active not recruiting | 36 | Sunnybrook Health Sciences Centre | Nov 2022 | |
| NCT05949424 | OPTI-DOSE | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults | P4 | unknown | 30 | University Medical Center Groningen | May 2024 |
| NCT05201612 | PEMBROLA | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). | P2 | unknown | 40 | Grupo Espanol Multidisciplinario del Cancer Digestivo | Jul 2022 |
| NCT03991832 | SOLID | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors | P2 | recruiting | 58 | University Health Network, Toronto | Dec 2019 |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | P1/P2 | completed | 45 | National Cancer Institute (NCI) | May 2016 | |
| NCT05174832 | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | P2 | unknown | 136 | Fudan University | Sep 2022 | |
| NCT04236414 | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | P1 | completed | 16 | AstraZeneca | Jan 2020 | |
| NCT03532880 | A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer | P1 | completed | 26 | Memorial Sloan Kettering Cancer Center | Jul 2018 | |
| NCT05340413 | RADIOLA | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. | P2 | completed | 65 | SOLTI Breast Cancer Research Group | Mar 2022 |
| NCT03534453 | L-MOCA | Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | P3 | completed | 229 | AstraZeneca | May 2018 |
| NCT05405309 | CORONADO CLL | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia | P1/P2 | terminated | 5 | University of Utah | Sep 2022 |
| NCT05268510 | Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma | P2 | completed | 31 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sep 2022 | |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | P2 | withdrawn | 0 | Ellipses Pharma | Apr 2023 | |
| NCT04633902 | HR | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | P2 | unknown | 41 | California Pacific Medical Center Research Institute | Mar 2021 |
| NCT04298021 | DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer | P2 | unknown | 74 | Seoul National University Hospital | Jun 2020 | |
| NCT04780945 | FAB | Functional Analysis of BRCAness | P2 | terminated | 27 | Leiden University Medical Center | Jan 2019 |
| NCT03579784 | MEDI4736 | Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer | P2 | unknown | 40 | Do-Youn Oh | Nov 2018 |
| NCT03801369 | AMTEC IIT | AMTEC IIT: Phase 2 Multiarm Study in TNBC | P2 | terminated | 24 | Gordon Mills, MD, PhD | Dec 2018 |
| NCT04306367 | Study of Pembrolizumab and Olaparib in Bile Duct Cancer | P2 | completed | 14 | Georgetown University | Apr 2020 | |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | P2 | terminated | 8 | Baptist Health South Florida | Dec 2020 | |
| NCT05167175 | The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | P2 | unknown | 30 | Hongqian Guo | Mar 2022 | |
| NCT05158062 | Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer | P2 | unknown | 35 | Kosei Hasegawa, MD, PhD | Apr 2022 | |
| NCT03838744 | TOMAS2 | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. | P2 | completed | 130 | Italian Sarcoma Group | May 2020 |
| NCT03498521 | CUPISCO | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | P2 | completed | 529 | Hoffmann-La Roche | Jul 2018 |
| NCT03782818 | OPTION | Olaparib for PAH: a Multicenter Clinical Trial | P1/P2 | terminated | 17 | Laval University | Nov 2019 |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | P2 | terminated | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2023 | |
| NCT04532645 | OVAL-1 | Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK | — | completed | 342 | AstraZeneca | Jan 2021 |
| NCT04076579 | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | P2 | completed | 29 | University of Michigan Rogel Cancer Center | Mar 2020 | |
| NCT03745950 | UTOLA | UTOLA: UTerin OLAparib | P2 | completed | 147 | ARCAGY/ GINECO GROUP | Feb 2019 |
| NCT02419495 | KPT-330 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | P1 | terminated | 221 | M.D. Anderson Cancer Center | Jun 2015 |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | P2 | completed | 40 | Roswell Park Cancer Institute | Jun 2017 | |
| NCT01078662 | Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats | P2 | completed | 298 | AstraZeneca | Feb 2010 | |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | P1 | terminated | 82 | Nuvation Bio Inc. | Mar 2022 | |
| NCT04375267 | LuPARP | 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours | P1 | completed | 18 | Vastra Gotaland Region | Apr 2020 |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | P2 | completed | 6 | National Cancer Institute (NCI) | Sep 2017 | |
| NCT05975944 | Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer | P1/P2 | unknown | 49 | Tianjin Medical University Cancer Institute and Hospital | Sep 2023 | |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | P1/P2 | terminated | 7 | Tango Therapeutics, Inc. | Dec 2023 | |
| NCT05262608 | PROspect | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation | P2 | unknown | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Dec 2021 |
| NCT03516812 | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | P2 | completed | 36 | University of Washington | Aug 2018 | |
| NCT04826198 | REVOCAN | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months | P1/P2 | terminated | 13 | Gustave Roussy, Cancer Campus, Grand Paris | Oct 2020 |
| NCT04538378 | LYNPARZA | Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors | P2 | terminated | 4 | National Cancer Institute (NCI) | Jul 2021 |
| NCT02229656 | Olaparib and Radiotherapy in Head and Neck Cancer | P1 | unknown | 12 | The Netherlands Cancer Institute | Sep 2014 | |
| NCT04015739 | BOLD | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse | P2 | unknown | 74 | ARCAGY/ GINECO GROUP | Mar 2019 |
| NCT03834519 | KEYLYNK-010 | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) | P3 | completed | 793 | Merck Sharp & Dohme LLC | May 2019 |
| NCT04641728 | Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer | P2 | unknown | 28 | Saitama Medical University International Medical Center | Jan 2021 | |
| NCT03278717 | ICON9 | Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients | P3 | unknown | 330 | University College, London | Jun 2018 |
| NCT03117933 | OCTOVA | Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | P2 | completed | 139 | University of Oxford | Mar 2017 |
| NCT03239015 | Efficacy and Safety of Precision Therapy in Refractory Tumor | P2 | unknown | 300 | Baodong Qin | Jan 2017 | |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | P1/P2 | unknown | 66 | Zofia Piotrowska | Oct 2015 | |
| NCT02117167 | SAFIR02_Lung | SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | P2 | completed | 999 | UNICANCER | Apr 2014 |
| NCT03127215 | NCT-PMO-1603 | Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors | P2 | completed | 102 | National Center for Tumor Diseases, Heidelberg | Oct 2018 |
| NCT05245994 | MEDI4736 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | P2 | unknown | 60 | Li Zhang, MD | Aug 2021 |
| NCT03182634 | plasmaMATCH | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | P2 | unknown | 1,150 | Institute of Cancer Research, United Kingdom | Dec 2016 |
| NCT02937818 | A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer | P2 | completed | 72 | AstraZeneca | Nov 2016 | |
| NCT04456699 | MK-7339 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | P3 | completed | 335 | Merck Sharp & Dohme LLC | Aug 2020 |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | P1/P2 | completed | 3 | Valerio Therapeutics | Feb 2023 | |
| NCT04939662 | SUKSES-B2 | Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects | P2 | completed | 25 | Se-Hoon Lee | Jun 2021 |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | P2 | terminated | 2 | University of Washington | Nov 2022 | |
| NCT04566952 | ANLOLA | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | P2 | unknown | 68 | Xiaoxiang Chen | Oct 2020 |
| NCT04091204 | MITO 31 | Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | P2 | unknown | 200 | National Cancer Institute, Naples | Jul 2019 |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | P2 | completed | 158 | AstraZeneca | Apr 2014 | |
| NCT02822157 | CLIO | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | P2 | unknown | 160 | Universitaire Ziekenhuizen KU Leuven | Aug 2016 |
| NCT03810105 | A Study of Olaparib and Durvalumab in Prostate Cancer | P2 | terminated | 5 | Memorial Sloan Kettering Cancer Center | Mar 2019 | |
| NCT04417192 | OLAPem | Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer | P2 | completed | 30 | National Cancer Center Hospital East | Dec 2020 |
| NCT03570437 | COPELIA | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? | P2 | unknown | 124 | University of Manchester | May 2018 |
| NCT01063517 | Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | P2 | completed | 124 | AstraZeneca | Feb 2010 | |
| NCT04166435 | TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer | P2 | completed | 11 | Yale University | Jun 2020 | |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | P2 | terminated | 3 | Sarah E Taylor | Jun 2020 | |
| NCT04669002 | EP0057 in Combination With Olaparib in Advanced Ovarian Cancer | P2 | completed | 34 | Ellipses Pharma | Dec 2020 | |
| NCT01924533 | Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. | P3 | completed | 525 | AstraZeneca | Sep 2013 | |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | P2 | withdrawn | 0 | National Cancer Institute (NCI) | Jun 2022 | |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | P3 | completed | 387 | AstraZeneca | Feb 2017 | |
| NCT02533765 | Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor | P2 | completed | 18 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Sep 2015 | |
| NCT02184195 | POLO | Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy | P3 | completed | 154 | AstraZeneca | Dec 2014 |
| NCT03378297 | IMPACT | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC | Early P1 | completed | 26 | Haukeland University Hospital | May 2018 |
| NCT05440578 | First-line Olaparib Combined With Bevacizumab Maintenance Therapy | — | unknown | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jun 2022 | |
| NCT05153603 | Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting | — | unknown | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Apr 2022 | |
| NCT03161132 | ROLANDO | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin | P2 | completed | 32 | Grupo Español de Investigación en Cáncer de Ovario | Dec 2017 |
| NCT04801966 | TAILOR | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | N/A | terminated | 3 | Peter MacCallum Cancer Centre, Australia | Sep 2021 |
| NCT00494234 | ICEBERG 1 | Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer | P2 | completed | 54 | AstraZeneca | Jun 2007 |
| NCT03205761 | COMETABreast | Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer | P2 | completed | 11 | Spanish Breast Cancer Research Group | Oct 2017 |
| NCT04261465 | NUVOLA | NUVOLA TRIAL Open-label Multicentre Study | P2 | unknown | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Dec 2019 |
| NCT05258747 | BRCA | A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer | P1 | completed | 70 | Sandoz | Apr 2022 |
| NCT04330040 | SOLI | Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer | P4 | completed | 202 | AstraZeneca | May 2020 |
| NCT03699449 | AMBITION | An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | P2 | unknown | 104 | Yonsei University | Nov 2018 |
| NCT04774406 | Arterial Hypertension Related to PARP Inhibitors (ArteRIB) | — | completed | 2,336 | University Hospital, Caen | Feb 2021 | |
| NCT06360445 | Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects | P1 | completed | 102 | CSPC Ouyi Pharmaceutical Co., Ltd. | May 2022 | |
| NCT03470805 | Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | P2 | completed | 9 | Grupo Español de Investigación en Cáncer de Ovario | Jun 2018 | |
| NCT02588105 | AToM | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | P1 | completed | 84 | AstraZeneca | Nov 2015 |
| NCT02282020 | SOLO3 | Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments | P3 | completed | 266 | AstraZeneca | Feb 2015 |
| NCT02677038 | Olaparib in Treating Patients With Stage IV Pancreatic Cancer | P2 | completed | 24 | M.D. Anderson Cancer Center | Nov 2016 | |
| NCT03167619 | DORA | Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) | P2 | completed | 45 | Duke University | Oct 2018 |
| NCT02787642 | RADIOSARP | A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma | P1 | completed | 41 | Institut Bergonié | Jan 2016 |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | P1/P2 | terminated | 19 | Opna Bio LLC | Sep 2020 | |
| NCT03434158 | IMANOL | Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) | P2 | completed | 16 | Spanish Oncology Genito-Urinary Group | Feb 2018 |
| NCT04410887 | LIGC | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | P1/P2 | unknown | 30 | Ruijin Hospital | Dec 2020 |
| NCT02681237 | A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer | N/A | completed | 34 | University Health Network, Toronto | Apr 2016 | |
| NCT02679963 | PIPSeN | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer | P2 | terminated | 180 | Gustave Roussy, Cancer Campus, Grand Paris | Feb 2016 |
| NCT02477644 | PAOLA-1 | Platine, Avastin and OLAparib in 1st Line | P3 | completed | 806 | Arcagy Research | May 2015 |
| NCT01921140 | To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours | P1 | completed | 60 | AstraZeneca | Sep 2013 | |
| NCT03402841 | OPINION | Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients | P3 | completed | 279 | AstraZeneca | Jan 2018 |
| NCT03931551 | OPHELIA | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer | P2 | terminated | 5 | MedSIR | Apr 2019 |
| NCT03106987 | OReO | A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. | P3 | completed | 220 | AstraZeneca | Jun 2017 |
| NCT03829345 | SOLAR | A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer | P2 | unknown | 54 | Royal Marsden NHS Foundation Trust | Jul 2019 |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | P1 | terminated | 3 | Vanderbilt-Ingram Cancer Center | Oct 2020 | |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | P1 | completed | 28 | National Cancer Institute (NCI) | May 2017 | |
| NCT03367689 | NOBROLA | A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent | P2 | terminated | 7 | MedSIR | Apr 2018 |
| NCT02855697 | MOLTO | Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer | Early P1 | completed | 28 | The Christie NHS Foundation Trust | May 2017 |
| NCT02476968 | ORZORA | To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer | P4 | completed | 181 | AstraZeneca | Sep 2015 |
| NCT03925233 | Breast Cancer Treatment Based on Organ-like Culture | — | unknown | 300 | Xijing Hospital | Jan 2019 | |
| NCT03432897 | 337 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes | P2 | terminated | 1 | Brown University | May 2018 |
| NCT03109080 | RadioPARP | Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) | P1 | completed | 24 | Institut Curie | Jul 2017 |
| NCT03561870 | OLAGLI | Olaparib in Recurrent IDH-mutant Glioma | P2 | completed | 35 | Hospices Civils de Lyon | Mar 2019 |
| NCT03448718 | Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations | P2 | completed | 19 | Matthew Galsky | Apr 2018 | |
| NCT03286842 | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. | P3 | completed | 256 | AstraZeneca | Jan 2018 | |
| NCT05860530 | Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers | N/A | completed | 48 | Qilu Pharmaceutical Co., Ltd. | May 2021 | |
| NCT03955640 | Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences | P1 | terminated | 3 | Thomas Jefferson University | May 2019 | |
| NCT03057145 | Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors | P1 | completed | 29 | Geoffrey Shapiro, MD, PhD | Mar 2017 | |
| NCT02511223 | 10 | Efficacy and Safety of PARPi to Treat Pancreatic Cancer | P2 | completed | 24 | Sheba Medical Center | Jul 2016 |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | P1 | completed | 49 | AstraZeneca | Jun 2017 | |
| NCT03314740 | BAROCCO | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib | P2 | completed | 123 | Mario Negri Institute for Pharmacological Research | Jun 2017 |
| NCT02889900 | CONCERTO | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer | P2 | completed | 62 | AstraZeneca | Jan 2017 |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy | P2 | terminated | 140 | Latin American Cooperative Oncology Group | Mar 2021 | |
| NCT03009682 | SUKSES-B | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations | P2 | completed | 15 | Samsung Medical Center | Aug 2016 |
| NCT04239014 | DUETTE | A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. | P2 | withdrawn | 0 | AstraZeneca | Aug 2020 |
| NCT03022409 | DDR | A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | P1 | completed | 21 | AstraZeneca | Sep 2017 |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | P2 | completed | 26 | Samsung Medical Center | Oct 2018 | |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | P1 | completed | 118 | Dana-Farber Cancer Institute | Sep 2012 | |
| NCT03878524 | SMMART | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | P1 | terminated | 2 | OHSU Knight Cancer Institute | Apr 2020 |
| NCT02983799 | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | P2 | completed | 272 | AstraZeneca | Dec 2016 | |
| NCT03544125 | Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer | P1 | completed | 3 | OHSU Knight Cancer Institute | May 2018 | |
| NCT03531840 | Olaparib in People With Malignant Mesothelioma | P2 | completed | 23 | National Cancer Institute (NCI) | Jul 2018 | |
| NCT02227082 | Olaparib and Radiotherapy in Inoperable Breast Cancer | P1 | completed | 7 | The Netherlands Cancer Institute | Oct 2013 | |
| NCT02121990 | IP | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | P1 | completed | 17 | Memorial Sloan Kettering Cancer Center | Apr 2014 |
| NCT03553108 | IVIVC | A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. | P1 | completed | 18 | AstraZeneca | May 2018 |
| NCT02755844 | ENDOLA | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients | P1/P2 | completed | 35 | Hospices Civils de Lyon | Sep 2016 |
| NCT02899728 | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer | P2 | terminated | 9 | National Cancer Institute (NCI) | Mar 2018 | |
| NCT03534492 | NEODURVARIB | Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB) | P2 | completed | 29 | Spanish Oncology Genito-Urinary Group | Nov 2018 |
| NCT01562210 | olaparib | Olaparib Dose Escalating Trial + Concurrent RT With or Without Cisplatin in Locally Advanced NSCLC | P1 | completed | 28 | The Netherlands Cancer Institute | Apr 2012 |
| NCT02485990 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | P1 | terminated | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2016 | |
| NCT01682772 | TOPARP | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer | P2 | unknown | 148 | Institute of Cancer Research, United Kingdom | Jul 2012 |
| NCT04152941 | RETROLA | Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients | — | completed | 130 | ARCAGY/ GINECO GROUP | Oct 2018 |
| NCT02882308 | OPHELIA | Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. | P2 | completed | 41 | Hellenic Cooperative Oncology Group | Oct 2016 |
| NCT01650376 | Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer | P1/P2 | unknown | 52 | Swedish Medical Center | Aug 2012 | |
| NCT01237067 | Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers | P1 | completed | 77 | National Cancer Institute (NCI) | Feb 2011 | |
| NCT03251872 | OPTION-p | Olaparib for PAH: a Pilot Study | Early P1 | terminated | 6 | Laval University | Oct 2018 |
| NCT02398058 | TOMAS | Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) | P1 | completed | 50 | Italian Sarcoma Group | Jul 2014 |
| NCT02684318 | Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors | P1/P2 | unknown | 100 | Poveda, Andrés, M.D. | Jul 2015 | |
| NCT02511795 | AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors | P1 | completed | 128 | AstraZeneca | Aug 2015 | |
| NCT02686008 | Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC | P1 | withdrawn | 0 | Yale University | Jan 2018 | |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | P2 | terminated | 2 | University of Washington | Sep 2018 | |
| NCT02392676 | Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations | P3 | withdrawn | 0 | AstraZeneca | Jul 2016 | |
| NCT02324998 | CaNCaP03 | Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy | P1 | completed | 20 | Cambridge University Hospitals NHS Foundation Trust | Dec 2016 |
| NCT03575078 | ARQ761 + PARP Inhibitor in Refractory Solid Tumors | P1 | withdrawn | 0 | University of Texas Southwestern Medical Center | Jun 2018 | |
| NCT02093351 | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | P1 | completed | 79 | AstraZeneca | Sep 2014 | |
| NCT02506816 | Polen | Preoperative Olaparib Endometrial Carcinoma Study (POLEN) | — | completed | 36 | MedSIR | Feb 2016 |
| NCT02418624 | REVIVAL | Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer | P1 | completed | 25 | The Netherlands Cancer Institute | May 2015 |
| NCT01788332 | PIN | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN) | P2 | unknown | 70 | Lisette Nixon | Jan 2014 |
| NCT01758731 | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History | P1 | completed | 17 | University of Colorado, Denver | Oct 2012 | |
| NCT01460888 | ROCOCO | Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus | P1 | unknown | 36 | The Christie NHS Foundation Trust | Jul 2013 |
| NCT02340611 | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | P2 | completed | 4 | University Health Network, Toronto | Jun 2015 | |
| NCT01390571 | Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma | P1 | completed | 34 | Cancer Research UK | Jul 2011 | |
| NCT01851265 | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours | P1 | completed | 32 | AstraZeneca | Jul 2013 | |
| NCT02430311 | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | P1 | completed | 36 | AstraZeneca | Jun 2015 | |
| NCT01894243 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | P1 | completed | 31 | AstraZeneca | Mar 2014 | |
| NCT02338622 | ComPAKT | Trial of Olaparib in Combination With AZD5363 (ComPAKT) | P1 | completed | 60 | Royal Marsden NHS Foundation Trust | Mar 2014 |
| NCT03079687 | Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | — | approved for marketing | 0 | AstraZeneca | — | |
| NCT03063710 | Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan | — | no longer available | 0 | AstraZeneca | — | |
| NCT02561832 | A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer | P1 | terminated | 15 | AstraZeneca | Nov 2015 | |
| NCT01929603 | Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours | P1 | completed | 32 | AstraZeneca | Dec 2013 | |
| NCT01900028 | To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours | P1 | completed | 85 | AstraZeneca | Oct 2013 | |
| NCT01813474 | Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies | P1 | completed | 23 | AstraZeneca | Mar 2013 | |
| NCT01513174 | GOAL | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone | P1/P2 | completed | 186 | Spanish Lung Cancer Group | Aug 2011 |
| NCT01894256 | Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function | P1 | completed | 56 | AstraZeneca | Nov 2013 | |
| NCT01296763 | Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer | P1 | completed | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jan 2011 | |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | P2 | unknown | 45 | Istituti Ospitalieri di Cremona | Jan 2016 | |
| NCT00535353 | AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer | P1 | completed | 26 | NCIC Clinical Trials Group | Jan 2008 | |
| NCT01583543 | Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma | P2 | completed | 12 | Massachusetts General Hospital | May 2012 | |
| NCT01661868 | Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer | P2 | withdrawn | 0 | Dana-Farber Cancer Institute | Aug 2012 | |
| NCT00912743 | MSI | Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status | P2 | completed | 33 | AstraZeneca | May 2009 |
| NCT01491139 | ORCA | Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | P1 | withdrawn | 0 | University College, London | — |
Olaparib clinical trials: frequently asked questions
- How many Olaparib clinical trials are there?
- 409 Olaparib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 83 are actively recruiting participants. 125 are marked completed.
- Are Olaparib clinical trials recruiting in 2026?
- Yes — 83 Olaparib trials are actively recruiting in 2026, with 2053 U.S. sites across 51 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Olaparib being studied for?
- Olaparib is being studied for Ovarian Cancer, Breast Cancer, Prostate Cancer, Fallopian Tube Cancer, BRCA1 Mutation and 775 more. The trials are grouped by indication on this page.
- What phase is Olaparib in?
- Olaparib clinical trials span 6 Phase 4, 41 Phase 3, 206 Phase 2, 88 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Olaparib clinical trials?
- The lead sponsor across the most Olaparib trials is AstraZeneca, with 186 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Olaparibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: